Bis(diazirine) derivatives as photocrosslinkers for the treatment of corneal ectatic disorders
Bis(diazirine) derivatives provide a solution to stabilize corneal reshaping by inducing cross-linking in response to electromagnetic radiation, addressing the instability of corneal collagen fibrils post-treatment and enhancing corneal stability in disorders like keratoconus and post-LASIK ectasia.
Patent Information
- Application Number
- JP2021543272
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-01-25
- Filing Date
- 2020-01-24
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2040-01-24
AI Technical Summary
Existing treatments for corneal ectatic disorders, such as keratoconus and post-LASIK ectasia, face challenges in maintaining the stability of corneal reshaping due to post-surgical changes in collagen fibrils, leading to complications like corneal steepening and thinning.
The use of bis(diazirine) derivatives as photocrosslinkers that respond to electromagnetic radiation to induce cross-linking in the cornea, stabilizing the corneal structure and enhancing collagen bonding without the need for supplemental oxygen, thereby addressing the instability issues.
The bis(diazirine) derivatives effectively strengthen and stabilize the cornea, reducing the progression of disorders by enhancing mechanical stiffness and maintaining the reshaped corneal structure, offering a more stable treatment outcome.
Smart Images

Figure 0007595576000001 
Figure 0007595576000002 
Figure 0007595576000003
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Patent Application No. 62 / 796,803, filed January 25, 2019, which is incorporated by reference in its entirety.
[0002] Technical Field The present disclosure features a chemical entity (e.g., a compound, or a pharma- ceutically acceptable salt and / or hydrate and / or prodrug of the compound) that causes cross-linking in the cornea in response to exposure to electromagnetic radiation. The present disclosure also features compositions containing the chemical entity, as well as other methods of using and making the chemical entity. The chemical entity is useful, for example, for treating a subject (e.g., a human) having a disease, disorder, or condition, in which an abnormal shape of the cornea (e.g., corneal thinning, e.g., bilateral corneal thinning, e.g., central, paracentral, or peripheral bilateral corneal thinning; or corneal steepening (e.g., bulging)) contributes to the pathology and / or symptoms and / or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include (i) corneal ectatic disorders, (ii) visual conditions, and (iii) diseases, disorders, or conditions that are sequelae or comorbidities of any of the foregoing or any of those disclosed herein. More specific non-limiting examples of such diseases, disorders, or conditions include keratoconus, keratoglobus, pellucid marginal degeneration, corneal ectasia (e.g., post-operative ectasia, e.g., post-LASIK ectasia), Therrien's peripheral corneal degeneration, myopia, hyperopia, astigmatism, irregular astigmatism, and presbyopia. [Background technology]
[0003] background Various eye disorders, such as myopia, keratoconus, and hyperopia, involve an abnormal shape of the cornea. For example, laser in situ keratomileusis (LASIK) is one of many corrective treatments that reshape the cornea so that light passing through it is properly focused onto the retina, located at the back of the eye. The success of a particular treatment that addresses the abnormal shape of the cornea depends on the stability of the changes in corneal structure after the treatment is applied.
[0004] Although a treatment may initially achieve the desired reshaping of the cornea, if collagen fibrils within the cornea continue to change after the desired reshaping is achieved, the desired effect of corneal reshaping may be at least partially reduced or reversed. For example, a complication known as post-LASIK ectasia may occur due to the thinning and weakening of the cornea caused by LASIK surgery. In post-LASIK ectasia, the cornea exhibits progressive steepening (bulging). To strengthen and stabilize the structure of the cornea after reshaping, some treatments may also initiate cross-linking within the corneal tissue. For example, a photosensitizing agent (e.g., riboflavin) is applied to the cornea as a cross-linking agent. Once the cross-linking agent is applied to the cornea, the cross-linking agent is activated by a light source (e.g., ultraviolet (UV) light), whereby the cross-linking agent absorbs sufficient energy to cause the release of free oxygen radicals (e.g., singlet oxygen) and / or other radicals within the cornea. When released, the radicals form covalent bonds between corneal collagen fibrils, thereby cross-linking the corneal collagen fibrils and strengthening and stabilizing the structure of the cornea.
[0005] Due to the beneficial structural changes caused by crosslinking agents, crosslinking agents may be applied as a key aspect of some treatments. For example, crosslinking agents may be applied to treat keratoconus. Crosslinking treatments may be used to induce refractive changes in the cornea to correct disorders such as myopia, hyperopia, astigmatism, irregular astigmatism, presbyopia, etc.
[0006] U.S. Patent Application Publication No. 2011 / 0237999 (Patent Document 1), filed March 18, 2011; U.S. Patent Application Publication No. 2012 / 0215155 (Patent Document 2), filed April 3, 2012; U.S. Patent Application No. 2014 / 0343480 (Patent Document 3), filed May 19, 2014; U.S. Patent Application No. 2013 / 0060187 (Patent Document 4), filed October 31, 2012; International Patent Application Publication No. 2011 / 130356 (Patent Document 5), filed April 13, 2011; International Patent Application Publication No. 2015 / 130944, filed Feb. 26, 2015 (Patent Document 6), and International Patent Application No. 2016 / 090016, filed Dec. 2, 2015 (Patent Document 7), describe systems and compositions (e.g., riboflavin or riboflavin phosphate eye drops) for producing cross-linking activity in the cornea of the eye in the treatment of ocular disorders such as keratoconus (e.g., progressive keratoconus) or corneal ectasia after refractive surgery with or without removal of corneal epithelial cells. PHOTREXA® VISCOUS (riboflavin 5'-phosphate in 20% dextran eye drops) 0.146% and PHOTREXA® (riboflavin 5'-phosphate eye drops) 0.146% are photoenhancements indicated for use with the KXL™ System for corneal collagen cross-linking for the treatment of progressive keratoconus.
[0007] US Patent Publication No. 20160083352 (Patent Document 8) disclosed diazirine compounds as photocrosslinkers for use in electronic and optoelectronic devices, and the like. [Prior art documents] [Patent documents]
[0008] [Patent Document 1] US Patent Application Publication No. 2011 / 0237999 [Patent Document 2] US Patent Application Publication No. 2012 / 0215155 [Patent Document 3] U.S. Patent Application No. 2014 / 0343480 [Patent Document 4] U.S. Patent Application No. 2013 / 0060187 [Patent Document 5] International Patent Application Publication No. 2011 / 130356 [Patent Document 6] International Patent Application Publication No. 2015 / 130944 [Patent Document 7] International Patent Application No. 2016 / 090016 [Patent Document 8] US Patent Application Publication No. 20160083352 Summary of the Invention
[0009] overview The present disclosure features a chemical entity (e.g., a compound, or a pharma- ceutically acceptable salt and / or hydrate and / or prodrug of the compound) that causes cross-linking in the cornea in response to exposure to electromagnetic radiation. The present disclosure also features compositions containing the chemical entity, as well as other methods of using and making the chemical entity. The chemical entity is useful, for example, for treating a subject (e.g., a human) having a disease, disorder, or condition, in which an abnormal shape of the cornea (e.g., corneal thinning, e.g., bilateral corneal thinning, e.g., central, paracentral, or peripheral bilateral corneal thinning; or corneal steepening (e.g., bulging)) contributes to the pathology and / or symptoms and / or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include (i) corneal ectasia disorders, (ii) visual conditions, and (iii) diseases, disorders, or conditions that are sequelae or co-morbidities of any of the above or any of the above disclosed herein. More specific non-limiting examples of such diseases, disorders, or conditions include keratoconus, keratoglobus, pellucid marginal degeneration, corneal ectasia (e.g., post-operative ectasia, e.g., post-LASIK ectasia), Therrien peripheral corneal degeneration, myopia, hyperopia, astigmatism, irregular astigmatism, and presbyopia. In some embodiments, the claimed method can be performed in the absence of added and supplemented oxygen levels, which may be advantageous in some applications.
[0010] In one aspect, the characteristic chemical entity has formula I: TIFF0007595576000001.tif19128, or a pharma- ceutically acceptable salt thereof; In the formula, A 1 , B 1 , and B. 2 may be as defined herein.
[0011] In one aspect, the characteristic chemical entity has formula I: TIFF0007595576000002.tif19128, or a pharma- ceutically acceptable salt thereof; In the formula, A 1 , B 1 , and B. 2 may be as defined herein.
[0012] In one aspect, the characteristic chemical entity has formula I: TIFF0007595576000003.tif21128, or a pharma- ceutically acceptable salt thereof; In the formula, E 1 , F 1 , G 1 , H 1 , J 1 , L 1 , M 1 , Q 1 , B 1 , and B. 2 may be as defined herein.
[0013] In one aspect, a pharmaceutical composition is characterized in that it comprises a chemical entity described herein (e.g., a compound described generally or specifically herein, or a pharma- ceutically acceptable salt thereof, or a composition containing same) and one or more pharma- ceutically acceptable excipients.
[0014] In one aspect, a method for producing cross-linking in a cornea is characterized in that it includes the steps of contacting the cornea with a chemical entity described herein (e.g., a compound described generally or specifically herein, or a pharma- ceutically acceptable salt thereof, or a composition containing same); and irradiating the cornea with electromagnetic radiation. Such methods may include, for example, administering a chemical entity to the cornea of an eye of a subject (e.g., a human) having a disease, disorder, or condition, where an abnormal shape of the cornea (e.g., corneal thinning, e.g., bilateral corneal thinning, e.g., central, paracentral, or peripheral corneal thinning; or corneal steepening (e.g., elevation)) contributes to the pathology and / or symptoms and / or progression of the disease, disorder, or condition (e.g., keratoconus, keratoglobus, Pelusid marginal degeneration, corneal ectasia (e.g., post-operative ectasia, e.g., post-LASIK ectasia), Therrien peripheral corneal degeneration, myopia, hyperopia, astigmatism, irregular astigmatism, and presbyopia), and irradiating the cornea with electromagnetic radiation. Methods may include, without limitation, providing refractive correction to the cornea (e.g., by imparting mechanical stiffness) to strengthen and stabilize the structure of the cornea.
[0015] In another aspect, the invention features a method of treating a disease, disorder, or condition in which an abnormal shape of the cornea (e.g., corneal thinning, e.g., bilateral corneal thinning, e.g., bilateral central, paracentral, or peripheral corneal thinning; or corneal steepening (e.g., elevation)) contributes to the pathology and / or symptoms and / or progression of the disease, disorder, or condition. The method includes administering a chemical entity described herein (e.g., a compound described generally or specifically herein, a pharma- ceutically acceptable salt thereof, or a composition containing same) in an amount effective to treat the disease, disorder, or condition.
[0016] In a further aspect, the invention features a method of treating a disease, disorder, or condition in which an abnormal shape of the cornea (e.g., corneal thinning, e.g., bilateral corneal thinning, e.g., bilateral central, paracentral, or peripheral corneal thinning; or corneal steepening (e.g., elevation)) contributes to the pathology and / or symptoms and / or progression of the disease, disorder, or condition. The method includes administering to the cornea of an eye of a subject in need of such treatment an effective amount of a chemical entity described herein (e.g., a compound generally or specifically described herein, a pharma- ceutically acceptable salt thereof, or a composition containing same); and irradiating the cornea with electromagnetic radiation.
[0017] Non-limiting examples of such diseases, disorders, and conditions include corneal ectasia disorder. In certain embodiments, the corneal ectasia disorder is keratoconus. In certain embodiments, the corneal ectasia disorder is corneal globus. In certain embodiments, the corneal ectasia disorder is Pelusid marginal corneal degeneration. In certain embodiments, the corneal ectasia disorder is corneal ectasia (e.g., post-operative ectasia, e.g., post-LASIK ectasia). In certain embodiments, the corneal ectasia disorder is Therrien peripheral corneal degeneration.
[0018] Another non-limiting example of such a disease, disorder, and condition is a visual condition. In certain aspects, the visual condition is myopia. In certain aspects, the visual condition is hyperopia. In certain aspects, the visual condition is myopia. In certain aspects, the visual condition is hyperopia. In certain aspects, the visual condition is astigmatism. In certain aspects, the visual condition is irregular astigmatism. In certain aspects, the visual condition is presbyopia.
[0019] Embodiments can include one or more of the following advantageous features.
[0020] In some embodiments, the claimed methods can be performed in the absence of added or supplemented oxygen levels, which can be advantageous in some applications.
[0021] In some aspects, the chemical entities and compositions described herein can be applied to the cornea without prior removal of corneal epithelial cells, thereby improving patient comfort.
[0022] In some aspects, the chemical entities and compositions described herein can be crosslinked within the cornea using relatively short duration electromagnetic radiation.
[0023] Other aspects include those described in the Detailed Description and / or claims.
[0024] Additional definitions In order to facilitate understanding of the disclosure described herein, some additional terms are defined below.Generally, the nomenclature used herein and the experimental procedures in organic chemistry, medicinal chemistry, and pharmacology described herein are well known and commonly used in the art.Unless otherwise defined, all technical and scientific terms used herein generally have the same meaning as commonly understood by those skilled in the art to which this disclosure belongs.Each of the patents, applications, published applications, and other publications mentioned throughout this specification and the appendix is incorporated herein by reference in its entirety.
[0025] As used herein, the term "acceptable" with respect to a formulation, composition, or ingredient means that it has no lasting deleterious effects on the overall health of the subject being treated.
[0026] The term "effective amount" or "therapeutically effective amount" as used herein refers to a sufficient amount of the administered chemical entity (e.g., a compound generally or specifically described herein, its pharma- ceutically acceptable salt, or a composition containing them) to relieve to some extent one or more of the symptoms of the disease or condition being treated. The result includes reduction and / or alleviation of the signs, symptoms, or causes of the disease, or any other desired change in a biological system. For example, an "effective amount" for therapeutic use is the amount of a composition containing a compound disclosed herein that is required to cause a clinically significant reduction in disease symptoms. The appropriate "effective" amount in any individual case is determined using any suitable technique, such as a dose escalation study.
[0027] The term "excipient" or "pharmaceutically acceptable excipient" refers to a pharma- ceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, carrier, solvent, or encapsulating material. In one aspect, each component is "pharmaceutically acceptable" in the sense of being compatible with the other components of the pharmaceutical formulation, suitable for use in contact with the tissues or organs of humans and animals without undue toxicity, irritation, allergic response, immunogenicity, or other problems or complications, and commensurate with a reasonable benefit / risk ratio. For example, Remington:The Science and Practice of Pharmacy,21st ed.;Lippincott Williams&Wilkins:Philadelphia,PA,2005;Handbook of Pharmaceutical Excipients,6th ed.;Rowe et al.,Eds.;The Pharmaceutical Press and the American Pharmaceutical Association:2009;Handbook of Pharmaceutical Additives,3rd ed.;Ash and Ash Eds.;Gower Publishing Company: 2007; Pharmaceutical Preformulation and Formulation, 2nd ed.; Gibson Ed.; CRC Press LLC: Boca Raton, FL, 2009.
[0028] The term "pharmaceutical acceptable salt" refers to a preparation of a compound that does not cause significant irritation to the organism to which it is administered and does not nullify the biological activity and properties of the compound. In certain examples, pharmaceutical acceptable salts are obtained by reacting a compound described herein with an acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, etc. In some examples, pharmaceutical acceptable salts are obtained by reacting a compound having an acidic group described herein with a base to form a salt, such as an ammonium salt, an alkali metal salt, such as a sodium salt or a potassium salt, an alkaline earth metal salt, such as a calcium salt or a magnesium salt, a salt of an organic base such as dicyclohexylamine, N-methyl-D-glucamine, tris(hydroxymethyl)methylamine, and a salt with an amino acid such as arginine, lysine, etc., or by other methods that are predefined. There is no particular limit to the pharmacologically acceptable salt, as long as it can be used in medicine. Examples of salts that the compounds described herein form with bases include: their salts with inorganic bases such as sodium, potassium, magnesium, calcium, and aluminum; their salts with organic bases such as methylamine, ethylamine, and ethanolamine; their salts with basic amino acids such as lysine and ornithine; and ammonium salts. The salts may be acid addition salts, which are specifically exemplified by the acid addition salts with mineral acids, such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, and phosphoric acid; organic acids, such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, and ethanesulfonic acid; acidic amino acids, such as aspartic acid and glutamic acid.
[0029] The term "pharmaceutical composition" refers to a mixture of the compounds described herein with other chemical components (collectively referred to herein as "excipients"), such as carriers, stabilizers, diluents, dispersants, suspending agents, and / or thickening agents. Pharmaceutical compositions facilitate the administration of compounds to living organisms. In the art, there are multiple techniques for administering compounds, including, but not limited to, rectal administration, oral administration, intravenous administration, aerosol administration, parenteral administration, ocular administration, pulmonary administration, and topical administration.
[0030] The term "subject" refers to an animal, including, but not limited to, a primate (e.g., a human), monkey, cow, pig, sheep, goat, horse, dog, cat, rabbit, rat, or mouse. As used herein, the terms "subject" and "patient" are used interchangeably to refer to a mammalian subject, such as, for example, a human.
[0031] In the context of treating a disease, disorder, or condition, the terms "treat," "treating," and "treatment" are meant to include alleviating or arresting the disorder, disease, or condition, or one or more of the symptoms associated with the disorder, disease, or condition, or to slow the progression, spread, or worsening of the disease, disorder, or condition, or one or more symptoms thereof.
[0032] The term "halo" refers to fluoro (F), chloro (Cl), bromo (Br), or iodo (I).
[0033] The term "alkyl" refers to a hydrocarbon chain, which may be a straight chain or branched chain, containing the indicated number of carbon atoms. For example, C 1~10 indicates that the group may have from 1 to 10 carbon atoms in it. Non-limiting examples include methyl, ethyl, iso-propyl, tert-butyl, n-hexyl.
[0034] The term "haloalkyl" refers to an alkyl in which one or more hydrogen atoms are replaced by an independently selected halo.
[0035] The term "alkoxy" refers to an -O-alkyl radical (eg, -OCH3).
[0036] The term "haloalkoxy" refers to an -O-haloalkyl radical (eg, -OCF3).
[0037] The term "alkylene" refers to a branched or unbranched divalent alkyl (eg, -CH2-).
[0038] The term "arylene" and the like refer to a divalent form of a ring system, here a divalent aryl.
[0039] The term "alkenyl" refers to a hydrocarbon chain that may be straight or branched, having one or more carbon-carbon double bonds. The alkenyl moiety contains the indicated number of carbon atoms. For example, C 2~6 indicates that the group may have at least 2 but no more than 6 carbon atoms in it.
[0040] The term "alkynyl" refers to a hydrocarbon chain that may be straight or branched, having one or more carbon-carbon triple bonds. The alkynyl moiety contains the indicated number of carbon atoms. For example, C 2~6 indicates that the group may have at least 2 but no more than 6 carbon atoms in it.
[0041] The term "aryl" refers to a 6-carbon monocyclic, 10-carbon bicyclic, or 14-carbon tricyclic aromatic ring system in which 0, 1, 2, 3, or 4 atoms of each ring may be substituted by substituents, the ring containing the monocyclic radical is aromatic, and at least one of the fused rings containing the bicyclic or tricyclic radical is aromatic, e.g., tetrahydronaphthyl. Examples of aryl groups also include phenyl, naphthyl, and the like.
[0042] As used herein, the term "cycloalkyl" refers to a saturated cyclic hydrocarbon group having 3 to 10 carbons, preferably 3 to 8 carbons, more preferably 3 to 6 carbons, which cycloalkyl groups may be substituted. Preferred cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl.
[0043] The term "heteroaryl" refers to an aromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms in the monocyclic, 1-6 heteroatoms in the bicyclic, or 1-9 heteroatoms in the tricyclic, selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of N, O, or S in the monocyclic, bicyclic, or tricyclic, respectively), in which 0, 1, 2, 3, or 4 atoms of each ring may be optionally substituted by a substituent, the ring containing the monocyclic radical is aromatic, and at least one of the fused rings containing the bicyclic or tricyclic radical is aromatic (but not necessarily the ring containing the heteroatom, e.g., tetrahydroisoquinolinyl). Exemplary heteroaryl systems are derived, without limitation, from the following ring systems: pyrrole, furan, thiophene, imidazole, pyrazole, oxazole (=[1, 3]oxazole), isoxazole (=[1,2]oxazole), thiazole (=[1,3]thiazole), isothiazole (=[1,2]thiazole), [1,2,3]triazole, [1,2,4]triazole, [1,2,4]oxadiazole, [1,3,4]oxadiazole, [1,2,4]thiadiazole, [1,3,4]thiadiazole, tetrazole, pyridine, pyridazine, pyrimidine, pyrazine, [1,2,3]triazole azines, [1,2,4]triazines, [1,3,5]triazines, indoles, isoindoles, benzofurans, benzothiophenes, [1,3]benzoxazoles, [1,3]benzothiazoles, benzimidazoles, indazoles, quinolines, isoquinolines, cinnolines, quinazolines, quinoxalines, phthalazines, various naphthyridines such as [1,8]naphthyridine, various thienopyridines such as thieno[2,3-b]pyridine, and purines.
[0044] The term "heterocyclyl" refers to a non-aromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms in the monocyclic, 1-6 heteroatoms in the bicyclic, or 1-9 heteroatoms in the tricyclic, selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of N, O, or S in the monocyclic, bicyclic, or tricyclic, respectively), in which 0, 1, 2, or 3 atoms of each ring may be optionally substituted by substituents. Examples of heterocyclyl groups include piperazinyl, pyrrolidinyl, dioxanyl, morpholinyl, tetrahydrofuranyl, and the like.
[0045] Additionally, atoms constituting the compounds of the present embodiment are intended to include all isotopic forms of such atoms. Isotopes, as used herein, include atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include tritium and deuterium, and isotopes of carbon include . 13 C and 14 Contains C.
[0046] [The present invention 1001] Formula (I): TIFF0007595576000004.tif19128 A compound of the formula: During the ceremony, L A and L B each independently represents 1 to 3 R a C may be substituted 1 ~C 5 is alkylene; A is a moiety that enhances delivery of the compound to the corneal stroma (e.g., through an intact corneal epithelium) and / or enhances binding of the compound to corneal collagen; B 1 and B. 2 Each of the -Z 1 -Z 2 -Z 3 where: ·Z 1 However, 1 to 4 R a C may be substituted 1~3 is alkylene; ·Z 2 is a bond, -N(R d )-, -O-, or -S-; and ·Z 3 Halo, H, or 1-4 R a C may be substituted 1~7 is alkyl; R a Each occurrence of -OH; -SH; -F; -Cl; -Br; -NR e R f ;C 1~4 Alkoxy;C 1~4 Haloalkoxy; -C(=O)O(C 1~4 alkyl);-C(=O)(C 1~4 alkyl);-C(=O)OH;-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 0~2 (C 1~4 alkyl; cyano; -NR'C(=NR')NR'R''; and 1 to 4 independently selected R b C may be substituted 3~6 independently selected from the group consisting of cycloalkyl; R b Each occurrence of -OH; -SH; -F; -Cl; -Br; -NR e R f ;C 1~4 Alkyl;C 1~4 Haloalkyl;C 1~4 Alkoxy;C 1~4 Haloalkoxy; -C(=O)O(C 1~4 alkyl);-C(=O)(C 1~4 alkyl;-C(=O)OH;-CON(R')(R'');oxo;-S(O) 1~2 (NR'R'');-S(O) 0~2 (C 1~4 alkyl; cyano; -NR'C(=NR')NR'R''; and 1 to 4 independently selected C 1~4 C optionally substituted by alkyl 3~6 independently selected from the group consisting of cycloalkyl; R d Each occurrence of H;C 1~6 Alkyl;C 3~6 Cycloalkyl; -C(O)(C 1~4 alkyl);-C(O)O(C 1~4 alkyl);-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 1~2 (C 1~4 alkyl);-OH; and C 1~4 alkoxy; R e and R f Each occurrence of H;C 1~6 Alkyl;C 3~6 Cycloalkyl; -C(O)(C 1~4 alkyl);-C(O)O(C 1~4 alkyl);-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 1~2 (C 1~4 alkyl);-OH; and C 1~4 alkoxy; and Each occurrence of R' and R'' is H and C 1~4 alkyl, or R′ and R″ taken together with the nitrogen atom to which they are each attached form a ring containing 3 to 8 ring atoms, wherein the ring is selected from the group consisting of: (a) H and C 1~3 (b) N(R d and 0 to 3 ring heteroatoms (in addition to the nitrogen atom bonded to R′ and R″) each independently selected from the group consisting of , O, and S; The compound, or a pharma- ceutically acceptable salt thereof. [The present invention 1002] The compound of the present invention, wherein A is a moiety that enhances delivery of said compound to the corneal stroma through the intact corneal epithelium and / or enhances binding of said compound to corneal collagen. [The present invention 1003] Formula (Ia): TIFF0007595576000005.tif19128 A compound of the formula: During the ceremony, A 1 However, there are 1 to 10 Rs (e.g., 1 to 5, 1 to 4, 1 to 3, 1 to 2, 1). 1 C is inserted 2 ~C 20 is alkylene; B 1 and B. 2 Each of the -Z 1 -Z 2 -Z 3 where: ·Z 1 However, 1 to 4 R a C may be substituted 1~3 is alkylene; ·Z 2 is a bond, -N(R d )-, -O-, or -S-; and ·Z 3 is H, halo, or 1-4 R a C may be substituted 1~7 is alkyl; R 1 Each occurrence of -N(R d1 )-; -N(R 3 )-; ·-O-; S(O) where p is 0, 1, or 2 p ; ·C(=O); ·C(=S); ·CHR 2 ; ·C(R 2 ) 2 ; -C(=O)CH(R 2 )N(R d1 )-; and -C(=O)CH(R 2 )CH 2 N(R d1 )- are more independently selected divalent groups; R 2 Each occurrence of (i)R a ; (ii) 1 to 3 R a C may be substituted 1 ~C 6 Alkyl; (iii) heterocyclyl contains 3 to 10 ring atoms, 1 to 3 of which are N(R d ), O, and S, and one or more of the heterocyclyl ring carbon atoms are selected from 1 to 4 independently selected R b L 2 -heterocyclyl; (iv) 1 to 4 R c L may be substituted by 2 -C 6 ~C 10 Aryl; (v) Heteroaryl contains 5 to 10 ring atoms, 1 to 4 of which are N, N(R d ), O, and S, and one or more of the heteroaryl ring carbon atoms are selected from 1 to 4 independently selected R c L 2 -heteroaryl; and (vi) H or (vii) -C(=O)CH(R 2 )N(R d1 )-group R 2 and R d1 are linked to form a ring containing 5 to 8 ring atoms, wherein the ring is 1~3 A ring having 3 to 6 ring carbon atoms (CH(R 2 ) plus;(b) N(R d1 0 to 3 ring heteroatoms (R d1 In addition to the nitrogen atom bonded to R 3 Each occurrence of (i) 1 to 3 R a C may be substituted 1 ~C 6 Alkyl; (ii) heterocyclyl contains 3 to 10 ring atoms, 1 to 3 of which are N(R d ), O, and S, and one or more of the heterocyclyl ring carbon atoms are selected from 1 to 4 independently selected R b L 3 -heterocyclyl; (iii) 1 to 4 R c L may be substituted by 3 -C 6 ~C 10 Aryl; and (iv) Heteroaryl contains 5 to 10 ring atoms, 1 to 4 of which are N, N(R d ), O, and S, and one or more of the heteroaryl ring carbon atoms are selected from 1 to 4 independently selected R c L 3 -heteroaryl independently selected from the group consisting of: R a Each occurrence of -OH; -SH; -F; -Cl; -Br; -NR e R f ;C 1~4 Alkoxy;C 1~4 Haloalkoxy; -C(=O)O(C 1~4 alkyl);-C(=O)(C 1~4 alkyl);-C(=O)OH;-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 0~2 (C 1~4 alkyl; cyano; -NR'C(=NR')NR'R''; and 1 to 4 independently selected R b C may be substituted 3~6 independently selected from the group consisting of cycloalkyl; R b Each occurrence of -OH; -SH; -F; -Cl; -Br; -NR e R f ;C 1~4 Alkyl;C 1~4 Haloalkyl;C 1~4 Alkoxy;C 1~4 Haloalkoxy; -C(=O)O(C 1~4 alkyl);-C(=O)(C 1~4 alkyl;-C(=O)OH;-CON(R')(R'');oxo;-S(O) 1~2 (NR'R'');-S(O) 0~2 (C 1~4 alkyl; cyano; -NR'C(=NR')NR'R''; and 1 to 4 independently selected C 1~4C optionally substituted by alkyl 3~6 independently selected from the group consisting of cycloalkyl; R c Each occurrence of -OH; -SH; -F; -Cl; -Br; -NR e R f ;C 1~4 Alkyl;C 1~4 Haloalkyl;C 1~4 Alkoxy;C 1~4 Haloalkoxy; -C(=O)O(C 1~4 alkyl);-C(=O)(C 1~4 alkyl);-C(=O)OH;-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 0~2 (C 1~4 alkyl; cyano; -NR'C(=NR')NR'R''; and 1 to 4 independently selected C 1~4 C optionally substituted by alkyl 3~6 independently selected from the group consisting of cycloalkyl; R d Each occurrence of H;C 1~6 Alkyl;C 3~6 Cycloalkyl; -C(O)(C 1~4 alkyl);-C(O)O(C 1~4 alkyl);-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 1~2 (C 1~4 alkyl);-OH; and C 1~4 alkoxy; R e and R f Each occurrence of H;C 1~6 Alkyl;C 3~6 Cycloalkyl; -C(O)(C 1~4 alkyl);-C(O)O(C 1~4 alkyl);-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 1~2 (C 1~4 alkyl);-OH; and C 1~4 alkoxy; and Each occurrence of R' and R'' is H and C1~4 alkyl, or R′ and R″ taken together with the nitrogen atom to which they are each attached form a ring containing 3 to 8 ring atoms, wherein the ring is selected from the group consisting of: (a) H and C 1~3 (b) N(R d ), O, and S; R d1 Each occurrence of H;C 1~6 Alkyl;C 3~6 Cycloalkyl; -C(O)(C 1~4 alkyl);-C(O)O(C 1~4 alkyl);-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 1~2 (C 1~4 alkyl);-OH; and C 1~4 alkoxy or -C(=O)CH(R 2 )N(R d1 )-group R 2 and R d1 are linked to form a ring containing 5 to 8 ring atoms as defined above; and L in each occurrence 2 and L 3 each independently represents a bond, or oxo and R a C which may be substituted by 1 to 3 substituents independently selected from 1 ~C 6 is alkylene, The compound. [The present invention 1004] A 1 is 1 to 4 (e.g., 1, 2 to 3, 3 to 4, 2, 3, or 4) independently selected R 1 C is inserted 4 ~C 8 (For example, C 4 ~C 6 ) alkylene. [The present invention 1005] One R 1 are independently -C(=O)CH(R 2 )N(R d1 )-or-N(R 3 )-(e.g., one R 1 -C(=O)CH(R 2 )N(Rd1 )-) and other R 1 Each of the groups is -N(R d1 )-, (C=O), -O-, S(O) p , -C(=O)CH(R 2 )N(R d1 )-, and -C(=O)CH(R 2 )CH 2 N(R d1 1004. A compound of the present invention, independently selected from the group consisting of: [The present invention 1006] Formula (Ib): TIFF0007595576000006.tif21128 A compound of the formula: During the ceremony, B 1 and B. 2 Each of the -Z 1 -Z 2 -Z 3 where: ·Z 1 However, 1 to 4 R a C may be substituted 1~3 is alkylene; ·Z 2 is a bond, -N(R d )-, -O-, or -S-; and ·Z 3 H, halo, or 1-4 R a C may be substituted 1~7 is alkyl; E 1 、F 1 、G 1 、H 1 、J 1 、L 1 、M 1 , and Q1 Each of ·Join; 1 to 3 R a C may be substituted 1 ~C 6 alkylene; and ·R 1 more independently selected; R 1 Each occurrence of -N(R d1 )-; -N(R 3 )-; ·-O-; S(O) where p is 0, 1, or 2 p ; ·C(=O); ·C(=S); ·CHR 2 ; ·C(R 2 ) 2 ; -C(=O)CH(R 2 )N(R d1 )-; and -C(=O)CH(R 2 )CH 2 N(R d1 )- independently selected from the group consisting of: However, E 1 and F 1 At least one of the following has 1 to 3 R a C may be substituted 1 ~C 6 Alkylene, where F 1 、G 1 、H 1、J 1 、L 1 , and M. 1 R, in which 1 to 4 are independently selected 1 and; R 2 Each occurrence of (i)R a ; (ii) 1 to 3 R a C may be substituted 1 ~C 6 Alkyl; (iii) heterocyclyl contains 3 to 10 ring atoms, 1 to 3 of which are N(R d ), O, and S, and one or more of the heterocyclyl ring carbon atoms are selected from 1 to 4 independently selected R b L 2 -heterocyclyl; (iv) 1 to 4 R c L may be substituted by 2 -C 6 ~C 10 Aryl; (v) Heteroaryl contains 5 to 10 ring atoms, 1 to 4 of which are N, N(R d ), O, and S, and one or more of the heteroaryl ring carbon atoms are selected from 1 to 4 independently selected R c L 2 -heteroaryl; and (vi) H or (vii) -C(=O)CH(R 2 )N(R d1 )-group R 2 and R d1 are linked to form a ring containing 5 to 8 ring atoms, wherein the ring is 1~3 A ring having 3 to 6 ring carbon atoms (CH(R 2 ) plus;(b) N(R d1 0 to 3 ring heteroatoms (R d1 In addition to the nitrogen atom bonded to R 3 Each occurrence of (i) 1 to 3 R a C may be substituted 1 ~C 6 Alkyl; (ii) heterocyclyl contains 3 to 10 ring atoms, 1 to 3 of which are N(R d ), O, and S, and one or more of the heterocyclyl ring carbon atoms are selected from 1 to 4 independently selected R b L 3 -heterocyclyl; (iii) 1 to 4 R c L may be substituted by 3 -C 6 ~C 10 Aryl; and (iv) Heteroaryl contains 5 to 10 ring atoms, 1 to 4 of which are N, N(R d ), O, and S, and one or more of the heteroaryl ring carbon atoms are selected from 1 to 4 independently selected R c L 3 -heteroaryl independently selected from the group consisting of: R a Each occurrence of -OH; -SH; -F; -Cl; -Br; -NR e R f ;C 1~4 Alkoxy;C 1~4 Haloalkoxy; -C(=O)O(C 1~4 alkyl);-C(=O)(C 1~4 alkyl);-C(=O)OH;-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 0~2 (C 1~4 alkyl; cyano; -NR'C(=NR')NR'R''; and 1 to 4 independently selected R b C may be substituted 3~6 independently selected from the group consisting of cycloalkyl; R b Each occurrence of -OH; -SH; -F; -Cl; -Br; -NR e R f ;C 1~4 Alkyl;C 1~4 Haloalkyl;C 1~4 Alkoxy;C 1~4 Haloalkoxy; -C(=O)O(C 1~4 alkyl);-C(=O)(C 1~4 alkyl;-C(=O)OH;-CON(R')(R'');oxo;-S(O)1~2 (NR'R'');-S(O) 0~2 (C 1~4 alkyl; cyano; -NR'C(=NR')NR'R''; and 1 to 4 independently selected C 1~4 C optionally substituted by alkyl 3~6 independently selected from the group consisting of cycloalkyl; R c Each occurrence of -OH; -SH; -F; -Cl; -Br; -NR e R f ;C 1~4 Alkyl;C 1~4 Haloalkyl;C 1~4 Alkoxy;C 1~4 Haloalkoxy; -C(=O)O(C 1~4 alkyl);-C(=O)(C 1~4 alkyl);-C(=O)OH;-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 0~2 (C 1~4 alkyl; cyano; -NR'C(=NR')NR'R''; and 1 to 4 independently selected C 1~4 C optionally substituted by alkyl 3~6 independently selected from the group consisting of cycloalkyl; R d Each occurrence of HC 1~6 Alkyl;C 3~6 Cycloalkyl; -C(O)(C 1~4 alkyl);-C(O)O(C 1~4 alkyl);-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 1~2 (C 1~4 alkyl);-OH; and C 1~4 alkoxy; R e and R f Each occurrence of H;C 1~6 Alkyl;C 3~6 Cycloalkyl; -C(O)(C 1~4 alkyl);-C(O)O(C 1~4 alkyl);-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 1~2(C 1~4 alkyl);-OH; and C 1~4 alkoxy; and Each occurrence of R' and R'' is H and C 1~4 alkyl, or R′ and R″ taken together with the nitrogen atom to which they are each attached form a ring containing 3 to 8 ring atoms, wherein the ring is selected from the group consisting of: (a) H and C 1~3 (b) N(R d ), O, and S; R d1 Each occurrence of H;C 1~6 Alkyl;C 3~6 Cycloalkyl; -C(O)(C 1~4 alkyl);-C(O)O(C 1~4 alkyl);-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 1~2 (C 1~4 alkyl);-OH; and C 1~4 alkoxy or -C(=O)CH(R 2 )N(R d1 )-group R 2 and R d1 are linked to form a ring containing 5 to 8 ring atoms as defined above; and L in each occurrence 2 and L 3 each independently represents a bond, or an oxo and R a C which may be substituted by 1 to 3 substituents independently selected from 1 ~C 6 is alkylene, The compound, or a pharma- ceutically acceptable salt thereof. [The present invention 1007] H 1 or J 1 One of the groups is -C(=O)CH(R 2 )N(R d1 )-, the compound of the present invention 1006. [The present invention 1008] E 1 and Q 1 Each of 1 to 3 Ra and independently selected C, which may be substituted by 1 ~C 6 Alkylene (e.g., C 2~4 Alkylene, e.g., unsubstituted C 2~4 Alkylene) The compound of the present invention 1006 or 1007, [The present invention 1009] F 1 But -N(R d1 )-(for example, -N(H)-), -O-, or -S-. [The present invention 1010] Formula II: TIFF0007595576000007.tif27128 or a pharma- ceutically acceptable salt thereof, During the ceremony, E 1 and Q 1 Each of 1 to 3 R a and independently selected C, which may be substituted by 1 ~C 6 Alkylene (e.g., C 2~4 Alkylene, e.g., unsubstituted C 2~4 Alkylene) and; F 1 But -N(R d1 )-(e.g., -N(H)-), -O-, or -S-; and H 1 、G 1 、L 1 , and M. 1 Each of ·Join; -N(R d1 )-; ·-O-; S(O) where p is 0, 1, or 2 p ; ·C(=O); ·C(=S); ·CHR 2 ; -C(=O)CH(R 2 )N(R d1 )-; and -C(=O)CH(R 2 )CH 2 N(R d1 )- More independently selected, The compound of the present invention 1006. [The present invention 1011] L 1 and M. 1 The compound of the present invention, wherein each of is a bond. [The present invention 1012] G 1 and H 1 The compound of any of claims 1010 to 1011, wherein each of is a bond. [The present invention 1013] F 1 -N(R d )-(e.g., NH). [The present invention 1014] Formula II-a: TIFF0007595576000008.tif24128 or a pharma- ceutically acceptable salt thereof. [The present invention 1015] G 1 S(O) p and p is 1 or 2. [The present invention 1016] F 1 The compound of the present invention 1015, wherein is -O-. [The present invention 1017] H 1 -N(R d1 )-(e.g., NH). [The present invention 1018] Formula II-b: TIFF0007595576000009.tif24128 or a pharma- ceutically acceptable salt thereof. [The present invention 1019] L 1 -C(=O)CH(R 2 )(CH 2 )N(R d1 )-, the compound of the present invention 1010. [The present invention 1020] M 1 、G 1 , and H 1 The compound of any of claims 1010 and 1019, wherein each of is a bond. [The present invention 1021] F 1 is -O- or -N(R d1 )-, any one of the compounds of the present invention 1019 to 1020. [The present invention 1022] Formula (II-c1) or (II-c2): TIFF0007595576000010.tif59128 or a pharma- ceutically acceptable salt thereof. [The present invention 1023] L 1 The compound of the present invention 1010, wherein is C(=O). [The present invention 1024] M 1 、G 1 , and H 1 The compound of any of claims 1010 and 1023, wherein each of is a bond. [The present invention 1025] F 1 is -O- or -N(R d1 )-, any one of compounds 1010 and 1023 to 1024 of the present invention. [The present invention 1026] Formula (II-d): TIFF0007595576000011.tif24128 or a pharma- ceutically acceptable salt thereof, [The present invention 1027] L 1 -C(=O)CH(R 2 )N(R d1 )-, the compound of the present invention 1010. [The present invention 1028] M 1 、G 1 , and H 1 The compound of any of claims 1010 and 1027, wherein each of is a bond. [The present invention 1029] F 1 is -O- or -N(R d1 )-(for example, -N(H)-), [The present invention 1030] Formula (II-e): TIFF0007595576000012.tif25128 or a pharma- ceutically acceptable salt thereof, [The present invention 1031] The following formula: TIFF0007595576000013.tif21128 The compound of the present invention, wherein [The present invention 1032] H 1 and J. 1 One of the -N(R 3 )-or-N(R d1 )-, the compound of the present invention 1006. [The present invention 1033] Formula (III): TIFF0007595576000014.tif21128 or a pharma- ceutically acceptable salt thereof. [The present invention 1034] E 1 and Q 1 Each of 1 to 3 R a and independently selected C, which may be substituted by 1 ~C 6 Alkylene (e.g., C 2 ~C 4 Alkylene, C 2 ~C 3 Alkylene, C 2 Alkylene, e.g., unsubstituted C 2 Alkylene) The compound of any one of 1006 and 1032 to 1033 of the present invention, [The present invention 1035] F 1 and M. 1 The compound of any one of 1006 and 1032 to 1034, wherein each of is a bond. [The present invention 1036] G 1 and L 1 Each of ·Join; ·-O-; S(O) where p is 0, 1, or 2 p ; ·C(=O); ·C(=S); ·CHR 2 ; -C(=O)CH(R 2 )N(R d1 )-; and -C(=O)CH(R 2 )CH 2 N(R d1 )- The compound of any one of 1006 and 1032 to 1035 of the present invention, independently selected from the following: [The present invention 1037] G 1 and L 1 The compound of any one of 1006 and 1032 to 1036, wherein each of is a bond. [The present invention 1038] H 1 The compound of any one of 1006 and 1032 to 1037 according to the present invention, wherein [The present invention 1039] H1 The compound according to any one of claims 1006 and 1032 to 1037, wherein is C(=O). [The present invention 1040] R 2 Each occurrence of ·H; -NH 2 , -OH, -SH, -SMe, -NH(C=NH)NH 2 , CO 2 H, and CO 2 NH 2 C which may be substituted by 1 to 2 substituents selected from 1 ~C 6 Alkyl; may be substituted with 1 to 2 -OH (C 1 ~C 6 Alkylene)-phenyl; ·(C 1 ~C 6 alkylene)-indolyl; and ·(C 1 ~C 6 Alkylene)-imidazolyl More independently selected, or -CH(R 2 )N(R d1 )-group R 2 and R d1 are linked to form a pyrrolidine ring, Any of the compounds of the present invention 1003 to 1039. [The present invention 1041] R 2 Each occurrence of ·H; -NH 2 , -OH, -NH(C=NH)NH 2 , CO 2 H, and CO 2 NH 2 C which may be substituted by 1 to 2 substituents selected from 1 ~C 6 Alkyl; and ·(C 1 ~C 6 (alkylene)-imidazolyl The compound of any one of 1003 to 1040 of the present invention, independently selected from the following: [The present invention 1042] R 2 Each occurrence of ·H; TIFF0007595576000015.tif59133 The compound of any one of 1003 to 1041 of the present invention, independently selected from the following: [The present invention 1043] R 3 Each occurrence of -NH 2 , -OH, -SH, -SMe, -NH(C=NH)NH 2 , CO 2 H, and CO 2 NH 2 C which may be substituted by 1 to 2 substituents selected from 1 ~C 6 Alkyl; may be substituted with 1 to 2 -OH (C 1 ~C 6 (alkylene)-phenyl; ·(C 1 ~C 6 alkylene)-indolyl; and ·(C 1 ~C 6 (alkylene)-imidazolyl The compound of any one of 1003 to 1042 of the present invention, independently selected from the following: [The present invention 1044] R 3 Each occurrence of -NH 2 , -OH, -NH(C=NH)NH 2 , CO 2 H, and CO 2 NH 2 C which may be substituted by 1 to 2 substituents selected from 1 ~C 6 Alkyl; and ·(C 1 ~C 6 (alkylene)-imidazolyl The compound of any one of 1003 to 1043 of the present invention, independently selected from the following: [The present invention 1045] R 3 Each occurrence of TIFF0007595576000016.tif61133 The compound of any one of 1003 to 1044 of the present invention, independently selected from the following: [The present invention 1046] R 3 Each occurrence of TIFF0007595576000017.tif15128 Any of the compounds of 1003 to 1045 of the present invention, independently selected from the following: [The present invention 1047] R 3 Each occurrence of L 3 -heterocyclyl, where the heterocyclyl contains 3 to 10 ring atoms and 1 to 3 ring atoms are selected from N(R d ), O, and S, and one or more of the heterocyclyl ring carbon atoms are selected from 1 to 4 independently selected R b The compound of any one of 1003 to 1042 of the present invention, which may be substituted by [The present invention 1048] R 3 Each occurrence of L 3 -heterocyclyl, where the heterocyclyl contains 4 to 6 (e.g., 5 to 6) ring atoms and 1 to 3 ring atoms are selected from N(R d ), O, and S, and one or more of the heterocyclyl ring carbon atoms are selected from 1 to 2 independently selected R b The compound of the present invention 1047 may be optionally substituted by (eg, heterocyclyl may be pyrrolidinyl, piperidinyl, or morpholinyl). [The present invention 1049] L 3 The compound of any one of 1047 to 1048, wherein is a bond. [The present invention 1050] L 3 is 1 to 3 independently selected R a C, which may be substituted (e.g., unsubstituted) 1~6 The compound of any one of 1047 to 1048, which is alkyl. [The present invention 1051] L 3 is substituted by one oxo 1~6 (For example, C 1~4 ) alkylene (e.g., TIFF0007595576000018.tif16128 (which may be any one of the compounds of the present invention Nos. 1047 to 1048). [The present invention 1052] R 3 but, TIFF0007595576000019.tif26128 The compound of any one of claims 1047 to 1048, selected from the following: [The present invention 1053] B 1 and B. 2 Each of the -Z 1 -Z 3 (i.e., Z 2 is a bond), any one of the compounds of 1001 to 1052 according to the present invention. [The present invention 1054] Z 3 H, halo, or C 1~3 The compound of any one of 1001 to 1053 of the present invention, which is alkyl. [The present invention 1055] Z 1 is 1 to 3 independently selected R a C may be substituted 1~3 The compound of any one of 1001 to 1054 of the present invention, which is alkylene. [The present invention 1056] B 1 and B. 2 Each of the 3 , C.H.R. a , CH(R a ) 2 , and C(R a ) 2 - The compound of any one of 1001 to 1055 of the present invention, independently selected from halo. [The present invention 1057] B 1 and B. 2 Each of the 3 , CHF 2 , C.H. 2 F, and CF 3 The compound of any one of 1001 to 1056 of the present invention, independently selected from the following: [The present invention 1058] R d1 Each occurrence of H;C 1~6 Alkyl;C 3~6 Cycloalkyl; -C(O)(C 1~4 alkyl);-C(O)O(C 1~4 alkyl);-CON(R')(R'');-S(O) 1~2 (NR'R''); and -S(O) 1~2 (C 1~4 alkyl), or -C(=O)CH(R 2 )N(R d1 )-group R 2 and R d1 are linked to form a ring containing 5 to 8 ring atoms as defined above. [The present invention 1059] R d1 Each occurrence of H;C 1~6 Alkyl; and C 3~6 The compound of any one of 1003 to 1058 of the present invention, independently selected from the group consisting of cycloalkyl. [The present invention 1060] R d1 Each occurrence of is H. [The present invention 1061] TIFF0007595576000020.tif116128TIFF0007595576000021.tif190128TIFF0007595576000022.tif210128TIFF0007595576000023.tif218128TIFF0007595576000024.tif33128 or a pharma- ceutically acceptable salt thereof. [The present invention 1062] A pharmaceutical composition comprising any one of the compounds of the present invention 1001 to 1061 or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable excipient. [The present invention 1063] administering to the cornea of a subject in need thereof any of the compounds of the present invention 1001-1061 or the pharmaceutical composition of the present invention 1062; and exposing the cornea to electromagnetic radiation, thereby causing cross-linking in the cornea. 16. A method for administering treatment to a cornea of an eye, comprising: [The present invention 1064] The method of claim 1063, used to treat one or more corneal ectatic disorders. [The present invention 1065] The method of claim 1064, wherein the one or more corneal ectatic disorders are selected from the group consisting of keratoconus, keratoglobus, pellucid marginal degeneration, post-operative ectasia, and Therrien's peripheral corneal degeneration. [The present invention 1066] The method of claim 10, wherein the corneal ectatic disorder is keratoconus (e.g., progressive keratoconus). [The present invention 1067] The method of claim 1065, wherein the corneal ectasia disorder is post-operative ectasia (e.g., post-LASIK ectasia). [The present invention 1068] The method of claim 1063, used to treat a visual condition selected from the group consisting of myopia, hyperopia, astigmatism, irregular astigmatism, and presbyopia. [The present invention 1069] The method of any of claims 1063 to 1068, wherein said compound or said composition is administered directly to said cornea (ie, without removing the corneal epithelium). [The present invention 1070] The method of any one of claims 1063 to 1069, wherein the electromagnetic radiation comprises ultraviolet light (e.g., UV-A light). [The present invention 1071] The method of any one of claims 1063 to 1070, wherein the electromagnetic radiation is laser radiation. [The present invention 1072] 1072. The method of any one of claims 1070 to 1071, wherein the duration of radiation is 1 to 60 minutes. [The present invention 1073] The method according to any one of claims 1063 to 1072, wherein the radiation has a wavelength of 350 to 380 nm (for example, 360 to 370 nm). [The present invention 1074] The irradiance of the electromagnetic radiation is 0.1 to 100 mW / cm 2 The method of any one of claims 1063 to 1073, [The present invention 1075] The method of any one of claims 1063 to 1074, further comprising the step of administering additional crosslinking agent to the cornea. [The present invention 1076] The method of claim 1075, wherein said additional cross-linking agent is selected from the group consisting of riboflavin, 2,3-butanedione, folic acid, quinoxaline, quinoline, dibucaine, methotrexate, menadione, and verteporfin, and derivatives thereof. [The present invention 1077] The method of any one of claims 1063 to 1076, further comprising the step of administering to the subject's cornea one or more additional substances different from the crosslinking agent. [The present invention 1078] The method of claim 1077, wherein the additive substance is selected from the group consisting of iron, copper, manganese, chromium, vanadium, aluminum, cobalt, mercury, cadmium, nickel, arsenic, 2,3-butanedione, and folic acid. [The present invention 1079] The method of any one of claims 1063 to 1078, further comprising the step of administering to the subject an additional ophthalmic therapeutic agent for inflammation, cataract, or lens disorder. The details of one or more aspects of the invention are set forth in the following description and the accompanying appendix, which are expressly incorporated into this disclosure. Other features and advantages will become apparent from the claims. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0047] Detailed Description The present disclosure features a chemical entity (e.g., a compound, or a pharma- ceutically acceptable salt and / or hydrate and / or prodrug of the compound) that produces crosslinks in the cornea in response to exposure to electromagnetic radiation. The present disclosure also features compositions containing the chemical entity, as well as other methods of using and making the chemical entity. The chemical entity is useful, for example, to treat a subject (e.g., a human) having a disease, disorder, or condition in which an abnormal shape of the cornea (e.g., corneal thinning, e.g., bilateral corneal thinning, e.g., central, paracentral, or peripheral corneal thinning; or corneal steepening (e.g., ridged)) contributes to the pathology and / or symptoms and / or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include (i) corneal ectasia disorders, (ii) visual conditions, and (iii) diseases, disorders, or conditions that are sequelae or comorbidities of any of the foregoing or any of those disclosed herein. More specific non-limiting examples of such diseases, disorders, or conditions include keratoconus, keratoglobus, Pelusid marginal corneal degeneration, corneal ectasia (e.g., post-operative ectasia, e.g., post-LASIK ectasia), Therrien peripheral corneal degeneration, myopia, hyperopia, astigmatism, irregular astigmatism, and presbyopia. In some embodiments, the claimed methods can be performed in the absence of added and supplemented oxygen levels, which can be advantageous in some applications.
[0048] Compounds of formula (I) In one aspect, the present disclosure provides a compound of formula (I): or a pharma- ceutically acceptable salt thereof, During the ceremony, L A and L B each independently represents 1 to 3 R a is a C1-C5 alkylene optionally substituted by A is a moiety that enhances delivery of the compound to the corneal stroma (e.g., through an intact corneal epithelium) and / or enhances binding of the compound to corneal collagen; B 1 and B.2 Each of the -Z 1 -Z 2 -Z 3 where: Z 1 is 1 to 4 R a C may be substituted 1~3 is alkylene; Z 2 is a bond, -N(R d )-, -O-, or -S-; and Z 3 is halo, H, or 1-4 R a C may be substituted 1~7 is alkyl; R a Each occurrence of is -OH; -SH; -F; -Cl; -Br; -NR e R f ;C 1~4 Alkoxy;C 1~4 Haloalkoxy; -C(=O)O(C 1~4 alkyl);-C(=O)(C 1~4 alkyl);-C(=O)OH;-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 0~2 (C 1~4 alkyl; cyano; -NR'C(=NR')NR'R''; and 1 to 4 independently selected R b C may be substituted 3~6 independently selected from the group consisting of cycloalkyl; R b Each occurrence of is -OH; -SH; -F; -Cl; -Br; -NR e R f ;C 1~4 Alkyl;C 1~4 Haloalkyl;C 1~4 Alkoxy;C 1~4 Haloalkoxy; -C(=O)O(C 1~4 alkyl);-C(=O)(C 1~4 alkyl;-C(=O)OH;-CON(R')(R'');oxo;-S(O) 1~2 (NR'R'');-S(O) 0~2 (C 1~4alkyl; cyano; -NR'C(=NR')NR'R''; and 1 to 4 independently selected C 1~4 C optionally substituted by alkyl 3~6 independently selected from the group consisting of cycloalkyl; R d Each occurrence of H;C 1~6 Alkyl;C 3~6 Cycloalkyl; -C(O)(C 1~4 alkyl);-C(O)O(C 1~4 alkyl);-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 1~2 (C 1~4 alkyl);-OH; and C 1~4 alkoxy; R e and R f Each occurrence of H;C 1~6 Alkyl;C 3~6 Cycloalkyl; -C(O)(C 1~4 alkyl);-C(O)O(C 1~4 alkyl);-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 1~2 (C 1~4 alkyl);-OH; and C 1~4 alkoxy; and Each occurrence of R' and R'' is H and C 1~4 alkyl, or R' and R'' taken together with the nitrogen atom to which they are each attached form a ring containing 3 to 8 ring atoms, wherein the ring is selected from the group consisting of: (a) H and C 1~3 (b) N(R d and 0 to 3 ring heteroatoms (in addition to the nitrogen atom bonded to R′ and R″) each independently selected from the group consisting of , O, and S.
[0049] Variable symbol A In some embodiments of Formula (I), A is a moiety that enhances delivery of the compound to the corneal stroma (e.g., through an intact corneal epithelium) and / or enhances binding of the compound to corneal collagen.
[0050] In some embodiments of formula (I), A is a moiety that enhances delivery of the compound to the corneal stroma through the intact corneal epithelium and / or enhances binding of the compound to corneal collagen.
[0051] In some embodiments of Formula (I), A is a moiety (eg, a small molecule moiety) that is capable of penetrating corneal epithelial cells.
[0052] In some embodiments, A is a peptide moiety.
[0053] In certain embodiments, A is L at the N-terminus. A , and L at the C-terminus B In certain other embodiments of formula (I), A is linked at the C-terminus to L A , and L at the N-terminus B is bound to.
[0054] In certain embodiments, A is a peptide moiety derived from a decorin sequence that binds to collagen. In certain of the aforementioned embodiments, A is a peptide moiety derived from a decorin sequence that binds to type I collagen (e.g., A is a peptide moiety derived from the decorin sequence SYIRIADTNIT reported in J.Biol.Chem.2007,282,16062, the entirety of which is incorporated herein by reference). As a non-limiting example of the aforementioned embodiment, A can include a peptide moiety of the sequence RIAD.
[0055] In certain embodiments, A is a peptide moiety derived from an asporin sequence (e.g., A is a peptide moiety derived from the asporin sequence HIRIAEAKLT reported in J. Biol. Chem. 2007, 282, 16062, the entirety of which is incorporated herein by reference). As a non-limiting example of the foregoing embodiment, A can be a peptide moiety of the sequence RIAE.
[0056] In certain embodiments, A is a peptide moiety derived from a biglycan sequence (e.g., A is a peptide moiety derived from the asporin sequence NYLRISEAKLT, reported in J. Biol. Chem. 2007, 282, 16062, the entirety of which is incorporated herein by reference).
[0057] In certain embodiments, A is a moiety that binds to lumican and / or fibromodulin.
[0058] Variable symbol L A and L B In some embodiments of Formula (I), L A and L B each independently represents 1 to 3 R a is a C1 to C3 alkylene optionally substituted by
[0059] In certain of the above embodiments, L A and L B Each of the groups independently comprises one or more R a is a C1 to C3 alkylene optionally substituted by
[0060] As a non-limiting example of the above embodiment, L A and L B Each of is independently an unsubstituted C1-C3 alkylene (e.g., an unsubstituted C 2~3 alkylene; for example, unsubstituted ethylene or propylene).
[0061] Variable symbol B 1 and B. 2 In some embodiments of formula (I), B 1 and B. 2 Each of the -Z 1 -Z 3 (i.e., Z 2 is a bond).
[0062] In some embodiments of Formula (I), Z 3is H, halo, or C 1~3 It is an alkyl.
[0063] In some embodiments of Formula (I), Z 3 is H or C 1~3 Alkyl (e.g., Z 3 can be H).
[0064] In some embodiments of Formula (I), Z 3 is a halo (e.g., Z 3 can be F).
[0065] In some embodiments of Formula (I), Z 1 is 1 to 3 independently selected R a C may be substituted 1~3 Alkylene (e.g., Z 1 can be methylene, CHF, or CF2).
[0066] In certain embodiments, Z 1 is unsubstituted C 1~3 Alkylene (eg, CH2).
[0067] In certain embodiments, Z 1 is unsubstituted C 1~3 alkylene, Z 3 is H.
[0068] In certain embodiments, Z 1 is C substituted by 1 to 2 independently selected halo (e.g., F); 1~3 It is alkylene.
[0069] In certain embodiments, B 1 and B. 2 Each of the a , CH(R a )2, and C(R a ) 2-halo.
[0070] As a non-limiting example of the above embodiment, B 1 and B.2 Each of may independently be CH3, CHF2, CH2F, and CF3 (e.g., CH3).
[0071] Compounds of formula (Ia) In another aspect, the present disclosure provides a compound of formula (Ia): Compound TIFF0007595576000026.tif19128 is featured, During the ceremony, A 1 is 1 to 10 (e.g., 1 to 5, 1 to 4, 1 to 3, 1 to 2, 1) R 1 C2~C are inserted 20 is alkylene; B 1 and B. 2 Each of the -Z 1 -Z 2 -Z 3 where: Z 1 is 1 to 4 R a C may be substituted 1~3 is alkylene; Z 2 is a bond, -N(R d )-, -O-, or -S-; and Z 3 is halo, H, or 1-4 R a C may be substituted 1~7 is alkyl; R 1 Each occurrence of -N(R d1 )-; -N(R 3 )-; ·-O-; S(O) where p is 0, 1, or 2 p ; ·C(=O); ·C(=S); ·CHR 2 ; ·C(R 2 )2; -C(=O)CH(R 2 )N(R d1 )-; and -C(=O)CH(R 2 )CH2N(R d1 )- are more independently selected divalent groups; R 2 Each occurrence of (i)R a ; (ii) 1 to 3 R a C1-C6 alkyl optionally substituted by; (iii) heterocyclyl contains 3 to 10 ring atoms, 1 to 3 of which are N(R d ), O, and S, and one or more of the heterocyclyl ring carbon atoms are selected from 1 to 4 independently selected R b L 2 -heterocyclyl; (iv) 1 to 4 R c L may be substituted by 2 -C6~C 10 Aryl; (v) Heteroaryl contains 5 to 10 ring atoms, 1 to 4 of which are N, N(R d ), O, and S, and one or more of the heteroaryl ring carbon atoms are selected from 1 to 4 independently selected R c L 2 -heteroaryl; and (vi) H or (vii) -C(=O)CH(R 2 )N(R d1 )-group R 2 and R d1 are linked to form a ring containing 5 to 8 ring atoms, where the ring is composed of (a) H and C 1~3 A ring having 3 to 6 ring carbon atoms (CH(R 2 ) plus;(b) N(R d10 to 3 ring heteroatoms (R d1 In addition to the nitrogen atom bonded to R 3 Each occurrence of (i) 1 to 3 R a C1-C6 alkyl optionally substituted by; (ii) heterocyclyl contains 3 to 10 ring atoms, 1 to 3 of which are N(R d ), O, and S, and one or more of the heterocyclyl ring carbon atoms are selected from 1 to 4 independently selected R b L 3 -heterocyclyl; (iii) 1 to 4 R c L may be substituted by 3 -C6~C 10 Aryl; and (iv) Heteroaryl contains 5 to 10 ring atoms, 1 to 4 of which are N, N(R d ), O, and S, and one or more of the heteroaryl ring carbon atoms are selected from 1 to 4 independently selected R c L 3 -heteroaryl independently selected from the group consisting of: R a Each occurrence of is -OH; -SH; -F; -Cl; -Br; -NR e R f ;C 1~4 Alkoxy;C 1~4 Haloalkoxy; -C(=O)O(C 1~4 alkyl);-C(=O)(C 1~4 alkyl);-C(=O)OH;-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 0~2 (C 1~4 alkyl; cyano; -NR'C(=NR')NR'R''; and 1 to 4 independently selected R bC may be substituted 3~6 independently selected from the group consisting of cycloalkyl; R b Each occurrence of is -OH; -SH; -F; -Cl; -Br; -NR e R f ;C 1~4 Alkyl;C 1~4 Haloalkyl;C 1~4 Alkoxy;C 1~4 Haloalkoxy; -C(=O)O(C 1~4 alkyl);-C(=O)(C 1~4 alkyl;-C(=O)OH;-CON(R')(R'');oxo;-S(O) 1~2 (NR'R'');-S(O) 0~2 (C 1~4 alkyl; cyano; -NR'C(=NR')NR'R''; and 1 to 4 independently selected C 1~4 C optionally substituted by alkyl 3~6 independently selected from the group consisting of cycloalkyl; R c Each occurrence of is -OH; -SH; -F; -Cl; -Br; -NR e R f ;C 1~4 Alkyl;C 1~4 Haloalkyl;C 1~4 Alkoxy;C 1~4 Haloalkoxy; -C(=O)O(C 1~4 alkyl);-C(=O)(C 1~4 alkyl);-C(=O)OH;-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 0~2 (C 1~4 alkyl; cyano; -NR'C(=NR')NR'R''; and 1 to 4 independently selected C 1~4 C optionally substituted by alkyl 3~6 independently selected from the group consisting of cycloalkyl; R d Each occurrence of H;C 1~6 Alkyl;C 3~6 Cycloalkyl; -C(O)(C 1~4 alkyl);-C(O)O(C1~4 alkyl);-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 1~2 (C 1~4 alkyl);-OH; and C 1~4 alkoxy; R e and R f Each occurrence of H;C 1~6 Alkyl;C 3~6 Cycloalkyl; -C(O)(C 1~4 alkyl);-C(O)O(C 1~4 alkyl);-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 1~2 (C 1~4 alkyl);-OH; and C 1~4 alkoxy; and Each occurrence of R' and R'' is H and C 1~4 alkyl, or R' and R'' taken together with the nitrogen atom to which they are each attached form a ring containing 3 to 8 ring atoms, wherein the ring is selected from the group consisting of: (a) H and C 1~3 (b) N(R d ), O, and S; R d1 Each occurrence of H;C 1~6 Alkyl;C 3~6 Cycloalkyl; -C(O)(C 1~4 alkyl);-C(O)O(C 1~4 alkyl);-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 1~2 (C 1~4 alkyl);-OH; and C 1~4 alkoxy or -C(=O)CH(R 2 )N(R d1 )-group R 2and R d1 are linked to form a ring containing 5 to 8 ring atoms as defined above; and L in each occurrence 2 and L 3 each independently represents a bond, or an oxo and R a and C1 to C6 alkylene optionally substituted by 1 to 3 substituents independently selected from the above.
[0072] Variable symbol A 1 In some embodiments of Formula (Ia), A 1 is 1 to 4 (e.g., 1, 2 to 3, 3 to 4, 2, 3, or 4) independently selected R 1 It is a C4-C8 alkylene with an inserted radical.
[0073] In certain embodiments, A 1 is 1 to 4 (e.g., 1, 2 to 3, 3 to 4, 2, 3, or 4) independently selected R 1 It is a C4-C6 alkylene with an inserted radical.
[0074] In certain embodiments, A 1 is one independently selected R 1 is inserted.
[0075] In certain embodiments, A 1 is 2 to 3 (e.g., 2 or 3) independently selected R 1 is inserted.
[0076] In certain embodiments, A 1 is 3 to 4 (e.g., 3 or 4) independently selected R 1 is inserted.
[0077] In certain embodiments, A 1 is 1 to 3 independently selected R 1 is inserted.
[0078] In certain embodiments, A 1 is 2 to 4 independently selected R 1 is inserted.
[0079] Variable symbol R 1 In some embodiments of formula (Ia), one R 1 are independently -C(=O)CH(R 2 )N(R d1 )-, or -N(R 3 )-(e.g., one R 1 is -C(=O)CH(R 2 )N(R d1 )- or one R 1 -N(R 3 )-is).
[0080] In certain of the above embodiments, other R 1 Each of the groups is -N(R d1 )-, (C=O), -O-, S(O) p , -C(=O)CH(R 2 )N(R d1 )-, and -C(=O)CH(R 2 )CH2N(R d1 )-.
[0081] As a non-limiting example of the above embodiment, other R 1 Each of the groups is -N(H)-, (C=O), -O-, S(O)2, -C(=O)CH(R 2 )N(H)-, and -C(=O)CHCHN(H)-.
[0082] Variable symbol R 2 and R 3 In some embodiments of Formula (Ia), R 2 is H.
[0083] In some embodiments of Formula (Ia), R 2 1 to 3 R a is C1-C6 alkyl optionally substituted by
[0084] In certain embodiments, R 2 1 to 2 R a C1-C4 alkyl optionally substituted by (e.g., one R a (C1-C4 alkyl substituted by).
[0085] In certain embodiments of the invention, (R 2 But 1-2 R a C1-C4 alkyl optionally substituted by (e.g., one R a (C1-C4 alkyl substituted by), each R a -OH;-SH;-NR e R f ;-C(=O)O(C 1~4 alkyl);-C(=O)OH;-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 0~2 (C 1~4 alkyl); cyano; and -NR'C(=NR')NR'R''.
[0086] As a non-limiting example of the foregoing embodiment, each R a can be independently selected from -NH, -OH, -SH, -SMe, -NH(C=NH)NH, COH, and CONH (e.g., each R a may be independently selected from -NH2, -OH, -NH(C=NH)NH2, CO2H, and CO2NH2).
[0087] In some embodiments of Formula (Ia), R 2 teeth, 1 to 4 R c L may be substituted by 2 -C6~C 10 aryl; or Heteroaryl contains 5 to 10 ring atoms, 1 to 4 of which are N, N(R d), O, and S, and one or more of the heteroaryl ring carbon atoms are selected from 1 to 4 independently selected R c L 2 -heteroaryl It is.
[0088] In certain embodiments, R 2 R has 1 to 2 phenyl groups. c L 2 -phenyl.
[0089] In certain embodiments, R 2 Heteroaryl contains 5 to 9 ring atoms, 1 to 4 of which are N, N(R d ), O, and S, and one or more of the heteroaryl ring carbon atoms are selected from 1 to 2 independently selected R c L 2 -heteroaryl.
[0090] As a non-limiting example of the above embodiment, R 2 is indolyl or imidazolyl, and 1 to 2 independently selected R c L 2 -Indolyl or L 2 -imidazolyl.
[0091] In certain embodiments of the invention, (R 2 is 1 to 4 R c L may be substituted by 2 -C6~C 10 The aryl or heteroaryl contains 5 to 10 ring atoms, and 1 to 4 ring atoms are N, N(R d ), O, and S, and one or more of the heteroaryl ring carbon atoms are selected from 1 to 4 independently selected R c L2 -heteroaryl), each R c is -OH;-SH;-F;-Cl;-Br;-NR e R f ;C 1~4 Alkyl;C 1~4 Haloalkyl;C 1~4 Alkoxy;C 1~4 Haloalkoxy; -C(=O)O(C 1~4 alkyl);-C(=O)OH;-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 0~2 (C 1~4 alkyl; cyano; -; and 1 to 4 independently selected C 1~4 C optionally substituted by alkyl 3~6 cycloalkyl.
[0092] As a non-limiting example of the foregoing embodiment, each R c -OH, F, -NR e R f , C 1~4 Alkyl; and C 1~4 haloalkyl (e.g., R c is OH).
[0093] In certain embodiments, L 2 1 to 3 R a C, which may be substituted (e.g., unsubstituted) 1~6 (For example, C 1~4 ) alkylene.
[0094] In some embodiments of Formula (Ia), R 2 Each occurrence of ·H; C1-C6 alkyl optionally substituted by 1-2 substituents selected from -NH2, -OH, -SH, -SMe, -NH(C=NH)NH2, CO2H, and CO2NH2; (C1-C6 alkylene)-phenyl optionally substituted by 1 to 2 -OH; (C1-C6 alkylene)-indolyl; and (C1-C6 alkylene)-imidazolyl More independently selected, or -CH(R 2 )N(R d1 )-group R 2 and R d1 are linked to form a pyrrolidine ring.
[0095] In certain embodiments, R 2 Each occurrence of ·H; C1-C6 alkyl optionally substituted by 1-2 substituents selected from -NH2, -OH, -NH(C=NH)NH2, CO2H, and CO2NH2; and (C1-C6 alkylene)-imidazolyl More independently selected.
[0096] As a non-limiting example of the above embodiment, R 2 Each occurrence of ·H; TIFF0007595576000027.tif69128 can be selected independently.
[0097] In some embodiments of Formula (Ia), R 3 Each occurrence of C1-C6 alkyl optionally substituted by 1 to 2 substituents selected from -NH2, -OH, -SH, -SMe, -NH(C=NH)NH2, CO2H, and CO2NH2; (C1-C6 alkylene)-phenyl optionally substituted by 1 to 2 -OH, (C1-C6 alkylene)-indolyl, and (C1-C6 alkylene)-imidazolyl More independently selected.
[0098] In some embodiments of Formula (Ia), R 3 1 to 3 R a is C1-C6 alkyl optionally substituted by
[0099] In certain embodiments, R 3 1 to 2 R a C1-C4 alkyl optionally substituted by (e.g., one R a (C1-C4 alkyl substituted by).
[0100] In certain embodiments of the invention, (R 3 But 1-2 R a C1-C4 alkyl optionally substituted by (e.g., one R a (C1-C4 alkyl substituted by), each R a -OH;-SH;-NR e R f ;-C(=O)O(C 1~4 alkyl);-C(=O)OH;-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 0~2 (C 1~4 alkyl); cyano; and -NR'C(=NR')NR'R''.
[0101] As a non-limiting example of the foregoing embodiment, each R a can be independently selected from -NH, -OH, -SH, -SMe, -NH(C=NH)NH, COH, and CONH (e.g., each R a may be independently selected from -NH, -OH, -NH(C=NH)NH, COH, and CONH; for example, each R a may be independently selected from -NH2 and CO2H).
[0102] In some embodiments of Formula (Ia), R 3 teeth, 1 to 4 R c L may be substituted by 3 -C6~C 10 aryl; or Heteroaryl contains 5 to 10 ring atoms, 1 to 4 of which are N, N(R d), O, and S, and one or more of the heteroaryl ring carbon atoms are selected from 1 to 4 independently selected R c L 3 -heteroaryl It is.
[0103] In certain embodiments, R 3 R has 1 to 2 phenyl groups. c L may be substituted by 3 -phenyl.
[0104] In certain embodiments, R 3 L 3 -heteroaryl, where heteroaryl contains 5 to 8 ring atoms and 1 to 4 ring atoms are selected from N, N(R d ), O, and S, and one or more of the heteroaryl ring carbon atoms are selected from 1 to 2 independently selected R c may be substituted by:
[0105] As a non-limiting example of the above embodiment, R 3 is indolyl or imidazolyl, and 1 to 2 independently selected R c L may be substituted by 3 -Indolyl or L 3 -imidazolyl.
[0106] In certain embodiments of the invention, (R 3 is 1 to 4 R c L may be substituted by 2 -C6~C 10 The aryl or heteroaryl contains 5 to 10 ring atoms, and 1 to 4 ring atoms are N, N(R d ), O, and S, and one or more of the heteroaryl ring carbon atoms are selected from 1 to 4 independently selected R c L3 -heteroaryl), each R c is -OH;-SH;-F;-Cl;-Br;-NR e R f ;C 1~4 Alkyl;C 1~4 Haloalkyl;C 1~4 Alkoxy;C 1~4 Haloalkoxy; -C(=O)O(C 1~4 alkyl);-C(=O)OH;-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 0~2 (C 1~4 alkyl; cyano; -; and 1 to 4 independently selected C 1~4 C optionally substituted by alkyl 3~6 cycloalkyl.
[0107] As a non-limiting example of the foregoing embodiment, each R c -OH, F, -NR e R f , C 1~4 Alkyl, and C 1~4 haloalkyl (e.g., R c is OH).
[0108] In certain embodiments, L 3 1 to 3 R a C, which may be substituted (e.g., unsubstituted) 1~6 (For example, C 1~4 ) alkylene.
[0109] In certain embodiments, L 3 is C substituted by one oxo 1~6 (For example, C 1~4 ) alkylene. Non-limiting examples of the above include L 3 teeth It could be TIFF0007595576000028.tif16128.
[0110] In certain embodiments, L 3 is a bond.
[0111] In certain embodiments, R 3 Each occurrence of C1-C6 alkyl optionally substituted by 1-2 substituents selected from -NH2, -OH, -NH(C=NH)NH2, CO2H, and CO2NH2; and (C1-C6 alkylene)-imidazolyl More independently selected.
[0112] As a non-limiting example of the above embodiment, R 3 Each occurrence of TIFF0007595576000029.tif75133 can be selected independently.
[0113] In certain embodiments, R 3 Each occurrence of is independently selected from C1-C6 alkyl optionally substituted with 1-2 substituents selected from -NH2, -OH, -NH(C=NH)NH2, CO2H, and CO2NH2.
[0114] As a non-limiting example of the above embodiment, R 3 Each occurrence of TIFF0007595576000030.tif15128 can be selected independently.
[0115] In some embodiments, R 3 Each occurrence of L 3 -heterocyclyl, where heterocyclyl contains 3 to 10 ring atoms and 1 to 3 ring atoms are selected from N(R d ), O, and S, and one or more of the heterocyclyl ring carbon atoms are selected from 1 to 4 independently selected R b may be substituted by:
[0116] In certain embodiments, R 3 Each occurrence of L 3-heterocyclyl, where heterocyclyl contains 4 to 6 (e.g., 5 to 6) ring atoms and 1 to 3 ring atoms are selected from N(R d ), O, and S, and one or more of the heterocyclyl ring carbon atoms are selected from 1 to 2 independently selected R b (eg, heterocyclyl can be pyrrolidinyl, piperidinyl, or morpholinyl).
[0117] In certain of these embodiments, L 3 is a bond.
[0118] In certain embodiments, (R 3 Each occurrence of L 3 -heterocyclyl, where heterocyclyl contains 3 to 10 ring atoms and 1 to 3 ring atoms are selected from N(R d ), O, and S, and one or more of the heterocyclyl ring carbon atoms are selected from 1 to 4 independently selected R b (optionally substituted by), L 3 is 1 to 3 independently selected R a C, which may be substituted (e.g., unsubstituted) 1~6 It is an alkyl.
[0119] In certain embodiments, (R 3 Each occurrence of L 3 -heterocyclyl, where heterocyclyl contains 3 to 10 ring atoms and 1 to 3 ring atoms are selected from N(R d ), O, and S, and one or more of the heterocyclyl ring carbon atoms are selected from 1 to 4 independently selected R b (optionally substituted by), L 3 is C substituted by one oxo 1~6 (For example, C 1~4 ) alkylene (e.g., TIFF0007595576000031.tif16128).
[0120] As a non-limiting example, R 3 teeth, TIFF0007595576000032.tif26128.
[0121] Variable symbol B 1 and B. 2 In some embodiments of Formula (Ia), B 1 and B. 2 Each of the -Z 1 -Z 3 (i.e., Z 2 is a bond).
[0122] In some embodiments of Formula (Ia), Z 3 is H, halo, or C 1~3 It is an alkyl.
[0123] In some embodiments of Formula (Ia), Z 3 is H or C 1~3 Alkyl (e.g., Z 3 can be H).
[0124] In some embodiments of Formula (Ia), Z 3 is a halo (e.g., Z 3 can be F).
[0125] In some embodiments of Formula (Ia), Z 1 is 1 to 3 independently selected R a C may be substituted 1~3 Alkylene (e.g., Z 1 can be methylene, CHF, or CF2).
[0126] In certain embodiments, Z 1 is unsubstituted C 1~3 Alkylene (eg, CH2).
[0127] In certain embodiments, Z 1 is unsubstituted C 1~3 alkylene, Z 3 is H.
[0128] In certain embodiments, Z 1 is C substituted by 1 to 2 independently selected halo (e.g., F); 1~3 It is alkylene.
[0129] In certain embodiments, B 1 and B. 2 Each of the a , CH(R a )2, and C(R a ) 2-halo.
[0130] As a non-limiting example of the above embodiment, B 1 and B. 2 Each of may independently be CH3, CHF2, CH2F, or CF3 (e.g., CH3).
[0131] Variable symbol R d1 In some embodiments of Formula (Ia), R d1 Each occurrence of H;C 1~6 Alkyl;C 3~6 Cycloalkyl; -C(O)(C 1~4 alkyl);-C(O)O(C 1~4 alkyl);-CON(R')(R'');-S(O) 1~2 (NR'R''); and -S(O) 1~2 (C 1~4 alkyl), or -C(=O)CH(R 2 )N(R d1 )-group R 2 and R d1 are linked to form a ring containing 5 to 8 ring atoms as defined above.
[0132] In certain embodiments, R d1 Each occurrence of H;C 1~6 Alkyl; and C 3~6cycloalkyl.
[0133] In certain embodiments, R d1 Each occurrence of is H.
[0134] Compound of formula (Ib) In another aspect, the present disclosure provides a compound of formula (Ib): TIFF0007595576000033.tif21128, or a pharma- ceutically acceptable salt thereof; During the ceremony, B 1 and B. 2 Each of the -Z 1 -Z 2 -Z 3 where: Z 1 is 1 to 4 R a C may be substituted 1~3 is alkylene; Z 2 is a bond, -N(R d )-, -O-, or -S-; and Z 3 is H, halo, or 1-4 R a C may be substituted 1~7 is alkyl; E 1 , F 1 , G 1 , H 1 , J 1 , L 1 , M 1 , and Q 1 Each of ·Join; 1 to 3 R a C1-C6 alkylene optionally substituted by ·R 1 More independently selected; R 1 Each occurrence of -N(R d1 )-; -N(R 3 )-; ·-O-; S(O) where p is 0, 1, or 2 p ; ·C(=O); ·C(=S); ·CHR 2 ; ·C(R 2 )2 -C(=O)CH(R 2 )N(R d1 )-; and -C(=O)CH(R 2 )CH2N(R d1 )- independently selected from the group consisting of: However, E 1 and F 1 At least one of the following has 1 to 3 R a C1-C6 alkylene optionally substituted by F 1 , G 1 , H 1 , J 1 , L 1 , and M. 1 1 to 4 of which are independently selected R 1 and; R 2 Each occurrence of (i)R a ; (ii) 1 to 3 R a C1-C6 alkyl optionally substituted by; (iii) heterocyclyl contains 3 to 10 ring atoms, 1 to 3 of which are N(R d ), O, and S, and one or more of the heterocyclyl ring carbon atoms are selected from 1 to 4 independently selected R b L 2 -heterocyclyl; (iv) 1 to 4 R c L may be substituted by 2 -C6~C 10 Aryl; (v) Heteroaryl contains 5 to 10 ring atoms, 1 to 4 of which are N, N(R d ), O, and S, and one or more of the heteroaryl ring carbon atoms are selected from 1 to 4 independently selected R c L 2 -heteroaryl; and (vi) H or (vii) -C(=O)CH(R 2 )N(R d1 )-group R 2 and R d1 are linked to form a ring containing 5 to 8 ring atoms, where the ring is composed of (a) H and C 1~3 A ring having 3 to 6 ring carbon atoms (CH(R 2 ) plus;(b) N(R d1 0 to 3 ring heteroatoms (R d1 In addition to the nitrogen atom bonded to R 3 Each occurrence of (i) 1 to 3 R a C1-C6 alkyl optionally substituted by; (ii) heterocyclyl contains 3 to 10 ring atoms, 1 to 3 of which are N(R d ), O, and S, and one or more of the heterocyclyl ring carbon atoms are selected from 1 to 4 independently selected R b L 3 -heterocyclyl; (iii) 1 to 4 R c L may be substituted by 3 -C6~C 10 Aryl; and (iv) Heteroaryl contains 5 to 10 ring atoms, 1 to 4 of which are N, N(R d), O, and S, and one or more of the heteroaryl ring carbon atoms are selected from 1 to 4 independently selected R c L 3 -heteroaryl independently selected from the group consisting of: R a Each occurrence of is -OH; -SH; -F; -Cl; -Br; -NR e R f ;C 1~4 Alkoxy;C 1~4 Haloalkoxy; -C(=O)O(C 1~4 alkyl);-C(=O)(C 1~4 alkyl);-C(=O)OH;-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 0~2 (C 1~4 alkyl; cyano; -NR'C(=NR')NR'R''; and 1 to 4 independently selected R b C may be substituted 3~6 independently selected from the group consisting of cycloalkyl; R b Each occurrence of is -OH; -SH; -F; -Cl; -Br; -NR e R f ;C 1~4 Alkyl;C 1~4 Haloalkyl;C 1~4 Alkoxy;C 1~4 Haloalkoxy; -C(=O)O(C 1~4 alkyl);-C(=O)(C 1~4 alkyl;-C(=O)OH;-CON(R')(R'');oxo;-S(O) 1~2 (NR'R'');-S(O) 0~2 (C 1~4 alkyl; cyano; -NR'C(=NR')NR'R''; and 1 to 4 independently selected C 1~4 C optionally substituted by alkyl 3~6 independently selected from the group consisting of cycloalkyl; R cEach occurrence of is -OH; -SH; -F; -Cl; -Br; -NR e R f ;C 1~4 Alkyl;C 1~4 Haloalkyl;C 1~4 Alkoxy;C 1~4 Haloalkoxy; -C(=O)O(C 1~4 alkyl);-C(=O)(C 1~4 alkyl);-C(=O)OH;-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 0~2 (C 1~4 alkyl; cyano; -NR'C(=NR')NR'R''; and 1 to 4 independently selected C 1~4 C optionally substituted by alkyl 3~6 independently selected from the group consisting of cycloalkyl; R d Each occurrence of HC 1~6 Alkyl;C 3~6 Cycloalkyl; -C(O)(C 1~4 alkyl);-C(O)O(C 1~4 alkyl);-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 1~2 (C 1~4 alkyl);-OH; and C 1~4 alkoxy; R e and R f Each occurrence of H;C 1~6 Alkyl;C 3~6 Cycloalkyl; -C(O)(C 1~4 alkyl);-C(O)O(C 1~4 alkyl);-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 1~2 (C 1~4 alkyl);-OH; and C 1~4 alkoxy; and Each occurrence of R' and R'' is H and C 1~4alkyl, or R' and R'' taken together with the nitrogen atom to which they are each attached form a ring containing 3 to 8 ring atoms, wherein the ring is selected from the group consisting of: (a) H and C 1~3 (b) N(R d ), O, and S; R d1 Each occurrence of H;C 1~6 Alkyl;C 3~6 Cycloalkyl; -C(O)(C 1~4 alkyl);-C(O)O(C 1~4 alkyl);-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 1~2 (C 1~4 alkyl);-OH; and C 1~4 alkoxy or -C(=O)CH(R 2 )N(R d1 )-group R 2 and R d1 are linked to form a ring containing 5 to 8 ring atoms as defined above; and L in each occurrence 2 and L 3 each independently represents a bond, or an oxo and R a and C1 to C6 alkylene optionally substituted by 1 to 3 substituents independently selected from the above.
[0135] In some embodiments of Formula (Ib), F 1 , G 1 , H 1 , J 1 , L 1 , and M. 1 1 to 4 of which are independently selected R 1 It is.
[0136] In certain embodiments, F 1, G 1 , H 1 , J 1 , L 1 , and M. 1 One to three (e.g., two to three) of the R 1 It is.
[0137] In certain of the above embodiments, F 1 , G 1 , H 1 , J 1 , L 1 , and M. 1 One to two (e.g., one or two) of 1 It is.
[0138] In certain of the above embodiments, F 1 , G 1 , H 1 , J 1 , L 1 , and M. 1 Two to three (e.g., two or three) of 1 It is.
[0139] In certain of the above embodiments, F 1 , G 1 , H 1 , J 1 , L 1 , and M. 1 Two to four (e.g., two, three, or four) of 1 It is.
[0140] Variable symbol H 1 and J. 1 In some embodiments of formula (Ib), H 1 and J. 1 Each of ·Join; 1 to 3 R a C1-C6 alkylene optionally substituted by -N(R d1 )-; -N(R 3 )-; ·-O-; S(O) where p is 0, 1, or 2 p ; ·C(=O); ·C(=S); ·CHR 2 ; -C(=O)CH(R 2 )N(R d1 )-; and -C(=O)CH(R 2 )CH2N(R d1 )- are independently selected from the group consisting of:
[0141] In certain embodiments, H 1 and J. 1 Each of ·Join; -N(R d1 )-; ·-O-; S(O) where p is 0, 1, or 2 p ; ·C(=O); ·C(=S); ·CHR 2 ; -C(=O)CH(R 2 )N(R d1 )-; and -C(=O)CH(R 2 )CH2N(R d1 )- are independently selected from the group consisting of:
[0142] In some embodiments of formula (Ib), H 1 and J. 1 one of which is independently -C(=O)CH(R 2 )N(R d1 )-(for example, J 1 is -C(=O)CH(R 2 )N(R d1 )-is).
[0143] In certain of the above embodiments, H 1 and J. 1 The other of ·Join; -N(R d1 )-; ·-O-; S(O) where p is 0, 1, or 2 p ; ·C(=O); ·C(=S); ·CHR 2 ; -C(=O)CH(R 2 )N(R d1 )-; and -C(=O)CH(R 2 )CH2N(R d1 )- are independently selected from the group consisting of:
[0144] In certain embodiments of the invention, (H 1 and J. 1 One of the groups is independently -C(=O)CH(R 2 )N(R d1 )-(for example, J 1 is -C(=O)CH(R 2 )N(R d1 )-, H 1 and J. 1 The other of the two is a bond, -N(R d1 )-, and -O- (e.g., H 1 Can be a bond or H 1 -N(R d1 ) (for example, it can be -N(H)-).
[0145] In some embodiments of formula (Ib), H 1 and J. 1 One of the groups is independently -N(R 3 )-or-N(R d1 In certain of the above embodiments, H 1 and J. 1 One of the two is independently -N(R 3 )-.
[0146] In certain embodiments of the invention, (H 1 and J. 1One of the two is independently -N(R 3 )-or-N(R d1 )-), H 1 and J. 1 The other of ·Join; ·-O-; S(O) where p is 0, 1, or 2 p ; ·C(=O); ·C(=S); ·CHR 2 ; -C(=O)CH(R 2 )N(R d1 )-; and -C(=O)CH(R 2 )CH2N(R d1 )- More independently selected.
[0147] As a non-limiting example of the above embodiment, H 1 and J. 1 One of the two is independently -N(R 3 )-or-N(R d1 )-, then H 1 and J. 1 The other of may be a bond or C(=O).
[0148] Variable symbol E 1 and Q 1 In some embodiments of Formula (Ib), E 1 and Q 1 Each of the following contains 1 to 3 R a is an independently selected C1-C6 alkylene optionally substituted by
[0149] In certain of the above embodiments, E 1 and Q 1 Each of the following contains 1 to 3 R a is an independently selected C1-C4 alkylene optionally substituted by
[0150] As a non-limiting example of the above embodiment, E 1and Q 1 Each of can be an unsubstituted, independently selected C2-C4 alkylene (eg, C2-C3 alkylene, such as C2 alkylene).
[0151] Variable symbol F 1 In some embodiments of Formula (Ib), F 1 teeth, ·Join; 1 to 3 R a C1-C6 alkylene optionally substituted by -N(R d1 )-; -N(R 3 )-; ·-O-; S(O) where p is 0, 1, or 2 p ; ·C(=O); ·C(=S); ·CHR 2 ; -C(=O)CH(R 2 )N(R d1 )-; and -C(=O)CH(R 2 )CH2N(R d1 )- is selected from the group consisting of:
[0152] In certain embodiments, F 1 is a bond, -N(R d1 )— (e.g., —N(H)—), —O—, and —S—.
[0153] In certain embodiments, F 1 is a bond.
[0154] In certain embodiments, F 1 is -N(R d1 )-(e.g., -N(H)-).
[0155] In certain embodiments, F 1 is -O-.
[0156] In certain embodiments, F 1 is -S-.
[0157] Variable symbol G 1 In some embodiments of Formula (Ib), G 1 teeth, ·Join; 1 to 3 R a C1-C6 alkylene optionally substituted by -N(R d1 )-; -N(R 3 )-; ·-O-; S(O) where p is 0, 1, or 2 p ; ·C(=O); ·C(=S); ·CHR 2 ; -C(=O)CH(R 2 )N(R d1 )-; and -C(=O)CH(R 2 )CH2N(R d1 )- is selected from the group consisting of:
[0158] In certain embodiments, G 1 teeth, ·Join; ·-O-; S(O) where p is 0, 1, or 2 p ; ·C(=O); ·C(=S); ·CHR 2 ; -C(=O)CH(R 2 )N(R d1 )-; and -C(=O)CH(R 2 )CH2N(R d1 )- is selected from the group consisting of:
[0159] In certain embodiments, G 1 is a bond.
[0160] In certain embodiments, G 1 is S(O) where p=1 or 2 (e.g., p=2) p It is.
[0161] Variable symbol M 1 In some embodiments of Formula (Ib), M 1 teeth, ·Join; 1 to 3 R a C1-C6 alkylene optionally substituted by -N(R d1 )-; -N(R 3 )-; ·-O-; S(O) where p is 0, 1, or 2 p ; ·C(=O); ·C(=S); ·CHR 2 ; -C(=O)CH(R 2 )N(R d1 )-; and -C(=O)CH(R 2 )CH2N(R d1 )- is selected from the group consisting of:
[0162] In certain embodiments, M 1 teeth, ·Join; ·-O-; S(O) where p is 0, 1, or 2 p ; ·C(=O); ·C(=S); ·CHR 2 ; -C(=O)CH(R 2 )N(R d1 )-; and -C(=O)CH(R 2 )CH2N(R d1 )- is selected from the group consisting of:
[0163] In certain embodiments, M 1 is a bond.
[0164] Variable symbol L 1 In some embodiments of Formula (Ib), L 1 teeth, ·Join; 1 to 3 R a C1-C6 alkylene optionally substituted by -N(R d1 )-; -N(R 3 )-; ·-O-; S(O) where p is 0, 1, or 2 p ; ·C(=O); ·C(=S); ·CHR 2 ; -C(=O)CH(R 2 )N(R d1 )-; and -C(=O)CH(R 2 )CH2N(R d1 )- is selected from the group consisting of:
[0165] In certain embodiments, L 1 teeth, ·Join; ·-O-; S(O) where p is 0, 1, or 2 p ; ·C(=O); ·C(=S); ·CHR 2 ; -C(=O)CH(R 2 )N(R d1 )-; and -C(=O)CH(R 2 )CH2N(R d1 )- is selected from the group consisting of:
[0166] In certain embodiments, L 1 is a bond.
[0167] In certain embodiments, L 1 is -C(=O)CH(R 2 )(CH2)N(R d1 )-(e.g., R 2 =H).
[0168] In certain embodiments, L 1 is C(=O).
[0169] In certain embodiments, L 1 is -C(=O)CH(R 2 )N(R d1 )-.
[0170] Variable symbol R 2 and R 3 In some embodiments of Formula (Ib), R 2 is H.
[0171] In some embodiments of Formula (Ib), R 2 1 to 3 R a is C1-C6 alkyl optionally substituted by
[0172] In certain embodiments, R 2 1 to 2 R a C1-C4 alkyl optionally substituted by (e.g., one R a (C1-C4 alkyl substituted by).
[0173] In certain embodiments of the invention, (R 2 But 1-2 R a C1-C4 alkyl optionally substituted by (e.g., one R a (C1-C4 alkyl substituted by), each R a -OH;-SH;-NR e R f ;-C(=O)O(C 1~4 alkyl);-C(=O)OH;-CON(R')(R'');-S(O) 1~2(NR'R'');-S(O) 0~2 (C 1~4 alkyl); cyano; and -NR'C(=NR')NR'R''.
[0174] As a non-limiting example of the foregoing embodiment, each R a can be independently selected from -NH, -OH, -SH, -SMe, -NH(C=NH)NH, COH, and CONH (e.g., each R a may be independently selected from -NH2, -OH, -NH(C=NH)NH2, CO2H, and CO2NH2).
[0175] In some embodiments of Formula (Ib), R 2 teeth, 1 to 4 R c L may be substituted by 2 -C6~C 10 aryl; or Heteroaryl contains 5 to 10 ring atoms, 1 to 4 of which are N, N(R d ), O, and S, and one or more of the heteroaryl ring carbon atoms are selected from 1 to 4 independently selected R c L 2 -heteroaryl It is.
[0176] In certain embodiments, R 2 R has 1 to 2 phenyl groups. c L 2 -phenyl.
[0177] In certain embodiments, R 2 is a heteroaryl containing 5 to 8 ring atoms, 1 to 4 of which are N, N(R d ), O, and S, and one or more of the heteroaryl ring carbon atoms are selected from 1 to 2 independently selected R c L2 -heteroaryl.
[0178] As a non-limiting example of the above embodiment, R 2 is indolyl or imidazolyl, and 1 to 2 independently selected R c L 2 -Indolyl or L 2 -imidazolyl.
[0179] In certain embodiments of the invention, (R 2 is 1 to 4 R c L may be substituted by 2 -C6~C 10 The aryl or heteroaryl contains 5 to 10 ring atoms, and 1 to 4 ring atoms are N, N(R d ), O, and S, and one or more of the heteroaryl ring carbon atoms are selected from 1 to 4 independently selected R c L 2 -heteroaryl), each R c is -OH;-SH;-F;-Cl;-Br;-NR e R f ;C 1~4 Alkyl;C 1~4 Haloalkyl;C 1~4 Alkoxy;C 1~4 Haloalkoxy; -C(=O)O(C 1~4 alkyl);-C(=O)OH;-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 0~2 (C 1~4 alkyl; cyano; -; and 1 to 4 independently selected C 1~4 C optionally substituted by alkyl 3~6 cycloalkyl.
[0180] As a non-limiting example of the foregoing embodiment, each R c -OH, F, -NR e R f , C1~4 Alkyl, and C 1~4 haloalkyl (e.g., R c is OH).
[0181] In certain embodiments, L 2 1 to 3 R a C, which may be substituted (e.g., unsubstituted) 1~6 (For example, C 1~4 ) alkylene.
[0182] In some embodiments of Formula (Ib), R 2 Each occurrence of ·H; C1-C6 alkyl optionally substituted by 1-2 substituents selected from -NH2, -OH, -SH, -SMe, -NH(C=NH)NH2, CO2H, and CO2NH2; (C1-C6 alkylene)-phenyl optionally substituted by 1 to 2 -OH; (C1-C6 alkylene)-indolyl; and (C1-C6 alkylene)-imidazolyl More independently selected, or -CH(R 2 )N(R d1 )-group R 2 and R d1 are linked to form a pyrrolidine ring.
[0183] In certain embodiments, R 2 Each occurrence of ·H; C1-C6 alkyl optionally substituted by 1-2 substituents selected from -NH2, -OH, -NH(C=NH)NH2, CO2H, and CO2NH2; and (C1-C6 alkylene)-imidazolyl More independently selected.
[0184] As a non-limiting example of the above embodiment, R 2 Each occurrence of ·H; TIFF0007595576000034.tif63133 can be selected independently.
[0185] In some embodiments of Formula (Ib), R 3 Each occurrence of C1-C6 alkyl optionally substituted by 1-2 substituents selected from -NH2, -OH, -SH, -SMe, -NH(C=NH)NH2, CO2H, and CO2NH2; (C1-C6 alkylene)-phenyl optionally substituted by 1 to 2 -OH; (C1-C6 alkylene)-indolyl; and (C1-C6 alkylene)-imidazolyl More independently selected.
[0186] In some embodiments of Formula (Ib), R 3 1 to 3 R a is C1-C6 alkyl optionally substituted by
[0187] In certain embodiments, R 3 1 to 2 R a C1-C4 alkyl optionally substituted by (e.g., one R a (C1-C4 alkyl substituted by).
[0188] In certain embodiments of the invention, (R 3 But 1-2 R a C1-C4 alkyl optionally substituted by (e.g., one R a (C1-C4 alkyl substituted by), each R a -OH;-SH;-NR e R f ;-C(=O)O(C 1~4 alkyl);-C(=O)OH;-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 0~2 (C 1~4alkyl); cyano; and -NR'C(=NR')NR'R''.
[0189] As a non-limiting example of the foregoing embodiment, each R a can be independently selected from -NH, -OH, -SH, -SMe, -NH(C=NH)NH, COH, and CONH (e.g., each R a may be independently selected from -NH, -OH, -NH(C=NH)NH, COH, and CONH; for example, each R a may be independently selected from -NH2, and CO2H).
[0190] In some embodiments of Formula (Ib), R 3 teeth, 1 to 4 R c L may be substituted by 3 -C6~C 10 aryl; or Heteroaryl contains 5 to 10 ring atoms, 1 to 4 of which are N, N(R d ), O, and S, and one or more of the heteroaryl ring carbon atoms are selected from 1 to 4 independently selected R c L 3 -heteroaryl It is.
[0191] In certain embodiments, R 3 R has 1 to 2 phenyl groups. c L may be substituted by 3 -phenyl.
[0192] In certain embodiments, R 3 L 3 -heteroaryl, where heteroaryl contains 5 to 8 ring atoms and 1 to 4 ring atoms are selected from N, N(R d ), O, and S, and one or more of the heteroaryl ring carbon atoms are selected from 1 to 2 independently selected Rc may be substituted by:
[0193] As a non-limiting example of the above embodiment, R 3 is indolyl or imidazolyl, and 1 to 2 independently selected R c L may be substituted by 3 -Indolyl or L 3 -imidazolyl.
[0194] In certain embodiments of the invention, (R 3 is 1 to 4 R c L may be substituted by 2 -C6~C 10 The aryl or heteroaryl contains 5 to 10 ring atoms, and 1 to 4 ring atoms are N, N(R d ), O, and S, and one or more of the heteroaryl ring carbon atoms are selected from 1 to 4 independently selected R c L 3 -heteroaryl), each R c is -OH;-SH;-F;-Cl;-Br;-NR e R f ;C 1~4 Alkyl;C 1~4 Haloalkyl;C 1~4 Alkoxy;C 1~4 Haloalkoxy; -C(=O)O(C 1~4 alkyl);-C(=O)OH;-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 0~2 (C 1~4 alkyl; cyano; -; and 1 to 4 independently selected C 1~4 C optionally substituted by alkyl 3~6 cycloalkyl.
[0195] As a non-limiting example of the foregoing embodiment, each R c -OH, F, -NR e R f , C1~4 Alkyl, and C 1~4 haloalkyl (e.g., R c is OH).
[0196] In certain embodiments, L 3 1 to 3 R a C, which may be substituted (e.g., unsubstituted) 1~6 (For example, C 1~4 ).
[0197] In certain embodiments, L 3 is C substituted by one oxo 1~6 (For example, C 1~4 ) alkylene. Non-limiting examples of the above include L 3 teeth It could be TIFF0007595576000035.tif16128.
[0198] In certain embodiments, L 3 is a bond.
[0199] In certain embodiments, R 3 Each occurrence of C1-C6 alkyl optionally substituted by 1-2 substituents selected from -NH2, -OH, -NH(C=NH)NH2, CO2H, and CO2NH2; and (C1-C6 alkylene)-imidazolyl More independently selected.
[0200] As a non-limiting example of the above embodiment, R 3 Each occurrence of TIFF0007595576000036.tif68130 can be selected independently.
[0201] In certain embodiments, R 3 Each occurrence of is independently selected from C1-C6 alkyl optionally substituted with 1-2 substituents selected from -NH2, -OH, -NH(C=NH)NH2, CO2H, and CO2NH2.
[0202] As a non-limiting example of the above embodiment, R 3 Each occurrence of TIFF0007595576000037.tif16128 can be selected independently.
[0203] In some embodiments, R 3 Each occurrence of L 3 -heterocyclyl, where heterocyclyl contains 3 to 10 ring atoms and 1 to 3 ring atoms are selected from N(R d ), O, and S, and one or more of the heterocyclyl ring carbon atoms are selected from 1 to 4 independently selected R b may be substituted by:
[0204] In certain embodiments, R 3 Each occurrence of L 3 -heterocyclyl, where heterocyclyl contains 4 to 6 (e.g., 5 to 6) ring atoms and 1 to 3 ring atoms are selected from N(R d ), O, and S, and one or more of the heterocyclyl ring carbon atoms are selected from 1 to 2 independently selected R b (eg, heterocyclyl can be pyrrolidinyl, piperidinyl, or morpholinyl).
[0205] In certain embodiments, (R 3 Each occurrence of L 3 -heterocyclyl, where heterocyclyl contains 3 to 10 ring atoms and 1 to 3 ring atoms are selected from N(R d ), O, and S, and one or more of the heterocyclyl ring carbon atoms are selected from 1 to 4 independently selected R b (optionally substituted by), L 3 is 1 to 3 independently selected R aC, which may be substituted (e.g., unsubstituted) 1~6 It is an alkyl.
[0206] In certain embodiments, (R 3 Each occurrence of L 3 -heterocyclyl, where heterocyclyl contains 3 to 10 ring atoms and 1 to 3 ring atoms are selected from N(R d ), O, and S, and one or more of the heterocyclyl ring carbon atoms are selected from 1 to 4 independently selected R b (optionally substituted by), L 3 is C substituted by one oxo 1~6 (For example, C 1~4 ) alkylene (e.g., TIFF0007595576000038.tif16128).
[0207] As a non-limiting example, R 3 teeth, TIFF0007595576000039.tif26128.
[0208] Variable symbol R d1 In some embodiments of Formula (Ib), R d1 Each occurrence of H;C 1~6 Alkyl;C 3~6 Cycloalkyl; -C(O)(C 1~4 alkyl);-C(O)O(C 1~4 alkyl);-CON(R')(R'');-S(O) 1~2 (NR'R''); and -S(O) 1~2 (C 1~4 alkyl), or -C(=O)CH(R 2 )N(R d1 )-group R 2 and R d1 are linked to form a ring containing 5 to 8 ring atoms as defined above.
[0209] In certain embodiments, R d1 Each occurrence of H;C 1~6 Alkyl; and C 3~6 cycloalkyl.
[0210] In certain embodiments, R d1 Each occurrence of is H.
[0211] Variable symbol B 1 and B. 2 In some embodiments of formula (Ib), B 1 and B. 2 Each of the -Z 1 -Z 3 (i.e., Z 2 is a bond).
[0212] In some embodiments of Formula (Ib), Z 3 is H, halo, or C 1~3 It is an alkyl.
[0213] In some embodiments of Formula (Ib), Z 3 is H or C 1~3 Alkyl (e.g., Z 3 can be H).
[0214] In some embodiments of Formula (Ib), Z 3 is a halo (e.g., Z 3 can be F).
[0215] In some embodiments of Formula (Ib), Z 1 is 1 to 3 independently selected R a C may be substituted 1~3 Alkylene (e.g., Z 1 can be methylene, CHF, or CF2).
[0216] In certain embodiments, Z 1 is unsubstituted C 1~3 Alkylene (eg, CH2).
[0217] In certain embodiments, Z 1 is unsubstituted C 1~3 alkylene, Z 3 is H.
[0218] In certain embodiments, Z 1 is C substituted by 1 to 2 independently selected halo (e.g., F); 1~3 It is alkylene.
[0219] In certain embodiments, B 1 and B. 2 Each of the a , CH(R a )2, and C(R a ) 2-halo.
[0220] As a non-limiting example of the above embodiment, B 1 and B. 2 Each of may independently be CH3, CHF2, CH2F, or CF3.
[0221] Non-limiting combinations of formula (Ib) [1] In some embodiments of formula (Ib), H 1 or J 1 One of them is -C(=O)CH(R 2 )N(R d1 )-and E 1 and Q 1 Each of the following contains 1 to 3 R a and independently selected C1-C6 alkylene (e.g., C 2~4 Alkylene, e.g., unsubstituted C 2~4 alkylene).
[0222] In certain of the above embodiments, F 1 is -N(R d1 )—(e.g., —N(H)—), —O—, or —S—).
[0223] In a particular embodiment of [1], the compound of formula (Ib) is a compound of formula (II): TIFF0007595576000040.tif26128 or a pharma- ceutically acceptable salt thereof; During the ceremony, E 1 and Q 1 Each of the following contains 1 to 3 R a and independently selected C1-C6 alkylene (e.g., C 2~4 Alkylene, e.g., unsubstituted C 2~4 alkylene); F 1 is -N(R d1 )-(e.g., -N(H)-), -O-, or -S-; and H 1 , G 1 , L 1 , and M. 1 Each of ·Join; -N(R d1 )-; ·-O-; S(O) where p is 0, 1, or 2 p ; ·C(=O); ·C(=S); ·CHR 2 ; -C(=O)CH(R 2 )N(R d1 )-; and -C(=O)CH(R 2 )CH2N(R d1 )- More independently selected.
[0224] [1-1] In some embodiments of Formula (II), L 1 and M. 1 Each of is a bond.
[0225] In some embodiments of formula (II), G 1 and H 1 Each of is a bond.
[0226] In some embodiments of formula (II), F 1 -N(R d )-(e.g., NH).
[0227] In certain embodiments, the compound of formula II has the formula (II-a): TIFF0007595576000041.tif24128 or a pharma- ceutically acceptable salt thereof.
[0228] [1-2] In some embodiments of formula (II), G 1 is S(O) p and p is 1 or 2.
[0229] In certain embodiments of the above, (wherein, in Formula II, G 1 S(O) p and p is 1 or 2), F 1 is -O-.
[0230] In certain embodiments, (wherein in Formula II, G 1 S(O) p and p is 1 or 2; and / or F 1 is -O-), H 1 -N(R d1 )-(e.g., NH).
[0231] In certain embodiments, the compound of formula (II) has the formula (II-b): TIFF0007595576000042.tif24128 or a pharma- ceutically acceptable salt thereof.
[0232] [1-3] In some embodiments of Formula (II), L 1 is -C(=O)CH(R 2 )(CH2)N(R d1 )-.
[0233] In the particular embodiment described above, (wherein in formula (II), L 1 -C(=O)CH(R 2)(CH2)N(R d1 )-, M 1 , G 1 , and H 1 Each of is a bond.
[0234] In certain embodiments of the above, (wherein, L 1 -C(=O)CH(R 2 )(CH2)N(R d1 )-; and / or in formula (II), M 1 , G 1 , and H 1 is a bond), F 1 is -O- or -N(R d1 )-(e.g., -N(H)-).
[0235] In certain embodiments, the compound of formula (II) has the formula (II-c1) or (II-c2): TIFF0007595576000043.tif59128 or a pharma- ceutically acceptable salt thereof.
[0236] [1-4] In some embodiments of Formula (II), L 1 is C(=O).
[0237] In the particular embodiment described above, (wherein in formula (II), L 1 is C(=O), M 1 , G 1 , and H 1 Each of is a bond.
[0238] In the particular embodiment described above, (wherein in formula (II), L 1 is C(=O); and / or in formula (II), M 1 , G 1 , and H 1 is a bond), F 1 is -O- or -N(R d1 )-.
[0239] In certain embodiments, the compound of formula (II) has the formula (II-d): TIFF0007595576000044.tif24128 or a pharma- ceutically acceptable salt thereof.
[0240] [1-5] In some embodiments of Formula (II), L 1 is -C(=O)CH(R 2 )N(R d1 )-.
[0241] In certain of the above embodiments, M 1 , G 1 , and H 1 Each of is a bond.
[0242] In certain embodiments (e.g., L 1 -C(=O)CH(R 2 )N(R d1 )- and / or M 1 , G 1 , and H 1 is a bond), F 1 is -O- or -N(R d1 )-(e.g., -N(H)-).
[0243] In certain embodiments, the compound of formula (II) has the formula (II-e): TIFF0007595576000045.tif25128 or a pharma- ceutically acceptable salt thereof.
[0244] As a non-limiting example of the foregoing embodiment, the compound has the following formula: has TIFF0007595576000046.tif21128.
[0245] [2] In some embodiments of formula (Ib), H 1 and J. 1 One of them is -N(R 3 )-or-N(R d1 )-(e.g., H 1 and J. 1 One of them is -N(R 3) is.
[0246] In certain of the aforementioned embodiments, the compound of formula (Ib) has formula (III): TIFF0007595576000047.tif22128 or a pharma- ceutically acceptable salt thereof.
[0247] In certain embodiments of formula (III), E 1 and Q 1 Each of the following contains 1 to 3 R a and is an independently selected C1-C6 alkylene (eg, C2-C4 alkylene, C2-C3 alkylene, C2 alkylene, for example, unsubstituted C2 alkylene), optionally substituted by
[0248] In certain of the above embodiments, F 1 and M. 1 Each of is a bond.
[0249] In certain embodiments, G 1 and L 1 Each of ·Join; ·-O-; S(O) where p is 0, 1, or 2 p ; ·C(=O); ·C(=S); ·CHR 2 ; -C(=O)CH(R 2 )N(R d1 )-; and -C(=O)CH(R 2 )CH2N(R d1 )- More independently selected.
[0250] As a non-limiting example of the above embodiment, G 1 and L 1 Each of is a bond.
[0251] In the particular embodiment of the above-mentioned [2], H 1 is a bond.
[0252] In the particular embodiment of the above-mentioned [2], H 1 is (C=O).
[0253] In certain embodiments of [1] (including [1-1] to [1-4]) and [2], R 2 each occurrence of is as defined in claims 40-42.
[0254] In certain embodiments of [1] (including [1-1] to [1-4]) and [2], R 2 Each occurrence of ·H; ·C1-C6 alkyl optionally substituted by 1-2 substituents selected from -NH2, -OH, -SH, -SMe, -NH(C=NH)NH2, CO2H, and CO2NH2; (C1-C6 alkylene)-phenyl optionally substituted by 1 to 2 -OH; (C1-C6 alkylene)-indolyl; and (C1-C6 alkylene)-imidazolyl More independently selected, or -CH(R 2 )N(R d1 )-group R 2 and R d1 are linked to form a pyrrolidine ring.
[0255] In certain embodiments of [1] (including [1-1] to [1-4]) and [2], R 2 Each occurrence of ·H; C1-C6 alkyl optionally substituted by 1-2 substituents selected from -NH2, -OH, -NH(C=NH)NH2, CO2H, and CO2NH2; and (C1-C6 alkylene)-imidazolyl More independently selected.
[0256] In certain embodiments of [1] (including [1-1] to [1-4]) and [2], R 2 Each occurrence of ·H; Selected independently from TIFF0007595576000048.tif63128.
[0257] In certain embodiments of [1] (including [1-1] to [1-4]) and [2], R 3 each occurrence of is as defined in claims 43-45.
[0258] In certain embodiments of [1] (including [1-1] to [1-4]) and [2], R 3 Each occurrence of ·C1-C6 alkyl optionally substituted by 1-2 substituents selected from -NH2, -OH, -SH, -SMe, -NH(C=NH)NH2, CO2H, and CO2NH2; (C1-C6 alkylene)-phenyl optionally substituted by 1 to 2 -OH; (C1-C6 alkylene)-indolyl; and (C1-C6 alkylene)-imidazolyl More independently selected.
[0259] In certain embodiments of [1] (including [1-1] to [1-4]) and [2], R 3 Each occurrence of C1-C6 alkyl optionally substituted by 1-2 substituents selected from -NH2, -OH, -NH(C=NH)NH2, CO2H, and CO2NH2; and (C1-C6 alkylene)-imidazolyl More independently selected.
[0260] In certain embodiments of [1] (including [1-1] to [1-4]) and [2], R 3 Each occurrence of Selected independently from TIFF0007595576000049.tif65129.
[0261] As a non-limiting example of the above embodiment, R 3 Each occurrence of TIFF0007595576000050.tif16128.
[0262] In certain embodiments of [1] (including [1-1] to [1-4]) and [2], R 3 Each occurrence of L 3 -heterocyclyl, where heterocyclyl contains 3 to 10 ring atoms and 1 to 3 ring atoms are selected from N(R d ), O, and S, and one or more of the heterocyclyl ring carbon atoms are selected from 1 to 4 independently selected R b may be substituted by:
[0263] In certain embodiments of [1] (including [1-1] to [1-4]) and [2], R 3 Each occurrence of L 3 -heterocyclyl, where heterocyclyl contains 4 to 6 (e.g., 5 to 6) ring atoms and 1 to 3 ring atoms are selected from N(R d ), O, and S, and one or more of the heterocyclyl ring carbon atoms are selected from 1 to 2 independently selected R b (eg, heterocyclyl can be pyrrolidinyl, piperidinyl, or morpholinyl).
[0264] In certain embodiments of [1] (including [1-1] to [1-4]) and [2], (R 3 L 3 -heterocyclyl), L 3 is a bond. In certain other embodiments, L 3 is 1 to 3 independently selected R a C, which may be substituted (e.g., unsubstituted) 1~6 In certain embodiments of [1] (including [1-1] to [1-4]) and [2], (R 3 L 3 -heterocyclyl), L 3is C substituted by one oxo 1~6 (For example, C 1~4 ) alkylene (e.g., TIFF0007595576000051.tif16128).
[0265] In certain embodiments of [1] (including [1-1] to [1-4]) and [2], (R 3 L 3 -heterocyclyl), R 3 teeth, Selected from TIFF0007595576000052.tif26128.
[0266] In certain embodiments of [1] (including [1-1] to [1-4]) and [2], B 1 and B. 2 Each of the above is as defined in claims 53 to 57.
[0267] In certain embodiments of [1] (including [1-1] to [1-4]) and [2], B 1 and B. 2 Each of the -Z 1 -Z 3 (i.e., Z 2 is a bond).
[0268] In certain embodiments of [1] (including [1-1] to [1-4]) and [2], Z 3 is H, halo, or C 1~3 In certain embodiments of [1] (including [1-1] to [1-4]) and [2], Z 1 is 1 to 3 independently selected R a C may be substituted 1~3 It is alkylene.
[0269] In certain embodiments of [1] (including [1-1] to [1-4]) and [2], B 1 and B. 2 Each of the a , CH(R a )2, and C(R a)2 - are independently selected from the halo.
[0270] In certain embodiments of [1] (including [1-1] to [1-4]) and [2], B 1 and B. 2 are each independently selected from CH3, CHF2, CH2F, and CF3.
[0271] In certain embodiments of [1] (including [1-1] to [1-4]) and [2], R d1 each occurrence of is as defined in claims 58-60.
[0272] In certain embodiments of [1] (including [1-1] to [1-4]) and [2], R d1 Each occurrence of H;C 1~6 Alkyl;C 3~6 Cycloalkyl; -C(O)(C 1~4 alkyl);-C(O)O(C 1~4 alkyl);-CON(R')(R'');-S(O) 1~2 (NR'R''); and -S(O) 1~2 (C 1~4 alkyl), or -C(=O)CH(R 2 )N(R d1 )-group R 2 and R d1 are linked to form a ring containing 5 to 8 ring atoms as defined above.
[0273] In certain embodiments of [1] (including [1-1] to [1-4]) and [2], R d1 Each occurrence of H;C 1~6 Alkyl; and C 3~6 As a non-limiting example of the above embodiment, each R d1 can be H.
[0274] In some embodiments, the compound is selected from Table A1 below, or a pharma- ceutically acceptable salt thereof.
[0275] [Table A-1] TIFF0007595576000054.tif185128TIFF0007595576000055.tif204128TIFF0007595576000056.tif186128
[0276] Pharmaceutical Compositions and Administration overview In some embodiments, a chemical entity (e.g., a compound, or a pharma- ceutically acceptable salt and / or hydrate and / or prodrug of the compound) that induces crosslinking in the cornea in response to exposure to photoactivating light is administered as a pharmaceutical composition comprising the chemical entity and one or more pharma- ceutically acceptable excipients, and, optionally, one or more additional therapeutic agents described herein.
[0277] In some embodiments, the pharmaceutical composition is as described in US2018 / 0236077, which is incorporated by reference in its entirety.
[0278] In some embodiments, the chemical entities described herein may be administered in combination with one or more delivery agents. Delivery agents include, but are not limited to, anesthetics, analgesics, tonicity agents, shear-thinning thickeners, surfactants (e.g., ionic or nonionic surfactants), or chelating agents. Non-limiting examples of anesthetics may include pilocarpine, proparacaine, tetracaine, or oxybuprocaine. Non-limiting examples of analgesics include menthol, benzyl alcohol, or phenylethyl alcohol. Non-limiting examples of tonicity agents include glycerin, propylene glycol, polyethylene glycol (PEG)-8, ethanol, benzyl alcohol, phenylethyl alcohol, or triacetin. Non-limiting examples of shear-thinning thickeners include carbomer, polycarbophil, gellan gum, xanthan gum, sodium carboxymethylcellulose, or sodium hyaluronate. Non-limiting examples of ionic surfactants include benzalkonium chloride. Non-limiting examples of non-ionic surfactants include poloxamer 407, tetron 1107, tetron 1304, polysorbate 80, polyethylene glycol (PEG)-40 hydrogenated castor oil, lecithin, polysorbate 60, polyethylene glycol (PEG)-35 castor oil, tocophersolan (TPGS), nonoxynol-9, or tyloxapol. Non-limiting examples of chelating agents include ethylenediaminetetraacetic acid (EDTA) or citrate.
[0279] In some embodiments, the chemical entities described herein may be administered to the corneal epithelium in combination with one or more preparatory formulations. In certain embodiments, the preparatory formulations increase the permeability of the corneal epithelium. As non-limiting examples of the foregoing, the preparatory formulations may include one or more of zinc metalloproteinase, copper metalloproteinase, papain, bromelain, actinidin, ficain, N-acetylcysteine, ambroxol, carbocysteine, or erdocysteine. In certain embodiments, the one or more preparatory formulations may further include one or more anesthetic agents (e.g., pilocarpine, proparacaine, tetracaine, or oxybuprocaine).
[0280] In some embodiments, the chemical entities described herein may be administered in combination with one or more enhancement formulations configured to perform one or more of the following: (i) remove one or more therapeutic formulations from the epithelium of the cornea without diluting the one or more therapeutic substances delivered to the stroma; (ii) tight junctions of the epithelium to control corneal hydration; (iii) promote oxidation of one or more therapeutic substances delivered to the stroma; or (iv) further deliver one or more therapeutic formulations from the epithelium to the stroma. As non-limiting examples of the foregoing, the enhancement formulation may include one or more of a divalent metal salt, one or more pro-oxidants, or one or more glycosaminoglycans.
[0281] In some aspects, the chemical entities described herein may be administered in combination with one or more post-treatment formulations in response to application of the one or more augmentation formulations, where the one or more post-treatment formulations may include at least one of one or more divalent metal salts, one or more viscosity agents, one or more glycosaminoglycans, or one or more antibiotics.
[0282] In some embodiments, chemical entities can be administered in combination with one or more conventional pharmaceutical excipients.Pharmaceutically acceptable excipients include, but are not limited to, ion exchange agents, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery system (SEDDS), such as d-α-tocopherol polyethylene glycol 1000 succinate, surfactants used in pharmaceutical dosage forms, such as Tween, poloxamer or other similar polymer delivery matrices, serum proteins, such as human serum albumin, buffer substances, such as phosphate, tris, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers and wool fat. Cyclodextrins, such as α-, β-, and γ-cyclodextrin, or chemically modified derivatives, such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl-β-cyclodextrin, or other solubilizing derivatives, can also be used to enhance delivery of the compounds described herein. Dosage forms or compositions may be prepared containing the chemical entities described herein in the range of 0.005% to 100%, with the remainder consisting of non-toxic excipients. Contemplated compositions may contain 0.001% to 100%, in one embodiment 0.1 to 95%, in another embodiment 75 to 85%, and in further embodiments 20 to 80% of the chemical entities provided herein. Actual methods of preparing such dosage forms will be known or apparent to those skilled in the art. For example, see Remington: The Science and Practice of Pharmacy, 22 nd Edition (Pharmaceutical Press, London, UK. 2012).
[0283] Route of Administration and Composition Components The composition can be prepared as a liquid solution or suspension. Solid forms suitable for use in preparing a solution or suspension by adding liquid prior to administration can also be prepared. Preparations can also be emulsified. Preparation of such formulations will be known to those skilled in the art in light of the present disclosure.
[0284] The compositions may be administered topically (eg, intraocularly as topical drops).
[0285] Pharmaceutical forms suitable for intraocular use include sterile aqueous solutions (e.g., buffered solutions, e.g., citrate buffer; eye drops, e.g., 20% dextran eye drops) or dispersions; formulations containing sesame oil, peanut oil or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile solutions or dispersions. In general, the form must be sterile and must be fluid to the extent that easy syringability exists. The form must also be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
[0286] The carrier may also be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, etc.), suitable mixtures thereof, and vegetable oils. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by maintaining the required particle size in the case of dispersion, and by the use of surfactants. Prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it is preferable to include an isotonic agent, for example, sugar or sodium chloride. Prolonged absorption of the composition can be brought about by using an agent that delays absorption, for example, aluminum monostearate and gelatin, in the composition.
[0287] Sterile solution is prepared by incorporating the active compound in the required amount in a suitable solvent together with various other components listed above, as necessary, followed by sterilization by filtration.Generally, dispersion is prepared by incorporating various sterilized active components into a sterile vehicle that contains basic dispersion medium and other necessary components listed above.For the case of sterilized powder for preparing sterile solution, the preferred preparation method is vacuum drying technology and freeze-drying technology, which obtains the powder of active component and any additional desired components from its previously sterilized filtered solution.
[0288] In certain embodiments, the excipients are sterile and generally free of undesirable substances.These compositions can be sterilized by conventional well-known sterilization techniques.For various oral dosage form excipients such as tablets and capsules, sterility is not required.USP / NF standards are usually sufficient.
[0289] Ophthalmic compositions may include, without limitation, one or more of any of the following: dextran, viscogen (e.g., carboxymethylcellulose, glycerin, polyvinylpyrrolidone, polyethylene glycol); stabilizers (e.g., pluronic (triblock copolymers), cyclodextrin); preservatives (e.g., benzalkonium chloride, ETDA, SofZia (boric acid, propylene glycol, sorbitol and zinc chloride; Alcon Laboratories, Inc.), Purite (stabilized oxychloro complex; Allergan, Inc.)).
[0290] The composition may include ointments and creams. Ointments are semi-solid preparations typically based on petrolatum or other petroleum derivatives. Creams containing selected active agents are typically viscous liquids or semi-solid emulsions, often either oil-in-water or water-in-oil. Cream bases are typically water-washable and contain an oil phase, an emulsifier, and an aqueous phase. The oil phase, sometimes called the "internal" phase, is generally composed of petrolatum and a fatty alcohol, such as cetyl alcohol or stearyl alcohol. The aqueous phase usually, but not necessarily, exceeds the oil phase in volume and generally contains a humectant. Emulsifiers in cream formulations are generally non-ionic, anionic, cationic, or amphoteric surfactants. As with other carriers or vehicles, ointment bases should be inert, stable, non-irritating, and non-sensitizing.
[0291] In certain aspects, the compounds and compositions disclosed herein can be applied to the cornea of the eye using an applicator, non-limiting examples of which can include an eye dropper or a syringe.
[0292] In certain aspects, the compounds and compositions described herein can be administered in a formulation that allows the compound of the composition to pass through the corneal epithelium to the underlying area of the corneal stroma. In other aspects, the corneal epithelium can be removed or otherwise dissected to allow the compound or composition provided herein to be applied more directly to the underlying tissue.
[0293] Thus, in some embodiments, the compounds and compositions described herein are applied directly to the cornea (e.g., without removing or otherwise dissecting the corneal epithelium). In other embodiments, the corneal epithelium is removed or otherwise dissected before the compounds and compositions described herein are applied.
[0294] Dosage Dosage may vary depending on the patient's requirements, the severity of the condition being treated, and the specific compound being used. The appropriate dosage for a particular situation can be determined by those skilled in the medical field. In some cases, the total dosage may be divided and administered in several portions throughout the procedure or by a means that provides continuous delivery.
[0295] In some embodiments, the composition is a solution (e.g., a buffer, e.g., a citrate buffer; e.g., an eye drop, e.g., a 20% dextran eye drop) containing 0.01 to 100 mg / mL (e.g., 0.02 to 50 mg / mL, 0.04 to 25 mg / mL, 0.08 to 12.5 mg / mL, 0.16 to 6.25 mg / mL, 0.2 to 5 mg / mL) of a chemical entity described herein. In certain of the foregoing embodiments, the unit dose is 0.001 to 1 mL (e.g., 0.002 to 0.5 mL, 0.010 to 0.25 mL, e.g., 0.020 to 0.1 mL).
[0296] In some embodiments, the composition is a solution (e.g., a buffer, e.g., citrate buffer; e.g., eye drops, e.g., 20% dextran eye drops) containing 0.001% to 20% (e.g., 0.002% to 10%, 0.004% to 5%, 0.008% to 2.5%) of a chemical entity described herein. In certain of the foregoing embodiments, the unit dose is 0.001 to 1 mL (e.g., 0.002 to 0.5 mL, 0.010 to 0.25 mL, e.g., 0.020 to 0.2 mL).
[0297] Regimen The aforementioned dosages can be administered periodically over a particular period of time. In some embodiments, the unit dosage can be administered every 1-1200 seconds (e.g., every 2-300 seconds, every 2-150 seconds, every 5-150 seconds, every 5-100 seconds, every 5-10 seconds, every 10-150 seconds, every 50-150 seconds). In certain of the aforementioned embodiments, the dosages are administered over a period of 1-1200 minutes (e.g., 1-600 minutes, 5-120 minutes, 10-120 minutes).
[0298] Treatment method overview The present disclosure features methods for treating a subject (e.g., a human) having a disease, disorder, or condition, where an abnormal shape of the cornea (e.g., corneal thinning, e.g., bilateral corneal thinning, e.g., central, paracentral, or peripheral corneal thinning; or corneal steepening (e.g., bulging)) contributes to the pathology and / or symptoms and / or progression of the disease, disorder, or condition. In certain aspects, the methods described herein may include or may further include treating one or more conditions associated with, comorbid to, or sequelae of any one or more of the conditions described herein.
[0299] In some embodiments, the method further comprises identifying the subject.
[0300] In certain aspects, the chemical entities described herein provide refractive correction to the cornea (e.g., by imparting mechanical rigidity). In certain aspects, the chemical entities described herein strengthen and stabilize the structure of the cornea. In certain aspects, the chemical entities described herein can be used for vision correction.
[0301] method In some embodiments, the methods include administering a compound disclosed herein, or a pharmaceutical composition thereof, to the cornea of an eye of a subject in need thereof, and irradiating the cornea with electromagnetic radiation (e.g., light), thereby causing cross-linking in the cornea.
[0302] In certain of the foregoing aspects, the method comprises administering a compound disclosed herein, or a pharmaceutical composition thereof, to the corneal stroma of the cornea of a subject in need thereof.
[0303] In certain aspects, a compound disclosed herein, or a pharmaceutical composition thereof, is administered to the cornea without removing corneal epithelial cells.
[0304] In some embodiments, the claimed methods can be performed in the absence of added or supplemented oxygen levels, which can be advantageous in some applications.
[0305] In other embodiments, the method further comprises increasing or decreasing the concentration of O2 at the cornea during irradiation.
[0306] In certain embodiments, the method further comprises administering one or more delivery agents to the cornea, where the one or more delivery agents are as described elsewhere herein.
[0307] In certain embodiments, the method further includes administering to a subject in need thereof (e.g., to the cornea of a subject in need thereof) one or more pre-formulations that increase the permeability of the corneal epithelium, wherein the one or more pre-formulations are as described elsewhere herein.
[0308] In certain embodiments, the method further comprises administering to the epithelium of the cornea one or more enhancement formulations, the one or more enhancement formulations comprising: (i) removing one or more therapeutic formulations from the epithelium of the cornea without diluting the one or more therapeutic substances delivered to the corneal stroma; (ii) epithelial tight junctions to control corneal hydration; (iii) promoting the oxidation of one or more therapeutic substances delivered to the corneal stroma; or (iv) further delivering one or more therapeutic formulations through the epithelium to the corneal stroma. and configured to perform one or more of: The one or more potentiating formulations are as described elsewhere herein.
[0309] In certain embodiments, the method further comprises administering to the subject in need thereof one or more post-treatment formulations in response to application of the one or more augmentation formulations, wherein the one or more augmentation formulations are as described elsewhere herein.
[0310] Electromagnetic radiation In some embodiments, the electromagnetic radiation that is applied to the cornea of the eye of the subject in need thereof is light radiation. In certain embodiments, the light radiation has a wavelength, energy, and duration that is suitable for causing the compounds described herein to react (e.g., photoinduced electron transfer and / or fragmentation), thereby allowing cross-linking.
[0311] In some aspects, the wavelength of light can be selected to correspond to or encompass the absorption of the compounds described herein and to reach areas of tissue in contact with the compounds described herein, e.g., to penetrate to areas where the compounds described herein are present.
[0312] In some embodiments, the energy of the irradiated electromagnetic radiation is 2000 J / cm 2 In the specific embodiment described above, the electromagnetic energy irradiated is 1 to 500 J / cm 2 The total dose of energy absorbed in the cornea can be described as the effective dose, which is the amount of energy absorbed through an area of the corneal epithelium. For example, the effective dose for an area of the corneal surface may be, for example, 5 J / cm 2 ~20J / cm 2 or 30 J / cm 2 (For example, 5.4 J / cm 2 ).
[0313] In some embodiments, the electromagnetic radiation is between about 0.1 and 100 mW / cm 2 (For example, 1 to 100 mW / cm 2 In certain embodiments, the electromagnetic radiation is irradiated at an irradiance of about 1 to 5 mW / cm 2 (For example, 3 mW / cm 2) is irradiated with an irradiance of
[0314] In some embodiments, the electromagnetic radiation has a wavelength within the visible spectrum, the infrared spectrum, or the ultraviolet spectrum. In some embodiments, the electromagnetic radiation comprises radiation with a wavelength of about 300 nm to about 800 nm (e.g., 300 nm to 700 nm). In certain embodiments, the electromagnetic radiation comprises ultraviolet A (UVA) light (e.g., with a wavelength of 350 to 380 nm, e.g., 360 to 370 nm, e.g., 365 nm). In certain embodiments, the electromagnetic radiation comprises visible wavelengths (e.g., with a wavelength of 400 nm to 550 nm, e.g., about 452 nm). In some embodiments, the electromagnetic radiation is laser radiation. In certain embodiments, the laser radiation is applied with an average power of 1 to 100 mW.
[0315] In some embodiments, the duration of radiation is between 30 seconds and 1 hour. In certain embodiments, the duration of irradiation is between 1 minute and 1 hour (e.g., 30 minutes).
[0316] In some aspects, the cornea of the eye can be more extensively treated with the compounds or compositions described herein. Radiation can be selectively directed to the areas of the cornea to be treated according to specific patterns.
[0317] In certain embodiments, the electromagnetic radiation may be directed or focused using one or more mirrors or lenses toward a particular pattern on the cornea (e.g., at a particular focal plane within the cornea, e.g., at a particular depth in the underlying region where cross-linking activity is desired).
[0318] In some embodiments, the particular regime of electromagnetic radiation can be modulated to achieve a desired degree of cross-linking within selected regions of the cornea. For example, electromagnetic radiation can be delivered according to any combination of wavelength, bandwidth, intensity, power, location, penetration depth, and / or treatment duration (duration of exposure cycle, dark cycle, and ratio of exposure cycle to dark cycle duration).
[0319] In some embodiments, the electromagnetic irradiation is delivered using a system that includes a digital micromirror device (DMD) for spatially and temporally modulating the irradiation of electromagnetic radiation. In certain embodiments described above, light is projected in precise spatial patterns generated by microscopically small mirrors arranged in a matrix on a semiconductor chip. Each mirror represents one or more pixels in the projected light pattern. The DMD can be used to perform topography-guided crosslinking. Control of the DMD according to the topography can use several different spatial and temporal irradiance and dose profiles. These spatial and temporal dose profiles can be created using continuous wave illumination, but may also be modulated via pulsed illumination by pulsing the illumination source under various frequency and duty cycle regimes, as described above. Alternatively, the DMD can be modulated with different frequencies and duty cycles per pixel, giving the ultimate flexibility using continuous wave illumination. Alternatively, both pulsed illumination and a combination of modulated DMD frequency and duty cycles may be combined. This allows for a specific amount of spatially determined corneal crosslinking. This spatially determined cross-linking may be combined with dosimetry, interferometry, optical coherence tomography (OCT), corneal topography, etc. for pre-treatment planning and / or real-time monitoring and modulation of corneal cross-linking during treatment. Additionally, pre-clinical patient information may be combined with finite element biomechanical computer modeling to generate patient-specific pre-treatment plans.
[0320] In some embodiments, the electromagnetic radiation is delivered using a multi-photon excitation microscope. In particular, rather than delivering a single photon of a particular wavelength to the cornea, multiple photons of relatively long wavelengths, i.e., relatively low energy, are delivered and combined to initiate cross-linking. Advantageously, longer wavelengths are scattered to a lesser extent in the cornea than shorter wavelengths, which allows longer wavelengths of light to penetrate the cornea more efficiently than shorter wavelengths. Also, the shielding effect of incident radiation at relatively deep depths in the cornea is reduced compared to conventional short wavelength illumination, since longer wavelengths are absorbed much less by photosensitizers. This allows for enhanced control over depth-specific cross-linking. For example, in some embodiments, two photons may be used, each photon having about half the energy required to excite molecules of the compounds or compositions disclosed herein to generate the photochemical kinetic reactions described further below. When the compounds disclosed herein simultaneously absorb both photons, they absorb enough energy to release reactive radicals in the corneal tissue. Embodiments may also utilize photons with relatively low energy, so that molecules of the compounds disclosed herein must absorb, for example, 3, 4, or 5 photons simultaneously to release reactive radicals.Since multiple photons are unlikely to be absorbed at nearly the same time, a high flux of excitation photons may be required, which can be delivered via a femtosecond laser.
[0321] In some embodiments, the electromagnetic radiation is applied continuously (continuous wave (CW)) or as pulsed radiation. In certain embodiments, this selection affects the amount, rate and extent of cross-linking. In certain embodiments, when the electromagnetic radiation light is applied as pulsed radiation, the duration of the exposure cycle, the dark cycle, and the ratio of the exposure cycle to the dark cycle duration affect the resulting corneal reinforcement. Pulsed radiation can be used to achieve greater or less reinforcement of the corneal tissue than can be achieved by continuous wave illumination when delivering the same amount or dose of energy. Light pulses of suitable length and frequency may be used to achieve further optimal chemical amplification. For pulsed light therapy, the on / off duty cycle may be about 1000 / 1 to about 1 / 1000. The irradiance may be about 0.1 mW / cm 2 ~About 1000mW / cm 2 and the pulse rate may be from about 0.01 Hz to about 1000 Hz or from about 1000 Hz to about 100,000 Hz.
[0322] In some embodiments, pulsed radiation can be delivered by using a DMD, electronically turning the light source 110 on and off, and / or using mechanical or optoelectronic (e.g., Pockels cell) shutters or mechanical choppers or rotating apertures. Due to the pixel-specific modulation capabilities of the DMD and subsequent stiffening based on the modulation frequency, duty cycle, irradiance and dose delivered to the cornea, complex biomechanical stiffening patterns can be imparted to the cornea to allow for different amounts of refractive correction. These refractive corrections can include combinations of complex corneal refractive surface corrections due to, for example, myopia, hyperopia, astigmatism, irregular astigmatism, presbyopia, and other conditions such as ocular conditions, for example, keratoconus, pellucid marginal disease, post-LASIK ectasia, and corneal biomechanical changes / degeneration. A specific advantage of the DMD system and method is that it allows for randomized asynchronous pulse topographic patterning, producing non-periodic and uniform appearing illumination, thereby eliminating the possibility of inducing photosensitive epileptic seizures or flicker vertigo at pulse frequencies between 2 Hz and 84 Hz.
[0323] Examples of systems and methods for delivering electromagnetic radiation are described, for example, in U.S. Patent Application Publication No. 2011 / 0237999, filed March 18, 2011, and entitled "Systems and Methods for Applying and Monitoring Eye Therapy," U.S. Patent Application Publication No. 2012 / 0215155, filed April 3, 2012, and entitled "Systems and Methods for Applying and Monitoring Eye Therapy," and U.S. Patent Application Publication No. 2013 / 0245536, filed March 15, 2013, and entitled "Systems and Methods for Corneal Cross-Linking with Pulsed Light," the contents of which are incorporated herein by reference in their entireties.
[0324] oxygen In some embodiments, the claimed methods can be performed in the absence of added or supplemental oxygen levels, which may be advantageous in some applications. In other embodiments, the claimed methods can be performed in the presence of added or supplemental oxygen levels, and as described herein, the claimed methods can further include administering one or more additional therapeutic agents (agents other than the compounds of formula I described herein) for which the use of added or supplemental oxygen levels may be beneficial.
[0325] In some embodiments, the concentration of O2 is actively increased or decreased (e.g., increased) during irradiation to control the cross-linking rate. Oxygen can be applied during cross-linking treatment in several different ways. In some embodiments, a pharmaceutical composition comprising a compound described herein can be supersaturated with O2. Thus, when a compound described herein is applied to the eye, a relatively high concentration of O2 is delivered directly into the cornea along with riboflavin, affecting the reaction involving O2 when riboflavin is exposed to electromagnetic radiation. According to another approach, a steady state of O2 (at a selected concentration, e.g., >21%) can be maintained at the surface of the cornea to expose the cornea to a selected amount of O2 and allow O2 to enter the cornea. Exemplary systems and methods for applying oxygen during cross-linking therapy are described, for example, in U.S. Pat. No. 8,574,277, filed Oct. 21, 2010, and entitled "Eye Therapy," and U.S. Patent Application Publication No. 2013 / 0060187, filed Oct. 31, 2012, and entitled "Systems and Methods for Corneal Cross-Linking with Pulsed Light," the contents of which are incorporated herein by reference in their entireties.
[0326] Thus, in some aspects, the method may further comprise applying a selected concentration of oxygen to the eye, the selected concentration being greater than the concentration of oxygen in atmospheric air.
[0327] Indications In some aspects, the condition, disease, or disorder is an ocular disorder.
[0328] In some aspects, the eye disorder is associated with a decrease in corneal stiffness.
[0329] Diastolic dysfunction In certain embodiments, the condition, disease, or disorder is corneal ectasia disorder.Non-limiting examples of ectasia disorder include keratoconus (e.g., keratoconus with nipple cone, oval cone, or globus cone; e.g., progressive keratoconus), keratoglobuliformis, pellucid marginal degeneration, corneal ectasia (e.g., postoperative ectasia, e.g., post-LASIK ectasia), and Therrien's peripheral corneal degeneration.
[0330] In certain embodiments, the condition, disease, or disorder is a corneal ectasia disorder (e.g., postoperative corneal ectasia) that develops after refractive surgery. Non-limiting examples of refractive surgery include radial keratotomy (RK), laser photorefractive keratectomy (PRK), or laser in situ keratomileusis (LASIK).
[0331] In certain aspects, the condition, disease, or disorder is bacterial keratitis.
[0332] Visual Status In some embodiments, the disease, condition, or disorder is myopia, hyperopia, astigmatism, irregular astigmatism, or presbyopia.
[0333] In some embodiments, the ocular disorder is a cataract (eg, nuclear, cortical, posterior, secondary, traumatic, or radiation cataract) or a lens disorder.
[0334] Combination therapy The present disclosure contemplates both monotherapy and combination therapy regimens.
[0335] In some embodiments, the methods described herein can further include administering one or more additional therapies (e.g., one or more additional therapeutic substances and / or one or more treatment regimens) in combination with the administration of the compounds described herein.
[0336] In some embodiments, the compound described herein can be administered in combination with one or more of additional therapeutic substances.Representative additional therapeutic substances include, but are not limited to, inflammation, cataract, lens disorder, or ectatic disorder, including, but are not limited to, keratoconus (e.g., keratoconus with papillary cone, ovoid cone, or spherocone), keratoglobus, pellucid marginal degeneration, corneal ectasia (e.g., postoperative ectasia, e.g., post-LASIK ectasia) and Therrien marginal corneal degeneration.
[0337] In some embodiments, the one or more additional therapeutic substances include those useful as crosslinkers, including, for example, those described in U.S. Provisional Patent Application entitled Compounds and Compositions for Eye Treatment, filed on even date herewith, and having Attorney Docket No. 45387-0003P01.
[0338] In some embodiments, the one or more additional therapeutic agents include those useful as crosslinking agents, including, for example, those described in U.S. Patent Application Publication No. 2014 / 0343480, filed May 19, 2014, which is incorporated by reference in its entirety. Non-limiting examples include: Riboflavin (e.g., riboflavin or riboflavin phosphate); 2,3-butanedione; Folic acid; Quinoxalines (e.g. Olaquidox); Quinolines (e.g. chloroquinine, hydroxychloroquinine and quinine); Dibucaine; Methotrexate; Menadione; and Verteporfin and derivatives thereof.
[0339] Additional non-limiting examples of cross-linking agents may include photosensitizers such as Rose Bengal, methylene blue, and N-hydroxypyridine-2-(1H)-thione. Further non-limiting examples of cross-linking agents may also include photosensitizers such as Photofrin.RTM, synthetic diporphyrins and dichlorins, phthalocyanines with or without metal substituents, chloroaluminum phthalocyanines with or without various substituents, O-substituted tetraphenylporphyrins, 3,1-mesotetrakis(o-propionamidophenyl)porphyrin, verdin, purpurin, tin and zinc derivatives of octaethylpurpurin, ethiopyridine, phthalocyanines ... Lupulin, hydroporphyrin, bacteriochlorins of the tetra(hydroxyphenyl)porphyrin series (e.g., protoporphyrin I to protoporphyrin IX, coproporphyrin, uroporphyrin, mesoporphyrin, hematoporphyrin, and sapphyrin), chlorins, chlorin e6, mono-1-aspartyl derivatives of chlorin e6, di-1-aspartyl derivatives of chlorin e6, tin(IV) chlorin e6, meta-tetrahydroxyphenyl chlorin (meta-tetrahydroxp henylchlorin, benzoporphyrin derivatives, benzoporphyrin monoacid derivatives, tetracyanoethylene adducts of benzoporphyrin, dimethylacetylene dicarboxylate adducts of benzoporphyrin, Diels-Adler adducts, monoacid ring "a" derivatives of benzoporphyrin, sulfonated aluminum PC, sulfonated AlPc, disulfonated, tetrasulfonated derivatives, sulfonated aluminum naphthalocyanines, naphthalocyanines with or without metal substituents and with or without various substituents, chlorophylis, bacteriochlorophyll A, anthracenediones, anthrapyrazoles, aminoanthraquinones, phenoxazine dyes, thiazines, methylene blue, phenothiazine derivatives, chalcogenapyrylium dyes, cationic selena and tellurapyrylium derivatives, ring-substituted cationic PC, pheophorbide derivatives, natural porphyrins, hematoporphyrin,ALA-induced protoporphyrin IX, endogenous metabolic precursors, 5-aminolevulinic acid, benzonaphthoporphyrazine, cationic iminium salts, tetracycline, lutetium texaphyrin, texaphyrin, tin-ethio-purpurin, porphycene, benzophenothiazinium, xanthene, rose bengal, eosin, erythrosine, cyanine, merocyanine 540, selenium-substituted cyanine, flavin, riboflavin, proflavin, quinone, anthraquinone, benzoquinone, naphthaldiimide, naphthalimide, Victoria blue, toluidine blue, dianthoquinone (e.g., hypericin), fullerene, rhodamine as well as photosensitive derivatives thereof.
[0340] In some embodiments, the one or more additional agents include a metal (including elemental and ionic forms) (e.g., a metal salt, e.g., a divalent metal salt). Non-limiting examples include, optionally in combination with hydrogen peroxide: Iron (e.g., iron(II), e.g., FeSO4) (in certain embodiments, the iron loading material may be dissolved in a citrate buffer); ·copper; ·manganese; ·chromium; ·vanadium; ·aluminum; ·cobalt; ·mercury; ·cadmium; Nickel; and Arsenic Examples include:
[0341] In some embodiments, the one or more additional therapeutic substances include those useful as anesthetics, for example. Non-limiting examples include pilocarpine, proparacaine, tetracaine, or oxybuprocaine.
[0342] In some embodiments, the one or more additional therapeutic substances include those useful as analgesics, for example. Non-limiting examples include menthol, benzyl alcohol, or phenylethyl alcohol.
[0343] In some embodiments, the one or more additional therapeutic substances include those useful for increasing the permeability of the corneal epithelium, for example. Non-limiting examples include zinc metalloproteinase, copper metalloproteinase, papain, bromelain, actinidin, ficain, N-acetylcysteine, ambroxol, carbocysteine, or erdocysteine.
[0344] In some embodiments, the one or more additional therapeutic agents include those useful as treatments for, for example, cataracts and / or lens disorders.
[0345] In some embodiments, the one or more additional therapeutic agents include those useful, for example, as antibiotics.
[0346] In some embodiments, the one or more additional therapeutic agents include those useful in gene therapy, for example.
[0347] In some embodiments, the one or more additional treatment regimens include treatment regimens for inflammation, cataracts, lens disorders, or ectatic disorders including, but not limited to, keratoconus (e.g., keratoconus with papillary cone, ovoid cone, or spherocone), keratoglobus, pellucid marginal corneal degeneration, corneal ectasia (e.g., post-operative ectasia, e.g., post-LASIK ectasia), and Therrien's peripheral corneal degeneration.
[0348] In some embodiments, the one or more additional treatment regimens include treatment regimens for myopia, hyperopia, astigmatism, irregular astigmatism, and presbyopia.
[0349] In some embodiments, the one or more additional therapeutic regimens comprise ophthalmic surgery. Non-limiting examples include: ·Cornea transplant surgery; · Cataract surgery; Laser surgery; Corneal transplantation (keratoplasty) (e.g. penetrating or lamellar keratoplasty); · Refractive surgery (e.g. resection keratomileusis (RK), laser photorefractive keratectomy (PRK) or laser in situ keratomileusis (LASIK)); Corneal reshaping; and Treatment of corneal lacerations Examples include:
[0350] Additional non-limiting examples of the one or more additional therapeutic regimens include contact lens therapy, amniotic membrane therapy, LASIK therapy, and administration of antibiotics.
[0351] Compound preparation and biological assays As can be understood by those skilled in the art, the method of synthesizing the compound of the formula herein will be clear to those skilled in the art.The synthetic chemical transformations and protective group methodologies (protection and deprotection) useful for synthesizing the compounds described herein are known in the art, and include those described in, for example, R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989);TW Greene and RGM. Wuts, Protective Groups in Organic Synthesis, 2d. Ed., John Wiley and Sons (1991);L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994);and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995) and its successive editions.
[0352] In some embodiments, intermediates useful for preparing the compounds described herein can be prepared using the chemistry described in any one or more of the following schemes and non-limiting examples.
[0353] compound preparation Abbreviation TIFF0007595576000057.tif155153 EXAMPLES
[0354] Synthesis Example Synthesis of intermediates I-1, I-2, I-3, and I-4 Intermediates I-1, I-2, I-3, and I-4 were synthesized according to the following scheme. TIFF0007595576000058.tif77143
[0355] Compound II To a stirred solution of 4-hydroxybutan-2-one (i) (50 g, 567 mmol) in 7 M ammonia in methanol (500 mL) was added dropwise a solution of hydroxylamine-O-sulfonic acid (96.27 g, 851 mmol) in dry methanol (200 mL) under nitrogen atmosphere at −40° C. The resulting mixture was stirred at 0° C. for at least 5 hours and then at 20° C. overnight. The mixture was filtered through Celite™ and the solvent was removed under reduced pressure to give compound (ii), which was used directly in the next step without further purification. ESI-MS m / z=103.2[M+H] + .
[0356] Intermediate I-1 To a solution of compound (ii) (340 mmol) and triethylamine (94.73 mL, 680 mmol) in DCM (1 L) was added iodine (86.4 g, 340 mmol) slowly under light protection until a persistent orange-brown color appeared. The resulting mixture was stirred at 20° C. for 2 h. The mixture was then washed with saturated brine and the solvent was removed under reduced pressure. The residue was purified by silica gel chromatography, elution gradient 0-30% EtOAc in petroleum ether to give intermediate (I-1) (13 g) as a yellow liquid. TIFF0007595576000059.tif12157
[0357] Intermediate I-2 To a solution of intermediate (I-1) (3 g, 30 mmol) in DCM (30 mL) was added tosyl chloride (6.1 g, 36 mmol). The mixture was stirred at 0° C. and triethylamine (6.06 g, 60 mmol) was added dropwise. The mixture was allowed to warm to room temperature and stirred for an additional 5 h in the dark. The mixture was then washed with saturated brine and the organic layer was concentrated and evaporated under reduced pressure. The residue was purified by silica gel chromatography to give intermediate (I-2) (5.9 g) as a colorless oil. TIFF0007595576000060.tif12157
[0358] compound iv To a stirred solution of 4-oxopentanoic acid (iii) (30 g, 258.36 mmol) in 7 M ammonia in methanol (400 mL) was added dropwise a solution of hydroxylamine-O-sulfonic acid (43.83 g, 387.54 mmol) in dry methanol (200 mL) under nitrogen atmosphere at −40° C. The resulting mixture was stirred at 0° C. for at least 5 hours and then at 20° C. overnight. The mixture was filtered through Celite™ and the solvent was removed under reduced pressure to give compound (iv), which was used directly in the next step without further purification. ESI-MS m / z=131.1[M+H] + .
[0359] Intermediate I-3 To a stirred solution of compound (iv) (40 g, 307.35 mmol) in DCM (400 mL) protected from light at 0° C., TEA (62.20 g, 614.69 mmol) and iodine (78.01 g, 307.35 mmol) were added portionwise. The resulting mixture was stirred at 20° C. for 2 h, washed with saturated brine (400 mL), and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography, elution gradient 20-40% EtOAc in petroleum ether to give intermediate (I-3) (15.1 g) as a yellow oil.
[0360] compound vi To a stirred solution of 3-[[(tert-butoxy)carbonyl]amino]propanoic acid (v) (60 g, 317.11 mmol), N-methoxy-methylamine hydrochloride (37.12 g, 380.53 mmol) and TEA (80.22 g, 792.77 mmol) in DMF was added HOBT (47.13 g, 348.82 mmol) and EDCl (121.58 g, 634.21 mmol) in portions at 0° C. The mixture was stirred at 20° C. for 5 h and then diluted with water (2 L). The resulting mixture was extracted with EtOAc (3×800 mL) and the combined organic layers were washed with water (3×800 mL), saturated brine (1 L) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue was purified by silica chromatography, elution gradient 0-30% EtOAc in petroleum ether to give compound (vi) (63.5 g) as a pale yellow oil. ESI-MS m / z=233.2[M+H] + .
[0361] compound vii To a stirred solution of compound (vi) (63.5 g, 273.38 mmol) in THF (1 L) at 0° C. under an argon atmosphere, a solution of methylmagnesium bromide 1 M in THF (328 mL, 328.07 mmol) was added dropwise. The mixture was stirred at 0° C. for 5 h, then quenched with aqueous NH4Cl (1 L) and extracted with EtOAc (3×800 mL). The combined organic layers were washed with water (3×1 L), saturated brine (1 L) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, elution gradient 0-15% EtOAc in petroleum ether to give compound (vii) (24.8 g) as a colorless oil. TIFF0007595576000061.tif19153
[0362] compound viii To a stirred solution of compound (vii) (24.8 g, 132.45 mmol) in 7 M ammonia in methanol (300 mL) was added dropwise a solution of hydroxylamine-O-sulfonic acid (29.96 g, 264.90 mmol) in dry methanol under nitrogen atmosphere at −40° C. The resulting mixture was stirred at 0° C. for at least 5 hours and then at 20° C. overnight. The mixture was filtered through Celite™ and the solvent was removed under reduced pressure to give compound (viii), which was used directly in the next step without further purification. ESI-MS m / z=202.3[M+H] + .
[0363] compound ix To a stirred solution of compound (viii) (30 g, 149.05 mmol) in DCM (300 mL) protected from light at 0° C., TEA (30.17 g, 298.11 mmol) and iodine (37.83 g, 149.05 mmol) were added portionwise. The resulting mixture was stirred at 20° C. for 2 h, washed with saturated brine (300 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue was purified by silica gel chromatography, elution gradient 0-30% EtOAc in petroleum ether to give compound (ix) (13 g) as a yellow oil. TIFF0007595576000062.tif19157
[0364] Intermediate I-4 To a stirred solution of compound (ix) (5 g, 25.09 mmol) in DCM (30 mL) at 0° C. was added TFA (15 mL). The mixture was stirred at 20° C. for 2 h and then concentrated under reduced pressure to give intermediate (I-4) trifluoroacetate, which was used in the following procedure without further purification. ESI-MS m / z=197.3[M+H] + .
[0365] Synthesis of Compound 2 (Example 1) Example 1 was synthesized according to the following scheme. TIFF0007595576000063.tif22128
[0366] compound 1 To a solution of intermediate (I-4) (900 mg, 4.5 mmol) obtained from compound (ix) in DCM (20 mL) was added 2-iodoacetic anhydride (354 mg, 6.75 mmol) and DIPEA (1.74 g, 13.5 mmol) in one portion. The mixture was stirred at room temperature for 3 h in the dark, quenched with saturated ammonium chloride, and extracted with EtOAc. The combined organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure to give compound (1) (1.38 g) as a yellow oil. m / z(ES+), [M+H] + =268.
[0367] Compound 2 (Example 1) A mixture of compound (1) (1.38 g), intermediate (I-4) (5 mmol) and potassium carbonate (2.78 g) in DMF (20 mL) was stirred at room temperature for 5 h under light protection. The mixture was diluted with EtOAc (100 mL) and washed with saturated brine and water. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by preparative HPLC, column: XBridge Shield RP18 OBD column 19×250 mm, 10 μm; mobile phase A: 0.05% TFA in water, mobile phase B: MeCN; flow rate: 25 mL / min; gradient: 2% B to 17% B in 7 min; 254 / 220 nm; Rt: 3.81 min to give compound (2) (Example 1) (173.5 mg) as a yellow solid. m / z(ES+), [M+H]+=239. TIFF0007595576000064.tif19157
[0368] Synthesis of Compound 6 (Example 2) Example 2 was synthesized according to the following scheme. TIFF0007595576000065.tif72132
[0369] compound 3 To a stirred room temperature solution of intermediate (I-4) (500 mg, 2.5 mmol) obtained from compound (ix), Fmoc-L-Arg(Pbf)-H (1.6 g, 2.5 mmol), HOBT (407 mg, 3 mmol) and EDCI (0.86 g, 5 mmol) in DMF (20 mL) was added DIPEA (0.96 g, 7.5 mmol) dropwise. The mixture was stirred at room temperature for 3 h under the exclusion of light, then quenched with water and extracted with EtOAc. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified using silica gel chromatography to give compound (3) (1.2 g) as a yellow oil. m / z(ES+), [M+H] + =730.
[0370] compound 4 Compound (3) (1.2 g, 1.65 mmol) was added to a solution of 10% diethylamine in THF (15 mL) and stirred at room temperature for 2 hours under light protection. The mixture was concentrated under reduced pressure to give compound (4), which was used in the next step without further purification. m / z(ES+), [M+H] + =508.
[0371] compound 5 A mixture of compound (4) (1.2 g, 1.65 mmol) obtained from compound (3), intermediate (I-2) (627.38 mg, 2.47 mmol) and potassium carbonate (458.7 mg, 3.3 mmol) in DMF (15 mL) was stirred at 55° C. for 10 hours under light-protected conditions. The mixture was diluted with ethyl acetate (50 mL) and washed with saturated brine and water. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified using silica gel chromatography to give compound (5) (300 mg) as a yellow oil. m / z(ES+), [M+H] + =590.
[0372] Compound 6 (Example 2) To a stirred solution of compound (5) (300 mg, 0.51 mmol) in DCM (10 mL) at 0° C., TFA (5 mL) was added. The mixture was stirred at 0° C. for 2 h, then at room temperature under light for 2 h. The mixture was concentrated under reduced pressure and the residue was purified using preparative HPLC, column: Atlantis Prep T3 OBD column 19×150 mm 5 μm; mobile phase A: water (0.05% TFA), mobile phase B: MeCN; flow rate: 20 mL / min; gradient: 14% B to 14% B in 10 min; 254 / 220 nm; Rt: 8.12 min to give compound (6) (Example 2) (40.8 mg) as a colorless oil after lyophilization. m / z(ES+), [M+H] + =339. TIFF0007595576000066.tif19157
[0373] Synthesis of Compound 10 (Example 3) Example 3 was synthesized according to the following scheme. TIFF0007595576000067.tif61154
[0374] compound 7 To a stirred room temperature solution of intermediate (I-4) (500 mg, 2.5 mmol) obtained from compound (ix), Fmoc-L-Gln(Trt)-OH (1.53 g, 2.5 mmol), HOBt (407 mg, 3 mmol) and EDCI (0.86 g, 5 mmol) in DMF (20 mL) was added DIPEA (0.96 g, 7.5 mmol) dropwise. The mixture was stirred at room temperature for 3 h under the exclusion of light, then quenched with water and extracted with EtOAc. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified using silica gel chromatography to give compound (7) (1.37 g) as a yellow oil. m / z(ES+), [M+H] + =692.
[0375] compound 8 Compound (7) (1.37 g, 2.92 mmol) was added to a solution of 10% diethylamine in THF (15 mL) and stirred at room temperature for 2 hours under light-protected conditions. The mixture was concentrated under reduced pressure, and the residue was purified using silica gel chromatography to give compound (8) (680 mg) as a yellow solid. m / z(ES+), [M+H] + =470.
[0376] compound 9 A mixture of compound (8) (680 mg, 1.45 mmol), intermediate (I-2) (551 mg, 2.17 mmol) and potassium carbonate (403.1 mg, 2.9 mmol) in DMF (15 mL) was stirred at 55° C. for 10 h under light protection. The mixture was diluted with ethyl acetate (50 mL) and washed with saturated brine and water. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give compound (9) as a yellow oil, which was used directly in the next step without further purification. m / z(ES+), [M+H] + =590.
[0377] Compound 10 (Example 3) To a stirred solution of compound (9) from the previous step in DCM (10 mL) at 0° C., TFA (5 mL) was added. The mixture was stirred at 0° C. for 2 h, then at room temperature under light for 2 h. The mixture was concentrated under reduced pressure and the residue was purified using preparative HPLC, column: SunFire C18 OBD column, 100 Å, 5 μm, 19 mm×250 mm; mobile phase A: water (0.05% TFA), mobile phase B: MeCN; flow rate: 25 mL / min; gradient: 10% B to 30% B in 10 min; 254 / 220 nm; Rt: 8.76 min to give compound (10) (Example 3) (39 mg) as a colorless oil after lyophilization. TIFF0007595576000068.tif27157
[0378] Synthesis of Compound 14 (Example 4) Example 4 was synthesized according to the following scheme. TIFF0007595576000069.tif54140
[0379] compound 11 To a stirred room temperature solution of intermediate (I-4) (500 mg, 2.5 mmol) obtained from compound (ix), Fmoc-L-Ser(tBu)-OH (960 mg, 2.5 mmol), HOBt (407 mg, 3 mmol) and EDCI (0.86 g, 5 mmol) in DMF (10 mL), DIPEA (0.96 g, 7.5 mmol) was added dropwise. The mixture was stirred at room temperature for 3 h under the exclusion of light, then quenched with water and extracted with EtOAc. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give compound (11) as a yellow oil, which was used in the next step without further purification. m / z(ES+), [M+H] + =465.
[0380] compound 12 Compound (11) from the previous step was added to a solution of 10% diethylamine in THF (15 mL) and stirred at room temperature for 2 hours under light protection. The mixture was concentrated under reduced pressure, and the residue was purified using silica gel chromatography to give compound (12) (480 mg) as a yellow solid. m / z(ES+), [M+H] + =243.
[0381] compound 13 A mixture of compound (12) (480 mg, 1.98 mmol), intermediate (I-2) (757 mg, 2.98 mmol) and potassium carbonate (550.4 mg, 3.96 mmol) in DMF (15 mL) was stirred at 55° C. for 10 h under light protection. The mixture was diluted with ethyl acetate (50 mL) and washed with saturated brine and water. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give compound (13), which was used directly in the next step without further purification. m / z(ES+), [M+H] + =324.
[0382] Compound 14 (Example 4) To a stirred solution of compound (13) from the previous step in DCM (10 mL) at 0° C., TFA (5 mL) was added. The mixture was stirred at 0° C. for 2 h, then at room temperature under light for 2 h. The mixture was concentrated under reduced pressure and the residue was purified using preparative HPLC, column: SunFire C18 OBD Prep column, 100 Å, 5 μm, 19 mm×250 mm; mobile phase A: water (0.05% TFA), mobile phase B: MeCN; flow rate: 25 mL / min; gradient: 10% B to 30% B in 10 min; 254 / 220 nm; Rt: 8.38 min to give compound (14) (Example 4) (71 mg) as a colorless oil after lyophilization. TIFF0007595576000070.tif27157
[0383] Synthesis of Compound 18 (Example 5) Example 5 was synthesized according to the following scheme. TIFF0007595576000071.tif59151
[0384] compound 15 To a stirred room temperature solution of intermediate (I-4) (500 mg, 2.5 mmol) obtained from compound (ix), Fmoc-L-Glu(tBu)-OH.HO (1.06 g, 2.5 mmol), HOBt (407 mg, 3 mmol) and EDCI (0.86 g, 5 mmol) in DMF (10 mL) was added DIPEA (0.96 g, 7.5 mmol) dropwise. The mixture was stirred at room temperature for 3 h under the exclusion of light, then quenched with water and extracted with EtOAc. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified using silica gel chromatography to give compound (15) (520 mg) as a yellow oil. m / z(ES+), [M+H] + =507.
[0385] compound 16 Compound (15) (520 mg, 1.03 mmol) was added to a solution of 10% diethylamine in THF (15 mL) and stirred at room temperature for 2 hours under light-protected conditions. The mixture was concentrated under reduced pressure to give compound (16), which was used in the next step without further purification. m / z(ES+), [M+H] + =285.
[0386] compound 17 A mixture of compound (16) obtained from the previous step, intermediate (I-2) (381 mg, 1.5 mmol), and potassium carbonate (278.1 mg, 2 mmol) in DMF (15 mL) was stirred at 55° C. for 10 h under light protection. The mixture was diluted with ethyl acetate (50 mL) and washed with saturated brine and water. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified using silica gel chromatography to give compound (17) (150 mg) as a yellow oil. m / z(ES+), [M+H] + =367.
[0387] Compound 18 (Example 5) To a stirred solution of compound (17) (150 mg, 0.51 mmol) in DCM (10 mL) at 0° C., TFA (5 mL) was added. The mixture was stirred at 0° C. for 2 h, then at room temperature under light for 2 h. The mixture was concentrated under reduced pressure and the residue was purified using preparative HPLC, column: Atlantis Prep T3 OBD column 19×150 mm 5 μm; mobile phase A: water (0.05% TFA), mobile phase B: MeCN; flow rate: 20 mL / min; gradient: 20% B to 20% B in 8 min; 254 / 220 nm; Rt: 7.57 min to give compound (18) (Example 5) (11.3 mg) as a colorless oil after lyophilization. TIFF0007595576000072.tif27157
[0388] Synthesis of Compound 25 (Example 6) Example 6 was synthesized according to the following scheme. TIFF0007595576000073.tif77149
[0389] compound 19 To a stirred solution of intermediate (I-2) (2.30 g, 9.04 mmol) and tert-butyl 3-aminopropanoate (5.25 g, 36.18 mmol) in MeCN (30 mL) at 0° C., K2CO3 (12.50 g, 90.45 mmol) was added. The mixture was stirred at 60° C. for 16 h and then concentrated under reduced pressure. The residue was diluted with water (100 mL) and extracted with EtOAc (3×100 mL). The combined organic layers were washed with water (3×100 mL), saturated brine (200 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography eluted with PE / EtOAc (3:1) to give compound (19) (1.5 g) as a colorless oil. ESI-MS m / z=228.5[M+H] + .
[0390] compound 20 To a stirred solution of compound (19) (1.50 g, 6.6 mmol) in DCM (10 mL) was added TFA (10 mL). The mixture was stirred at 20° C. for 6 h and then concentrated under reduced pressure to give compound (20), which was used in the next step without further purification. ESI-MS m / z=172.2[M+H] + .
[0391] compound 21 To a stirred 0° C. mixture of compound (20) (1 g, 5.84 mmol) in 1,4-dioxane (50 mL) and saturated aqueous NaHCO3 (50 mL) was added di-tert-butyl dicarbonate (1.91 g, 8.75 mmol) in portions. The mixture was then stirred at 20° C. for 16 h and then concentrated under reduced pressure. The residue was extracted with EtOAc (2×100 mL), which was discarded, and the remaining solution was acidified to pH 6 with 1 M HCl. The resulting mixture was extracted with EtOAc (3×300 mL). The combined organic layers were washed with water (2×300 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue was purified using reverse-phase silica gel chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.05% formic acid in water, B: MeCN, gradient from 10% to 100% in 25 min; detector, UV 200 nm to give compound (21) (1 g) as a colorless oil. ESI-MS m / z=272.3[M+H] + ;294.2[M+Na] + .
[0392] compound 22 To a stirred solution of compound (21) (3 g, 7.29 mmol) in DMF (100 mL) at 0° C., intermediate (I-1) (0.80 g, 8.02 mmol), DIPEA (1884.68 mg, 14.58 mmol), HOBT (197.04 mg, 1.46 mmol) and EDCI (1471.46 mg, 9.48 mmol) were added. The resulting mixture was stirred at 20° C. for 16 h, then diluted with water (300 mL) and extracted with EtOAc (3×300 mL). The combined organic layers were washed with water (2×300 mL), saturated aqueous NaCl solution (300 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography eluted with PE / EtOAc (4:1) to give compound (22) (3 g) as an off-white solid. TIFF0007595576000074.tif41157
[0393] compound 23 To a stirred solution of compound (22) (2 g, 4.05 mmol) in THF (30 ml) at 0° C. was added diethylamine (15 mL) dropwise. The mixture was stirred at 20° C. for 4 h and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with PE / EtOAc (10:1) followed by DCM / MeOH (7:1) to give compound (23) (1 g) as a pale yellow oil. ESI-MS m / z=272.2[M+H] + .
[0394] compound 24 To a stirred solution of compound (23) (600 mg, 2.21 mmol) and compound (21) (600 mg, 2.21 mmol) in DMF (5 mL) at 0° C., DIPEA (857.44 mg, 6.63 mmol) and HATU (1261.28 mg, 3.32 mmol) were added. The mixture was stirred at 0° C. for 2 h, then diluted with water (50 mL) and extracted with EtOAc (3×30 mL). The combined organic layers were washed with water (3×30 mL), saturated brine (50 mL), and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue was purified by reversed-phase silica gel chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.05% formic acid in water, B: MeCN, 0-100% B in 30 min, detector, UV 200 nm to give compound (24) (800 mg) as a pale yellow oil. ESI-MS m / z=525.3[M+H] + ;547.3[M+Na] + .
[0395] Compound 25 (Example 6) To a stirred solution of compound (24) (800 mg, 1.53 mmol) in 1,4-dioxane (10 mL) at 0° C. was added a solution of 4 M HCl in 1,4-dioxane (20 mL) dropwise. The resulting mixture was stirred at 20° C. for 6 hours and then concentrated under reduced pressure to provide compound (25) (Example 6) (550 mg) as a pale yellow oil. TIFF0007595576000075.tif34157
[0396] Synthesis of Compound 29 (Example 7) Example 7 was synthesized according to the following scheme. TIFF0007595576000076.tif60145
[0397] compound 26 To a solution of Fmoc-L-His(Trt)-OH (774.7 mg, 1.25 mmol), intermediate (I-1) (250 mg, 2.5 mmol) and N,N-dimethylaminopyridine (5 mg, 0.125 mmol) in DCM (15 mL) was added EDCI (361 mg, 1.88 mmol). The mixture was stirred at room temperature for 2 h in the dark, then diluted with DCM (50 mL) and washed with water (20 mL) and saturated brine (10 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and evaporated. The residue was purified using silica gel chromatography to give compound (26) (841 mg). m / z(ES+), [M+H] + =702.
[0398] compound 27 Compound (26) (841 mg, 1.2 mmol) was dissolved in a solution of 10% diethylamine in THF (10 mL) and stirred at room temperature for 2 hours under light-protected conditions. The mixture was concentrated under reduced pressure, and the residue was purified using silica gel chromatography to give compound (27) (420 mg) as a yellow solid. TIFF0007595576000077.tif34157
[0399] compound 28 A mixture of compound (27) (420 mg, 0.88 mmol), compound (21) (271 mg, 1.00 mmol), PyBOP (0.91 g, 1.75 mmol), and DIPEA (338.6 mg, 2.63 mmol) in DMF (10 mL) was stirred overnight at room temperature under light protection. The mixture was quenched and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give compound (28) (490 mg). m / z(ES+), [M+H] + =733.
[0400] Compound 29 (Example 7) To a solution of compound (28) (490 mg, 0.67 mmol) in DCM (10 mL) at 0° C., TFA (5 mL) was added. The mixture was stirred at 0° C. for 2 h, then at room temperature under light for 2 h. The mixture was concentrated under reduced pressure, and the residue was purified by preparative HPLC, column: XBridge Prep Phenyl OBD column 19×150 mm, 5 μm; mobile phase A: water (0.05% TFA), mobile phase B: MeCN; flow rate: 20 mL / min; gradient: 15% B to 15% B in 7 min; 254 / 220 nm; Rt: 4.92 min, to give compound (29) (Example 7) (62.7 mg) as a colorless oil after lyophilization. TIFF0007595576000078.tif34157
[0401] Synthesis of Compound 33 (Example 8) Example 8 was synthesized according to the following scheme. TIFF0007595576000079.tif60139
[0402] compound 30 To a solution of Fmoc-L-Lys(Boc)-OH (585.7 mg, 1.25 mmol), intermediate (I-1) (250 mg, 2.5 mmol) and N,N-dimethylaminopyridine (5 mg, 0.13 mmol) in DCM (15 mL) was added EDCI (361 mg, 1.88 mmol). The mixture was stirred at room temperature for 2 h under light protection, then diluted with DCM (50 mL) and washed with water (20 mL) and saturated brine (10 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified using silica gel chromatography to give compound (30) (717 mg). m / z(ES+), [M+Na] + =573.
[0403] compound 31 Compound (30) (717 mg, 1.31 mmol) was dissolved in a solution of 10% diethylamine in THF (10 mL), and the mixture was stirred at room temperature for 2 h under light protection. The mixture was concentrated under reduced pressure, and the residue was purified using silica gel chromatography to give compound (31) (240 mg) as a yellow solid. m / z(ES+), [M+H] + =329.
[0404] compound 32 A solution of compound (31) (240 mg, 0.73 mmol), compound (21) (271 mg, 1.00 mmol), PyBOP (0.76 g, 1.46 mmol) and DIPEA (282 mg, 2.19 mmol) in DMF (10 mL) was stirred overnight at room temperature under light protection. The mixture was quenched with water and extracted with EtOAc. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give compound (32) (620 mg). m / z(ES+), [M+H] + =582.
[0405] Compound 33 (Example 8) To a solution of compound (32) (620 mg, 1.07 mmol) in DCM (10 mL) at 0° C., TFA (5 mL) was added. The mixture was stirred at 0° C. for 2 h, then at room temperature under light for 2 h. The mixture was concentrated under reduced pressure, and the residue was purified by preparative HPLC, column: XBridge Prep Phenyl OBD column 19×150 mm, 5 μm; mobile phase A: water (0.05% TFA), mobile phase B: MeCN; flow rate: 20 mL / min; gradient: 15% B to 15% B in 7 min; 254 / 220 nm; Rt: 4.92 min to give compound (33) (Example 8) (47.7 mg) as a colorless oil after lyophilization. TIFF0007595576000080.tif27157
[0406] Synthesis of Compound 37 (Example 9) Example 9 was synthesized according to the following scheme. TIFF0007595576000081.tif65145
[0407] compound 34 To a stirred solution of (2S)-4-(tert-butoxy)-2-([[(9H-fluoren-9-yl)methoxy]carbonyl]amino)-4-oxobutanoic acid (6.23 g, 15.13 mmol) and intermediate (I-4) (1.50 g, 15.13 mmol) in DMF (50 mL) at 0° C., DIPEA (11.73 g, 90.78 mmol) and HATU (8.63 g, 22.69 mmol) were added in portions. The mixture was stirred at 0° C. for 2 h, then diluted with water (100 mL) and extracted with EtOAc (3×100 mL). The organic layer was washed with water (2×100 mL), saturated brine (100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure, and the residue was purified using silica gel column chromatography eluted with PE / EtOAc (3:1) to give compound (34) (2 g) as a pale yellow solid. ESI-MS m / z=493[M+H] + ;515[M+Na] + .
[0408] compound 35 To a stirred solution of compound (34) (600 mg, 1.25 mmol) in THF (15 mL) at 0° C. was added diethylamine (15 mL). The mixture was stirred at 20° C. for 4 h and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with PE / EtOAc=10:1, then DCM / MeOH (10:1) to give compound (35) (300 mg) as a pale yellow oil. ESI-MS m / z=271.4[M+H] + .
[0409] compound 36 To a stirred solution of compound (21) (300 mg, 1.11 mmol) and compound (35) (300 mg, 1.11 mmol) in DMF (5.00 mL) at 0 °C, DIPEA (428.72 mg, 3.32 mmol) and HATU (630.64 mg, 1.66 mmol) were added in portions. The mixture was stirred at 0 °C for 2 h, then concentrated under reduced pressure, and the residue was purified by reversed-phase silica gel chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.5% NH4HCO3 aqueous solution, 0-100 B% in 30 min, B: MeCN, detector: UV 200 nm, 60% B to give compound (36) (300 mg) as a colorless oil. ESI-MS m / z=524.4[M+H] + ;546.3[M+Na] + .
[0410] Compound 37 (Example 9) A solution of compound (36) (180 mg, 34.40 mmol) in 4 M HCl in 1,4-dioxane (4.0 mL) was stirred at 20° C. The mixture was concentrated under reduced pressure and the residue was purified by reverse-phase silica gel chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.01% HCl in water; B: MeCN, gradient 0% to 100% in 25 min; detector, UV 200 nm to give compound (37) (Example 9) (144 mg, 99.78%) as a pale yellow semi-solid. TIFF0007595576000082.tif27158
[0411] Synthesis of Compound 43 (Example 10) Example 10 was synthesized according to the following scheme. TIFF0007595576000083.tif60157
[0412] compound 38 To a stirred solution of intermediate (I-4) (800 mg, 4.10 mmol) and (2S)-6-[[(tert-butoxy)carbonyl]amino]-2-([[(9H-fluoren-9-yl)methoxy]carbonyl]amino)hexanoic acid (1920.83 mg, 4.10 mmol) in DMF (10 mL) at 0° C., DIPEA (3179.01 mg, 24.6 mmol) and HATU (2026.08 mg, 5.33 mmol) were added. The mixture was stirred at 0° C. for 2 h, then diluted with water (200 mL) and extracted with EtOAc (3×100 mL). The combined organic layers were washed with water (2×100 mL), saturated brine (200 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue was purified by reverse-phase silica gel chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.05% NH4HCO3 in water; B: MeCN, detector: 200 nm, 80% B to give compound (38) (1.2 g) as a pale yellow solid. ESI-MS m / z=572.4[M+Na] + .
[0413] compound 39 To a solution of compound (38) (600 mg, 1091.56 mmol) in THF (60 mL) was added diethylamine (30 mL). The resulting mixture was stirred at 20° C. for 4 h and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with PE / EtOAc (10:1) followed by DCM / MeOH (7:1) to give compound (39) (300 mg) as a colorless oil. ESI-MS m / z=328.2[M+H] + .
[0414] compound 40 To a stirred solution of compound (21) (248.59 mg, 0.92 mmol) and compound (39) (300 mg, 0.92 mmol) in DMF (5 mL) at 0° C., DIPEA (355.25 mg, 2.75 mmol) and HATU (522.57 mg, 1.37 mmol) were added. The mixture was stirred at 0° C. for 2 h, then concentrated under reduced pressure, and the residue was purified by reverse-phase silica gel chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.05% NH4HCO3 in water, B: MeCN; detector, 200 nm, gradient of 10% to 80% in 20 min to give compound (40) (300 mg) as a colorless oil. ESI-MS m / z=581.4[M+H] + .
[0415] compound 41 Compound (40) (300 mg) was stirred in a solution of 4 M HCl in 1,4-dioxane (15 mL) for 6 h at 20° C. The resulting mixture was concentrated under reduced pressure to give compound (41), which was used in the next step without further purification. ESI-MS m / z=381.3[M+H] + .
[0416] compound 42 To a stirred solution of compound (41) (290 mg, 0.76 mmol) and tert-butyl N-[(1E)-[[(tert-butoxy)carbonyl]amino][(methylsulfanyl)amino]methylidene]carbamate (465.51 mg, 1.52 mmol) in DMF (5.00 mL) at 0 °C, TEA (0.23 g, 2.27 mmol) and N,N-dimethylaminopyridine (18.62 mg, 0.15 mmol) were added in portions. The mixture was stirred at 20 °C overnight, then concentrated under reduced pressure, and the residue was purified by reversed-phase silica gel chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.05% formic acid in water, B: MeCN, detector, UV 254 nm, gradient 10% to 90% in 25 min to give compound (42) (200 mg) as a yellow oil. ESI-MS m / z=623.5[M+H]+ .
[0417] Compound 43 (Example 10) Compound (42) (200 mg, 0.32 mmol) in a solution of 4 M HCl in 1,4-dioxane (5 mL) was stirred for 6 h at 20° C. The mixture was concentrated under reduced pressure and the residue was purified by reverse-phase silica gel chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.01% HCl in water; B: MeCN, gradient 0% to 100% in 30 min; detector, UV 200 nm to give compound (43) (Example 10) (83 mg) as a pale yellow semi-solid. TIFF0007595576000084.tif27157
[0418] Synthesis of Compound 45 (Example 11) Example 11 was synthesized according to the following scheme. TIFF0007595576000085.tif25152
[0419] compound 44 To a stirred solution of intermediate (I-3) (94.79 mg, 0.74 mmol) and compound (35) (200 mg, 0.74 mmol) in DMF (2 mL) at 0° C., DIPEA (382.47 mg, 2.96 mmol) and HATU (365.74 mg, 0.96 mmol) were added. The mixture was stirred at 0° C. for 2 h, concentrated under reduced pressure, and the residue was purified by reverse-phase silica gel chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.05% NH4HCO3 in water; B: MeCN, 70% B to give compound (44) (300 mg) as a pale yellow oil. ESI-MS m / z=381.2[M+H] + .
[0420] Compound 45 (Example 11) Compound (44) (100 mg, 0.53 mmol) in a solution of 4 M HCl in dioxane (5 mL) was stirred for 6 h at 20° C. The resulting mixture was concentrated under vacuum and the residue was purified by reverse-phase silica gel chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.01% formic acid in water; B: MeCN, gradient 10% to 60% in 20 min; detector, UV 200 nm to give compound (45) (Example 11) (53 mg) as a white solid. TIFF0007595576000086.tif34153
[0421] Synthesis of Compound 49 (Example 12) Example 12 was synthesized according to the following scheme. TIFF0007595576000087.tif63150
[0422] compound 46 To a stirred solution of intermediate (I-4) (800 mg, 8.07 mmol) and (2S)-4-[[(tert-butoxy)carbonyl]amino]-2-([[(9H-fluoren-9-yl)methoxy]carbonyl]amino)butanoic acid (3.55 g, 8.07 mmol) in DMF (10.00 mL) at 0° C., DIPEA (3.13 g, 24.21 mmol) and HATU (4.60 g, 12.10 mmol) were added. The mixture was stirred at 0° C. for 2 h, then diluted with water (100 mL) and extracted with EtOAc (3×100 mL). The combined organic layer was washed with water (2×200 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography eluted with PE / EtOAc (3:1) to give compound (46) (1 g) as a white solid. ESI-MS m / z=522.3[M+H] + .
[0423] compound 47 A solution of compound (46) (1 g, 1.92 mmol) and diethylamine (4 mL) in THF (20 mL) was stirred for 4 h at 20° C. The mixture was concentrated under reduced pressure and the residue was purified by silica gel column chromatography eluted with PE / EtOAc (10:1) followed by DCM / MeOH (7:1) to give compound (47) (300 mg) as a pale yellow oil. ESI-MS m / z=300.4[M+H] + .
[0424] compound 48 To a stirred solution of compound (47) (300 mg, 1.0 mmol) and intermediate (I-3) (128.4 mg, 1.0 mmol) in DMF (5.00 mL) at 0 °C, HATU (495.33 mg, 1.30 mmol) and DIPEA (388.54 mg, 3.01 mmol) were added. The mixture was stirred at 0 °C for 2 h, then concentrated under reduced pressure, and the residue was purified by reverse-phase silica gel chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.05% NH4HCO3 aqueous solution; B: MeCN, detector: UV 200 nm, 0-100% B, 50% B in 25 min to give compound (48) (300 mg) as a colorless oil. ESI-MS m / z=410.3[M+H] + .
[0425] Compound 49 (Example 12) Compound (48) (300 mg, 0.73 mmol) in a solution of 4 M HCl in dioxane (3 ml) was stirred for 2 h at 20° C. The mixture was concentrated under reduced pressure and the residue was purified by reverse-phase silica gel chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.05% NH4HCO3 in water; B: MeCN, gradient 10% to 70%; detector, UV 200 nm to give compound (49) (Example 12) (206.8 mg) as a white solid. TIFF0007595576000088.tif27157
[0426] Synthesis of Compound 52 (Example 13) Example 13 was synthesized according to the following scheme. TIFF0007595576000089.tif59128
[0427] compound 50 To a stirred solution of intermediate (I-2) (2 g, 7.87 mmol) and tert-butyl 2-aminoacetate hydrochloride (3.09 g, 23.59 mmol) in MeCN (20 mL) at room temperature was added K2CO3 (6.53 g, 47.33 mmol). After stirring the mixture at 70° C. for 16 h, it was concentrated under reduced pressure, diluted with water (200 mL) and extracted with EtOAc (3×200 mL). The combined organic layers were washed with water (2×300 mL), dried over anhydrous Na2SO4, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography eluted with PE / EtOAc (3:1) to give compound (50) (1.2 g) as a pale yellow oil. ESI-MS m / z=214.3[M+H] + .
[0428] compound 51 To a stirred solution of compound (50) (1.2 g, 5.63 mmol) in DMF (10 mL) at 0° C., NaH (0.68 g, 17.10 mmol) was added portionwise. The mixture was stirred at 0° C. for 0.5 h, and then a solution of intermediate (I-2) (1.43 g, 5.63 mmol) in DMF (3 mL) was added dropwise. The resulting mixture was stirred at 20° C. for 4 h, and then quenched with saturated aqueous NH4Cl (40 mL) at 0° C. The mixture was extracted with EtOAc (3×30 mL), and the combined organic layers were washed with water (2×40 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue was purified by reverse-phase silica gel chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.05% NH4HCO3 water, B: MeCN, gradient 0% to 100% in 25 min; detector, UV 200 nm to give compound (51) (300 mg) as a pale yellow oil. ESI-MS m / z=296.2[M+H] + .
[0429] Compound 52 (Example 13) Compound (51) (200 mg, 0.68 mmol) in a solution of 4 M HCl in dioxane (10 mL) was stirred for 6 h at 20° C. The mixture was concentrated under reduced pressure and the residue was purified by preparative HPLC using the following conditions: Column: SunFire Prep C18 OBD column 19×150 mm, 5 μm; Mobile phase A: water (0.1% formic acid), Mobile phase B: MeCN; Flow rate: 25 mL / min; Gradient: 5% B to 25% B in 8 min; 254 / 220 nm; Rt: 7.23 min to give compound (52) (Example 13) (53 mg) as a colorless oil. TIFF0007595576000090.tif19157
[0430] Synthesis of Compound 54 (Example 14) Example 14 was synthesized according to the following scheme. TIFF0007595576000091.tif21150
[0431] compound 53 To a stirred solution of compound (50) (300 mg, 1.41 mmol) and intermediate (I-3) (180.23 mg, 1.41 mmol) in DMF (5.00 mL) at 0 °C, DIPEA (545.38 mg, 4.22 mmol) and HATU (802.24 mg, 2.11 mmol) were added. The mixture was stirred at 0 °C for 2 h, then concentrated under reduced pressure, and the residue was purified by reverse-phase silica gel chromatography using the following conditions: column, C18 silica gel; mobile phase, A: NH4HCO3 aqueous solution; B: MeCN, detector, UV 200 nm. 0-100% B, 50% B in 25 min to give compound (53) (200 mg) as a pale yellow oil. ESI-MS m / z=324.3[M+H] + .
[0432] Compound 54 (Example 14) To a stirred solution of compound (53) (200 mg, 0.62 mmol) in 1,4-dioxane at 0° C. was added 4 M HCl in 1,4-dioxane. The mixture was stirred at 20° C. for 6 h, then concentrated under reduced pressure and the residue was purified by reverse-phase silica gel chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.1% formic acid in water; B: MeCN, gradient 10% to 70% in 20 min; detector, UV 200 nm to give compound (54) (Example 14) (50 mg) as a white solid. TIFF0007595576000092.tif27153
[0433] Synthesis of Compound 57 (Example 15) Example 15 was synthesized according to the following scheme. TIFF0007595576000093.tif78136
[0434] compound 55 To a stirred solution of tert-butyl N-(2-aminoethyl)carbamate (630.03 mg, 3.93 mmol) and intermediate (I-2) (500 mg, 1.97 mmol) in MeCN (20 mL) at 0° C. was added K2CO3 (543.44 mg, 3.99 mmol) and KI (32.63 mg, 0.2 mmol). The mixture was stirred at 70° C. for 16 h, then concentrated under reduced pressure, diluted with water (20 mL), and extracted with EtOAc (3×20 mL). The combined organic layer was washed with water (20 mL), dried over anhydrous Na2SO4, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with PE / EtOAc (1:1) to give compound (55) (280 mg) as a pale yellow oil. ESI-MS m / z=243.3[M+H] + .
[0435] compound 56 To a stirred solution of intermediate (I-3) (148.05 mg, 1.16 mmol) and compound (55) (280 mg, 1.16 mmol) in DMF (2 mL) at 0° C., DIPEA (448.01 mg, 3.47 mmol) and HATU (571.15 mg, 1.50 mmol) were added. The mixture was stirred at 20° C. for 2 h and then concentrated under reduced pressure. The residue was purified by reverse-phase silica gel chromatography using the following conditions: column, C18 silica gel; mobile phase, A: NH4HCO3 aqueous solution, B: MeCN, detector, 200 nm, 70% B to give compound (56) (270 mg) as a colorless oil. ESI-MS m / z=353.3[M+H] + .
[0436] Compound 57 (Example 15) To a stirred solution of compound (56) (200 mg) in 1,4-dioxane at 0° C. was added dropwise a solution of 4 M HCl in 1,4-dioxane (6 mL). The mixture was stirred at 20° C. for 6 h and then concentrated in vacuo to give compound (57) (Example 15) (100 mg) as a colorless oil. TIFF0007595576000094.tif27152
[0437] Synthesis of Compound 60 (Example 16) Example 16 was synthesized according to the following scheme. TIFF0007595576000095.tif78131
[0438] compound 58 To a stirred solution of tert-butyl 1-oxa-6-azaspiro[2.5]octane-6-carboxylate (600 mg, 2.81 mmol) and intermediate (I-4) (278.90 mg, 2.81 mmol) in ethanol (50 mL) at 0° C., NaHCO3 (708.88 mg, 8.44 mmol) was added in portions. The mixture was stirred at 80° C. for 16 h and then concentrated under reduced pressure. The residue was purified by reversed-phase silica gel chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.05% formic acid in water; B: MeCN, detector, UV 200 nm, 20% B to give compound (58) (500 mg) as a yellow oil. ESI-MS m / z=313.4[M+H] + .
[0439] compound 59 To a stirred solution of intermediate (I-3) (236.4 mg, 1.85 mmol) and compound (58) (524 mg, 1.68 mmol) in DMF (5 mL) at 0 °C, DIPEA (650 mg, 5.04 mmol) and HATU (829.07 mg, 2.18 mmol) were added. The mixture was stirred at 0 °C for 2 h and then concentrated under reduced pressure. The residue was purified by reverse-phase silica gel chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.05% formic acid in water; B: MeCN, detector, UV 254 nm, 0-100% B in 30 min to give compound (59) (300 mg) as a colorless oil. ESI-MS m / z=445.3[M+Na] + .
[0440] Compound 60 (Example 16) To a stirred solution of compound (59) (200 mg, 0.47 mmol) in MeCN at 0° C. was added dropwise a solution of 4 M HCl in 1,4-dioxane (4 mL). The mixture was stirred at 20° C. for 2 h and then concentrated under reduced pressure. The residue was purified by reverse phase silica gel chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.05% formic acid in water; B: MeCN, detector, UV 200 nm, 0-100%, 20% B in 25 min to give compound (60) (Example 16) (100 mg) as a colorless oil. TIFF0007595576000096.tif27157
[0441] Synthesis of Compound 64 (Example 17) Example 17 was synthesized according to the following scheme. TIFF0007595576000097.tif44150
[0442] compound 61 To a stirred solution of compound (50) (750 mg) in DCM (15 mL) was added TFA (15 mL) at 20° C. The mixture was stirred at 20° C. for 6 h and then concentrated under reduced pressure to give compound (61), which was used in the next step without further purification. ESI-MS m / z=158.2[M+H] + .
[0443] compound 62 To a stirred solution of compound (61) (750 mg, 0.48 mol) in 1,4-dioxane (10 mL) and saturated aqueous NaHCO3 (10 mL) at 0 °C, di-tert-butyl dicarbonate (2.3 g, 10.75 mmol) was added portionwise. The resulting mixture was stirred at 20 °C for 16 h and then neutralized to pH 6-7 with 1 M HCl. The aqueous layer was extracted with EtOAc (3 × 50 mL) and the combined organic layers were washed with water (3 × 50 mL), saturated brine (100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue was purified by reversed-phase silica gel chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.05% aqueous formic acid, B: MeCN, gradient 0%-100% in 30 min, UV 200 nm to give compound (62) (250 mg) as a pale yellow oil. ESI-MS m / z=258.2[M+H] + .
[0444] compound 63 To a stirred solution of compound (62) (237.94 mg, 0.93 mmol) and compound (35) (250 mg, 0.93 mmol) in DMF (5 mL) at 0° C., DIPEA (358.57 mg, 2.77 mmol) and HATU (457.12 mg, 1.2 mmol) were added in portions. The mixture was stirred at 20° C. for 2 h, then concentrated under reduced pressure, and the residue was purified by reversed-phase silica gel chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.05% formic acid in water; B: MeCN, gradient 0% to 100% in 30 min; detector, UV 200 nm, to give compound (63) (380 mg) as a pale yellow oil. ESI-MS m / z=510.3[M+H] + .
[0445] Compound 64 (Example 17) To a stirred solution of compound (63) (200 mg, 0.39 mmol) in 1,4-dioxane at 0° C. was added dropwise 4M HCl in 1,4-dioxane (3 mL). The mixture was stirred at 20° C. for 6 h and then concentrated under reduced pressure. The residue was purified by reverse-phase silica gel chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.05% acetic acid in water; B: MeCN, 20% B to give compound (64) (Example 17) (75 mg) as a white solid. TIFF0007595576000098.tif29157
[0446] Synthesis of Compound 68 (Example 18) Example 18 was synthesized according to the following scheme. TIFF0007595576000099.tif54150
[0447] compound 65 To a stirred solution of intermediate (I-2) (1 g, 3.93 mmol) and tert-butyl (2S)-2-amino-3-hydroxypropanoate (633.9 mg, 3.93 mmol) in MeCN (100 mL) at 0° C., K2CO3 (1.09 g, 7.86 mmol) was added. After stirring the mixture at 60° C. for 48 h, it was concentrated under reduced pressure, diluted with water (100 mL) and extracted with EtOAc (3×100 mL). The combined organic layer was washed with water (2×200 mL), dried over anhydrous Na2SO4, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by reverse-phase silica gel chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.05% formic acid in water; B: MeCN, gradient from 10% to 90% in 25 min; detector, UV 200 nm. to give compound (65) (0.50 g) as a yellow oil. ESI-MS m / z=244.4[M+H] + .
[0448] compound 66 To a stirred solution of compound (65) (0.50 g, 2.05 mmol) in DCM (15 mL) at 0° C. was added TFA (15 mL) dropwise. The mixture was stirred at 20° C. for 6 h and then concentrated under reduced pressure to give compound (66), which was used in the next step without further purification. ESI-MS m / z=188.2[M+H] + .
[0449] compound 67 To a stirred solution of compound (66) (55.38 mg, 0.3 mmol) and compound (35) (80 mg, 0.3 mmol) in DMF (2 mL) at 0° C., DIPEA (114.74 mg, 0.89 mmol) and HATU (146.28 mg, 0.39 mmol) were added. The mixture was stirred at 0° C. for 2 h, then concentrated under reduced pressure, and the residue was purified by reverse-phase silica gel chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.05% formic acid in water; B: MeCN, gradient 10% to 50% in 20 min; detector, UV 200 nm, to give compound (67) (70 mg) as a white solid. ESI-MS m / z=440.2[M+H] + .
[0450] Compound 68 (Example 18) To a stirred solution of compound (67) (70 mg, 0.16 mmol), a solution of 4 M HCl in 1,4-dioxane (2 mL) was added dropwise at 20° C. The mixture was stirred at 20° C. for 6 h and then concentrated under reduced pressure. The residue was purified by reverse-phase silica gel chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.05% formic acid in water; B: gradient from 10% to 90% in 25 min; detector, UV 200 nm, 15% B to give compound (68) (Example 18) (51 mg) as a white solid. TIFF0007595576000100.tif34153
[0451] Synthesis of Compound 73 (Example 19) Example 19 was synthesized according to the following scheme. TIFF0007595576000101.tif59147
[0452] compound 69 To a stirred solution of tert-butyl (2S)-2-amino-6-[[(tert-butoxy)carbonyl]amino]hexanoate (1.19 g, 3.93 mmol) and intermediate (I-2) (1 g, 3.93 mmol) in MeCN (100 mL) at 0° C., K2CO3 (1.09 g, 7.86 mmol) was added in portions. The mixture was stirred at 60° C. for 48 h and then concentrated under reduced pressure. The residue was diluted with water (100 mL) and extracted with EtOAc (3×100 mL). The combined organic layers were washed with water (2×200 mL), dried over anhydrous Na2SO4, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with PE / EtOAc (5:1 to 3:1) to give compound (69) (1 g) as a pale yellow oil. ESI-MS m / z=385.2[M+H] + .
[0453] compound 70 To a stirred solution of compound (69) (570 mg) in DCM (30 mL) at 0° C. was added TFA (30 mL) dropwise. The mixture was stirred at 20° C. for 6 h and then concentrated under reduced pressure to give (compound 70), which was used in the next step without further purification. ESI-MS m / z=229.2[M+H] + .
[0454] compound 71 To a stirred solution of compound (70) (1 g, 4.38 mmol) in 1,4-dioxane (30 mL) at 0° C., saturated aqueous NaHCO3 (30 mL) and di-tert-butyl dicarbonate (955.98 mg, 4.38 mmol) were added in portions. The resulting mixture was stirred at 25° C. for 16 h and then neutralized to pH 6-7 with 1 M HCl. The aqueous layer was extracted with EtOAc (3×50 mL) and the combined organic layers were washed with water (2×100 mL), dried over anhydrous Na2SO4, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by reversed-phase silica gel chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.05% formic acid in water; B: MeCN, gradient 10%-50% in 20 min; detector, UV 200 nm to give compound (71) (200 mg) as a pale yellow oil. ESI-MS m / z=329.3[M+H] + .
[0455] compound 72 To a stirred solution of compound (71) (170 mg, 0.52 mmol) and compound (35) (153.93 mg, 0.57 mmol) in DMF (3 mL) at 0° C., HATU (236.19 mg, 0.62 mmol) and DIPEA (200.7 mg, 1.55 mmol) were added in portions. The mixture was stirred at 0° C. for 2 h and then concentrated under reduced pressure. The residue was purified by reversed-phase silica gel chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.05% formic acid in water; B: MeCN, gradient 10% to 80% in 20 min; detector, UV 200 nm to give compound (72) (100 mg) as a pale yellow oil. ESI-MS m / z=581.6[M+H] + .
[0456] Compound 73 (Example 19) To a stirred solution of compound (72) (100 mg, 0.17 mmol) in 1,4-dioxane at 20° C. was added dropwise 4 M HCl in 1,4-dioxane (4 mL). The mixture was stirred at 20° C. for 6 h and then concentrated under reduced pressure. The residue was purified by preparative HPLC using the following conditions: Column: SunFire C18 OBD Prep column, 100 Å, 5 μm, 19 mm×250 mm; Mobile phase A: water (0.1% formic acid), Mobile phase B: MeCN; Flow rate: 25 mL / min; Gradient: 1% B to 1% B in 7 min; 200 nm; Rt: 5.6 min) to give compound (73) (Example 19) (34.6 mg) as a white solid. TIFF0007595576000102.tif27157
[0457] Synthesis of Compound 75 (Example 20) Example 20 was synthesized according to the following scheme. TIFF0007595576000103.tif35147
[0458] compound 74 To a stirred solution of intermediate (I-2) (1.41 g, 5.55 mmol) in MeCN (20 mL) at room temperature, intermediate (I-4) (500 mg, 5.04 mmol) and K2CO3 (2.11 g, 15.13 mmol) were added portionwise. The mixture was stirred at 70 °C for 16 h, cooled to room temperature and concentrated under reduced pressure. The residue was diluted with water (100 mL) and extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with water (2 x 200 mL), dried over anhydrous Na2SO4, filtered and the filtrate was concentrated under reduced pressure to give compound (74), which was used in the next step without further purification. ESI-MS m / z=182.2[M+H] + .
[0459] Compound 75 (Example 20) To a stirred solution of morpholin-4-ylacetic acid (286.47 mg, 1.97 mmol) in DMF (2 mL) at 0° C. was added compound (74) (300 mg, 1.79 mmol), DIPEA (695.62 mg, 5.38 mmol) and HATU (886.82 mg, 2.33 mmol) in portions. The mixture was stirred at 0° C. for 2 h and then concentrated under reduced pressure. The residue was purified by preparative HPLC using the following conditions (Column: XBridge Prep OBD C18 column 19×250 mm, 5 μm; Mobile phase A: water (10 mmol / L NH4HCO3), Mobile phase B: MeCN; Flow rate: 25 mL / min; Gradient: 32% B to 40% B in 12 min; 220 / 200 nm; Rt: 9.98 min) to give compound (75) (Example 20) (16.6 mg) as a colorless oil. TIFF0007595576000104.tif27157
[0460] Synthesis of Compound 78 (Example 21) Example 21 was synthesized according to the following scheme. TIFF0007595576000105.tif65146
[0461] compound 76 To a stirred solution of intermediate (I-2) (500 mg, 1.967 mmol) in MeCN (10 mL) at room temperature, tert-butyl (2S)-3-amino-2-[(tert-butoxycarbonyl)amino]propanoate (511.86 mg, 1.97 mmol) and K2CO3 (815.21 mg, 5.9 mmol) were added portionwise. The mixture was stirred at 70 °C for 16 h, then cooled to room temperature and concentrated under reduced pressure. The residue was diluted with water (50 mL) and the aqueous layer was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with water (2 x 100 mL), dried over anhydrous Na2SO4, filtered and the filtrate was concentrated under reduced pressure to give compound (76), which was used in the next step without further purification. ESI-MS m / z=343.5[M+H] + .
[0462] compound 77 To a stirred solution of compound (76) (800 mg, 2.34 mmol) in DMF (5 mL) at 0° C., intermediate (I-3) (329.27 mg, 2.57 mmol), DIPEA (905.8 mg, 7.01 mmol) and HATU (1065.94 mg, 2.80 mmol) were added in portions. The mixture was stirred at 0° C. for 2 h, then concentrated under reduced pressure and the residue was purified by reversed-phase silica gel chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.1% formic acid in water, mobile phase B: MeCN; gradient from 0% to 100% in 30 min; detector, UV 220 nm, 70% B to give compound (77) (200 mg) as a colorless oil. ESI-MS m / z=453.4[M+H] + .
[0463] Compound 78 (Example 21) To a solution of compound (77) (200 mg, 0.44 mmol) in 1,4-dioxane at 20° C. was added a solution of 4 M HCl in 1,4-dioxane (20 mL). The mixture was stirred at 20° C. for 6 h and then concentrated under reduced pressure. The residue was purified by reverse-phase silica gel chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.1% formic acid in water; B: MeCN; detector, UV 200 nm, gradient 10% to 100% in 30 min, 20% B to give compound (78) (Example 21) (40.1 mg) as a white solid. TIFF0007595576000106.tif27153
[0464] Synthesis of Compound 81 (Example 22) Example 22 was synthesized according to the following scheme. TIFF0007595576000107.tif25150
[0465] compound 79 To a stirred solution of intermediate (I-2) (507.88 mg, 2.0 mmol) in MeCN (40 mL) at room temperature, tert-butyl 4-aminopiperidine-1-carboxylate (400 mg, 2.0 mmol) and K2CO3 (828.07 mg, 5.99 mmol) were added portionwise. The mixture was stirred at 70 °C for 16 h, then cooled to room temperature and concentrated under reduced pressure. The residue was diluted with water (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with water (2 x 100 mL), dried over anhydrous Na2SO4, filtered, and the filtrate was concentrated under reduced pressure to give compound (79), which was used in the next step without further purification. ESI-MS m / z=283.3[M+H] + .
[0466] compound 80 To a stirred solution of compound (79) (600 mg, 2.13 mmol) in DMF (5 mL) at 0° C., intermediate (I-3) (299.47 mg, 2.34 mmol), DIPEA (823.82 mg, 6.37 mmol) and HATU (1.05 g, 2.76 mmol) were added portionwise. The mixture was stirred at 0° C. for 2 h and then concentrated under reduced pressure. The residue was purified by reversed-phase silica gel chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.1% formic acid in water; B: gradient from 0% to 100% in 30 min; detector, UV 220 nm, 60%, to give compound (80) (300 mg) as a colorless oil. ESI-MS m / z=415.3[M+Na] + .
[0467] Compound 81 (Example 22) A solution of 4M HCl in 1,4-dioxane (20 mL) was added dropwise to a room temperature solution of compound (80) (300 mg) and stirred at 20° C. for 4 hours. The mixture was concentrated under reduced pressure and the residue was purified by reversed-phase silica gel chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.1% formic acid in water, B: MeCN; detector, UV 220 nm, gradient 0% to 100% in 30 min, 20%, to give compound (81) (Example 22) (200 mg) as a colorless oil. TIFF0007595576000108.tif34157
[0468] Synthesis of Compound 84 (Example 23) Example 23 was synthesized according to the following scheme. TIFF0007595576000109.tif22152
[0469] compound 82 To a stirred solution of intermediate (I-2) (600.75 mg, 2.36 mmol) in MeCN (40 mL) at room temperature, tert-butyl (3R)-3-aminopyrrolidine-1-carboxylate (400 mg, 2.15 mmol) and K2CO3 (890.43 mg, 6.44 mmol) were added portionwise. The mixture was stirred at 70 °C for 16 h, then cooled to room temperature and concentrated under reduced pressure. The residue was diluted with water (100 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with water (2 x 100 mL), dried over anhydrous Na2SO4, filtered, and the filtrate was concentrated under reduced pressure to give compound (82), which was used in the next step without further purification. ESI-MS m / z=257.1[M+H] + .
[0470] compound 83 To a stirred solution of intermediate (I-3) (315.12 mg, 2.46 mmol) in DMF (5 mL) at 0° C., compound (82) (600 mg, 2.24 mmol), DIPEA (866.88 mg, 6.71 mmol) and HATU (1105.15 mg, 2.91 mmol) were added in portions. The mixture was stirred at 0° C. for 16 h and then concentrated under reduced pressure. The residue was purified by reversed-phase silica gel chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.1% formic acid in water; B: MeCN; detector, UV 220 nm, gradient 0% to 100% in 30 min, 70% to give compound (83) (200 mg) as a colorless oil. ESI-MS m / z=412.9[M+H] + .
[0471] Compound 84 (Example 23) To a solution of compound (83) (200 mg, 0.53 mmol) in 1,4-dioxane at 20° C. was added a solution of 4 M HCl in 1,4-dioxane (15 mL). The mixture was stirred at 20° C. for 4 h and then concentrated under reduced pressure. The residue was purified by reverse-phase silica gel chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.1% formic acid in water; B: MeCN; detector, UV 254 nm, gradient 0% to 100% in 30 min, 20%, to give compound (84) (Example 23) (100 mg) as a pale yellow oil. TIFF0007595576000110.tif34157
[0472] Methods for evaluating compounds: Pig corneal flattening assay Pig whole eyes in 4°C saline were warmed to room temperature. The corneal epithelium was then removed using a blunt scalpel blade, and the eye was placed in a custom movable eye holder in a horizontal position with the cornea facing up. The eye holder was then placed inside a sealed chamber (typically a 37.0°C water bath) that allows for control of atmosphere, temperature, and humidity. IOP is maintained at a constant pressure by inserting a blood bank buffered saline line from a standard height IV bag inserted into each eye via a syringe needle. Eyes are stabilized by dripping 5% dextran T500 in blood bank buffered saline onto the corneal surface of each eye every 90 seconds for 2 hours. The dripping of dextran is discontinued, and the corneal surface of the test eye is immersed in a solution of the test compound held in place by a small rubber O-ring over the center of the cornea. After a set immersion time (typically 10 minutes), the O-ring is removed and saline is used to wash away excess test solution. The test eye is then turned to a vertical position and the pre-treatment surface keratometry of the cornea is measured using a Pentacam® HR device fine cornea 100 scan. The eye is then returned to a horizontal position and a specific pattern of 365 nm UVA light is administered to the cornea for the desired administration period. After resuming 5% dextran drops for another 1.5 hours, the eye is returned to a vertical position and the post-treatment surface keratometry of the cornea is measured using a Pentacam® HR device fine cornea 100 scan as before. A difference map between the pre- and post-treatment corneal images is obtained and the overall change in keratometry (Km) of the central 3 mm zone is recorded as a change in diopters.
[0473] The notes below provide further explanation of certain steps in the assay. (1) After warming porcine eyes to room temperature in saline, the eyes were either immediately placed into a custom movable eye holder with the cornea facing up, or the epithelium was first removed using a blunt scalpel blade before placement in the holder. (2) As used herein, IOP refers to “intraocular pressure.” IOP was maintained by inserting a blood bank buffered saline line from a standard height IV bag via a needle into each eye. (3) 0.5%-10% (typically 5%) dextran T500 in blood bank buffered saline is dropped onto the cornea of each eye every 90 seconds for 2 hours to stabilize the eye. The test eye is then oriented in a vertical position and a pre-treatment surface keratometry scan of the cornea is taken using a Pentacam® HR device (fine cornea 100 scan). The eye is then returned to a horizontal position and the dextran droplet is replaced with a solution of the test compound (typically 0.22% w / v in saline) held in place by a small rubber O-ring over the center of the cornea. (4) After a set immersion time of 5 to 30 minutes (typically 10 minutes), the O-ring is removed and excess test solution is washed away using saline.
[0474] Representative porcine corneal flattening data* for selected embodiments of the present disclosure are listed below in Table B-1.
[0475] [Table B-1] *UVA light was applied at 365 nm, 30 mW / cm under normal (21% O2) atmosphere at 37.0°C. 2 The irradiation was performed in a 4 mm circle with an irradiance of 100 nm, continuous wave (CW) for 8.1 min, and a total dose of 15 J.
[0476] Pig corneal reinforcement assay Pig whole eyes in 4°C saline were warmed to room temperature. Eyes were either immediately placed in a custom movable eye holder in a horizontal position with the cornea facing up, or the epithelium was first removed using a blunt scalpel blade before being placed in the holder. The eye holder was then placed inside a sealed chamber (typically a 37.0°C water bath) that allows for control of atmosphere, temperature, and humidity. The corneal surface of the test eye is then immersed in a solution of the test compound, held in place by a small rubber O-ring over the center of the cornea. After a set immersion time (typically 10 minutes), the O-ring is removed and excess test solution is washed away using saline. A specific pattern of 365 nm UVA light is administered to the cornea of the test eye for the desired administration period. A corneal flap of the desired thickness (typically 200 μm) is then ablated from the eye using a femtosecond laser (Zeimer, LDV1). The corneal flap is placed in saline for 20 minutes at ambient temperature and then mounted onto a biaxial extensometer (CellScale Biotester5000, Waterloo, ON) using a biorake attachment (5 tines spanning a width of 3.5 mm). The corneal flap is stretched at a constant rate of 4 μm / s in 37° C. saline until the sample breaks. The maximum slope of the force versus distance curve is calculated and compared to the slope obtained from an untreated cornea.
[0477] The notes below provide further explanation of certain steps in the assay. (1) The corneal surface of the test eye is then immersed in a solution of the test compound (typically 0.22% w / v in saline), held in place by a small rubber O-ring over the center of the cornea. After a set immersion time of 5-30 minutes (typically 10 minutes), the O-ring is removed and excess test solution is washed away with saline. (2) A corneal flap of the desired thickness and diameter (typically 200 μm thick × 8 mm diameter) is then excised from the eye using a femtosecond laser (Zeimer, LDV1). The corneal flap is placed in saline for 20 minutes at ambient temperature and then mounted on a biaxial extensometer (CellScale Biotester5000, Waterloo, ON) in saline or directly on the tester in 5% dextran T500 / saline. (3) A Biorake attachment (5 tines spanning a width of 3.5 mm) is used to hold the valve while it is stretched simultaneously in both the X (5 N load cell) and Y (10 N load cell) directions at a constant rate of 4 μm / s at 37° C. (4) The maximum slope of the force versus distance curve corresponds to the reinforcement value, which is compared to that obtained from untreated corneas.
[0478] Representative porcine supplementation data** for selected examples of the present disclosure are listed in Table C-1 below.
[0479] [Table C-1] **UVA light at 37.0℃ under normal (21% O2) atmosphere, 365nm, 30mW / cm 2 The irradiation was performed in a 9 mm circle with an irradiance of 100 nm, continuous wave (CW) for 8.1 min, and a total dose of 15 J. Maximum slope value for untreated cornea = 10.1. #Ocular epithelium was not removed prior to treatment.
[0480] Having described several aspects of the invention, it will be understood that various modifications can be made without departing from the spirit and scope of the invention. Accordingly, other aspects are within the scope of the following claims.
Claims
1. Formula II: or a pharma- ceutically acceptable salt thereof, During the ceremony, B 1 and B. 2 Each of the -Z 1 -Z 2 -Z 3 where: ・Z 1 But, C 1~3 is alkylene; ・Z 2 is a single bond, -N(R d ) -, -O-, or -S-; and ・Z 3 H, halo, or C 1~7 is alkyl; E 1 and Q 1 Each of 1 to 3 R a and optionally substituted by independently selected C 1 ~C 6 is alkylene; R 2 Each occurrence of (i)R a ; (ii) 1 to 3 R a C replaced by 1 ~C 6 Alkyl; (iii) heterocyclyl contains 3 to 10 ring atoms, 1 to 3 of which are N(R d ), O, and S; and one or more of the heterocyclyl ring carbon atoms are selected from 1 to 4 independently selected R b L 2 -heterocyclyl; (iv) 1 to 4 R c L may be substituted by 2 -C 6 ~C 10 Aryl; (v) Heteroaryl contains 5 to 10 ring atoms, 1 to 4 of which are N, N(R d ), O, and S, and one or more of the heteroaryl ring carbon atoms are selected from 1 to 4 independently selected R c L 2 -heteroaryl; and (vi) H or (vii) -C(=O)CH(R 2 )N(R d1 )-group R 2 and R d1 are linked to form a ring containing 5 to 8 ring atoms, wherein the ring is selected from the group consisting of (a) H and C 1~3 A cyclic alkyl group having 3 to 6 ring carbon atoms (CH(R 2 ) plus; (b) N(R d1 0 to 3 ring heteroatoms (R d1 In addition to the nitrogen atom bonded to R a Each occurrence of -OH; -SH; -F; -Cl; -Br; -NR e R f ;C 1~4 Alkoxy;C 1~4 Haloalkoxy; -C(=O)O(C 1~4 alkyl);-C(=O)(C 1~4 alkyl);-C(=O)OH;-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 0~2 (C 1~4 alkyl); cyano; -NR'C(=NR')NR'R''; and 1 to 4 independently selected R b C may be substituted 3~6 independently selected from the group consisting of cycloalkyl; R b Each occurrence of -OH; -SH; -F; -Cl; -Br; -NR e R f ;C 1~4 Alkyl;C 1~4 Haloalkyl;C 1~4 Alkoxy;C 1~4 Haloalkoxy; -C(=O)O(C 1~4 alkyl);-C(=O)(C 1~4 alkyl);-C(=O)OH;-CON(R')(R'');oxo;-S(O) 1~2 (NR'R'');-S(O) 0~2 (C 1~4 alkyl); cyano; -NR'C(=NR')NR'R''; and 1 to 4 independently selected C 1~4 C optionally substituted by alkyl 3~6 independently selected from the group consisting of cycloalkyl; R c Each occurrence of -OH; -SH; -F; -Cl; -Br; -NR e R f ;C 1~4 Alkyl;C 1~4 Haloalkyl;C 1~4 Alkoxy;C 1~4 Haloalkoxy; -C(=O)O(C 1~4 alkyl);-C(=O)(C 1~4 alkyl);-C(=O)OH;-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 0~2 (C 1~4 alkyl); cyano; -NR'C(=NR')NR'R''; and 1 to 4 independently selected C 1~4 C optionally substituted by alkyl 3~6 independently selected from the group consisting of cycloalkyl; R d Each occurrence of H;C 1~6 Alkyl;C 3~6 Cycloalkyl; -C(O)(C 1~4 alkyl);-C(O)O(C 1~4 alkyl);-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 1~2 (C 1~4 alkyl); -OH; and C 1~4 alkoxy; R e and R f Each occurrence of H;C 1~6 Alkyl;C 3~6 Cycloalkyl; -C(O)(C 1~4 alkyl);-C(O)O(C 1~4 alkyl);-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 1~2 (C 1~4 alkyl); -OH; and C 1~4 alkoxy; and Each occurrence of R' and R'' is H and C 1~4 alkyl, or R′ and R″ taken together with the nitrogen atom to which they are each attached form a ring containing 3 to 8 ring atoms, wherein the ring is selected from the group consisting of: (a) H and C 1~3 (b) N(R d ), O, and S; R d1 Each occurrence of H;C 1~6 Alkyl;C 3~6 Cycloalkyl; -C(O)(C 1~4 alkyl);-C(O)O(C 1~4 alkyl);-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 1~2 (C 1~4 alkyl); -OH; and C 1~4 alkoxy or -C(=O)CH(R 2 )N(R d1 )-group R 2 and R d1 are linked to form a ring containing 5 to 8 ring atoms as defined above; Each occurrence of L 2 is independently a single bond, or oxo and R a C optionally substituted by 1 to 3 independently selected substituents 1 ~C 6 alkylene; and F 1 But -N(R d1 ) -, -O-, or -S-; and H 1 , G 1 , L 1 , and M. 1 Each of - single bond; ・-N(R d1 )-; ・-O-; ・S(O) where p is 0, 1, or 2 p ; C(=O); · C (= S); ・CHR 2 ; -C(=O)CH(R 2 )N(R d1 ) -; and ・-C(=O)CH(R 2 )CH 2 N(R d1 )- More independently selected, The compound, or a pharma- ceutically acceptable salt thereof.
2. L 1 and M. 1 is a single bond, and G 1 and H 1 each of is a single bond, and F 1 -N(R d 2. The compound of claim 1, wherein
3. The compound is represented by the following formula (II-a), formula (II-c1), formula (II-c2), formula (II-d), or formula (II-e): or a pharma- ceutically acceptable salt thereof.
4. E 1 and Q 1 Each of the following may be independently selected: C 1 ~C 6 Alkylene and G 1 and L 1 Each of - single bond; -C(=O)CH(R 2 )N(R d1 ) -; and ・-C(=O)CH(R 2 )CH 2 N(R d1 )- The compound of claim 1, wherein:
5. R 2 Each occurrence of ・H; -NH 2 , -OH, -SH, -SMe, -NH (C=NH)NH 2 , CO 2 H, and CO 2 NH 2 C which is optionally substituted by 1 to 2 substituents selected from 1 ~C 6 Alkyl; Optionally substituted with 1 to 2 -OH (C 1 ~C 6 alkylene)-phenyl; ・(C 1 ~C 6 alkylene)-indolyl; and ・(C 1 ~C 6 Alkylene)-imidazolyl More independently selected, or -CH(R 2 )N(R d1 )-group R 2 and R d1 are linked to form a pyrrolidine ring, A compound according to any one of claims 1 to 4.
6. R 2 Each occurrence of ・H; The compound of any one of claims 1 to 4, independently selected from:
7. Formula (III): or a pharma- ceutically acceptable salt thereof, During the ceremony, B 1 and B. 2 Each of the -Z 1 -Z 2 -Z 3 where: ・Z 1 But, C 1~3 is alkylene; ・Z 2 is a single bond, -N(R d ) -, -O-, or -S-; and ・Z 3 H, halo, or C 1~7 is alkyl; E 1 , F 1 , G 1 , H 1 , L 1 , M 1 , and Q 1 Each of - single bond; ・1 to 3 R a C may be substituted 1 ~C 6 alkylene; and ・R 1 more independently selected; R 1 Each occurrence of ・-N(R d1 )-; ・-N(R 3 )-; ・-O-; ・S(O) where p is 0, 1, or 2 p ; C(=O); · C (= S); ・CHR 2 ; ・C(R 2 ) 2 ; -C(=O)CH(R 2 )N(R d1 ) -; and ・-C(=O)CH(R 2 )CH 2 N(R d1 )- independently selected from the group consisting of: However, E 1 and F 1 At least one of the following has 1 to 3 R a C may be substituted 1 ~C 6 Alkylene, where F 1 , G 1 , H 1 , L 1 , and M. 1 R, one to four of which are independently selected 1 and; R 2 Each occurrence of (i)R a ; (ii) 1 to 3 R a C may be substituted 1 ~C 6 Alkyl; (iii) heterocyclyl contains 3 to 10 ring atoms, 1 to 3 of which are N(R d ), O, and S; and one or more of the heterocyclyl ring carbon atoms are selected from 1 to 4 independently selected R b L 2 -heterocyclyl; (iv) 1 to 4 R c L may be substituted by 2 -C 6 ~C 10 Aryl; (v) Heteroaryl contains 5 to 10 ring atoms, 1 to 4 of which are N, N(R d ), O, and S, and one or more of the heteroaryl ring carbon atoms are selected from 1 to 4 independently selected R c L 2 -heteroaryl; and (vi) H or (vii) -C(=O)CH(R 2 )N(R d1 )-group R 2 and R d1 are linked to form a ring containing 5 to 8 ring atoms, wherein the ring is selected from the group consisting of (a) H and C 1~3 A cyclic alkyl group having 3 to 6 ring carbon atoms (CH(R 2 ) plus; (b) N(R d1 0 to 3 ring heteroatoms (R d1 In addition to the nitrogen atom bonded to R 3 Each occurrence of (i) 1 to 3 R a C replaced by 1 ~C 6 Alkyl; (ii) heterocyclyl contains 3 to 10 ring atoms, 1 to 3 of which are N(R d ), O, and S; and one or more of the heterocyclyl ring carbon atoms are selected from 1 to 4 independently selected R b L 3 -heterocyclyl; (iii) 1 to 4 R c L may be substituted by 3 -C 6 ~C 10 Aryl; and (iv) Heteroaryl contains 5 to 10 ring atoms, 1 to 4 of which are N, N(R d ), O, and S, and one or more of the heteroaryl ring carbon atoms are selected from 1 to 4 independently selected R c L 3 -heteroaryl independently selected from the group consisting of: R a Each occurrence of -OH; -SH; -F; -Cl; -Br; -NR e R f ;C 1~4 Alkoxy;C 1~4 Haloalkoxy; -C(=O)O(C 1~4 alkyl);-C(=O)(C 1~4 alkyl);-C(=O)OH;-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 0~2 (C 1~4 alkyl); cyano; -NR'C(=NR')NR'R''; and 1 to 4 independently selected R b C may be substituted 3~6 independently selected from the group consisting of cycloalkyl; R b Each occurrence of -OH; -SH; -F; -Cl; -Br; -NR e R f ;C 1~4 Alkyl;C 1~4 Haloalkyl;C 1~4 Alkoxy;C 1~4 Haloalkoxy; -C(=O)O(C 1~4 alkyl);-C(=O)(C 1~4 alkyl);-C(=O)OH;-CON(R')(R'');oxo;-S(O) 1~2 (NR'R'');-S(O) 0~2 (C 1~4 alkyl); cyano; -NR'C(=NR')NR'R''; and 1 to 4 independently selected C 1~4 C optionally substituted by alkyl 3~6 independently selected from the group consisting of cycloalkyl; R c Each occurrence of -OH; -SH; -F; -Cl; -Br; -NR e R f ;C 1~4 Alkyl;C 1~4 Haloalkyl;C 1~4 Alkoxy;C 1~4 Haloalkoxy; -C(=O)O(C 1~4 alkyl);-C(=O)(C 1~4 alkyl);-C(=O)OH;-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 0~2 (C 1~4 alkyl); cyano; -NR'C(=NR')NR'R''; and 1 to 4 independently selected C 1~4 C optionally substituted by alkyl 3~6 independently selected from the group consisting of cycloalkyl; R d Each occurrence of H; C 1~6 Alkyl;C 3~6 Cycloalkyl; -C(O)(C 1~4 alkyl);-C(O)O(C 1~4 alkyl);-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 1~2 (C 1~4 alkyl); -OH; and C 1~4 alkoxy; R e and R f Each occurrence of H;C 1~6 Alkyl;C 3~6 Cycloalkyl; -C(O)(C 1~4 alkyl);-C(O)O(C 1~4 alkyl);-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 1~2 (C 1~4 alkyl); -OH; and C 1~4 alkoxy; and Each occurrence of R' and R'' is H and C 1~4 alkyl, or R′ and R″ taken together with the nitrogen atom to which they are each attached form a ring containing 3 to 8 ring atoms, wherein the ring is selected from the group consisting of: (a) H and C 1~3 (b) N(R d ), O, and S; R d1 Each occurrence of H;C 1~6 Alkyl;C 3~6 Cycloalkyl; -C(O)(C 1~4 alkyl);-C(O)O(C 1~4 alkyl);-CON(R')(R'');-S(O) 1~2 (NR'R'');-S(O) 1~2 (C 1~4 alkyl); -OH; and C 1~4 alkoxy or -C(=O)CH(R 2 )N(R d1 )-group R 2 and R d1 are linked to form a ring containing 5 to 8 ring atoms as defined above; and L in each occurrence 2 and L 3 each independently represents a single bond, or oxo and R a C optionally substituted by 1 to 3 independently selected substituents 1 ~C 6 is alkylene, The compound, or a pharma- ceutically acceptable salt thereof.
8. E 1 and Q 1 Each of the following may be independently selected: C 1 ~C 6 Alkylene, and F 1 , G 1 , H1, L 1 and each of M 1 is a single bond; The compound of claim 7.
9. R 3 Each occurrence of More independently selected, or R 3 Each occurrence of L 3 -heterocyclyl, where the heterocyclyl contains 3 to 10 ring atoms and 1 to 3 ring atoms are N(R d ), O, and S; and one or more of the heterocyclyl ring carbon atoms are selected from 1 to 4 independently selected R b 9. The compound of claim 7 or 8, optionally substituted by:
10. R 3 but, 9. The compound according to claim 7 or 8, selected from:
11. B 1 and B. 2 Each of the -Z 1 -Z 3 The compound according to any one of claims 1 to 10,
12. Z 1 But, C 1~3 alkylene; Z 3 H, halo, or C 1~3 12. The compound of any one of claims 1 to 11, which is alkyl.
13. B 1 and B. 2 Each of the 3 , and C.H. 2 13. The compound of any one of claims 1 to 12, wherein R is independently selected from H and F.
14. B 1 and B. 2 Each of the 3 14. The compound of any one of claims 1 to 13, wherein
15. R d1 Each occurrence of H;C 1~6 Alkyl;C 3~6 Cycloalkyl; -C(O)(C 1~4 alkyl);-C(O)O(C 1~4 alkyl);-CON(R')(R'');-S(O) 1~2 (NR'R''); and -S(O) 1~2 (C 1~4 alkyl), or -C(=O)CH(R 2 )N(R d1 )-group R 2 and R d1 is linked to form a ring containing from 5 to 8 ring atoms as defined above.
16. R d1 16. The compound of any one of claims 1-15, wherein each occurrence of is H.
17. The compound of claim 1 selected from: [0043] or a pharma- ceutically acceptable salt thereof.
18. and 1. A compound selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.
19. 20. A pharmaceutical composition for treating a cornea of an eye comprising a compound according to any one of claims 1 to 18 or a pharma- ceutically acceptable salt thereof, said treatment comprising exposing said cornea to electromagnetic radiation, thereby causing cross-linking in said cornea.
20. 20. The pharmaceutical composition of claim 19, wherein the pharmaceutical composition treats one or more corneal ectatic disorders selected from the group consisting of keratoconus, keratoglobus, pellucid marginal degeneration, post-operative ectasia, and Therrien's peripheral corneal degeneration.
21. 21. The pharmaceutical composition of claim 19 or 20, wherein the electromagnetic radiation comprises ultraviolet radiation.
22. The pharmaceutical composition of any one of claims 19 to 21, wherein the treatment further comprises the use of an additional cross-linking agent.
Citation Information
Patent Citations
Systems, methods and compositions for ocular cross-linking treatment
JP2018501216A
Systems and methods for applying and monitoring eye therapy
US20110237999A1
Controlled cross-linking initiation and corneal topography feedback systems for directing cross-linking
US20120215155A1
Systems and methods for corneal cross-linking with pulsed light
US20130060187A1
Systems, methods, and compositions for cross-linking
US20140343480A1
